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SUMMARY
The cytoplasmic ribonuclease inhibitor-ribonuclease system  has 
been detected in  a w ide variety of tissues and species and is 
thought to play an essential role in the regulation o f  R N A  
m etabolism  and hence pro tein  synthesis. This hypothesis is based 
on the observation that tissues w ith high levels o f R N A  and 
pro tein  synthesis are associated w ith correspondingly h igh  levels 
o f free inhibitor and vice versa. How ever, the precise nature o f 
this regulatory function is unknow n. Therefore, the aim  o f this 
project was to isolate cD N A  clones o f ribonuclease inhib itor from  
a rat liver library in  the expression vector, Xgtl l  using polyclonal 
antiserum , to characterise the resultant clones and to  use  the 
clones to determine the extent to w hich ribonuclease inhibitor 
activities are controlled at the level o f gene expression 
The initial task was to obtain a high titre, highly specific 
antiserum  to be used as a probe in the screening o f the library. 
Thus, inhibitor protein was purified from  rat liver and  used  to 
raise polyclonal antiserum  in  rabbits. Analysis of the im m une 
serum  by western blotting revealed that, in  addition to recognising 
purified ribonuclease inhibitor, the antiserum  also recognised  
several other unknown proteins from  a preparation o f  ra t liver 
cytoplasm . These contam inating antibodies were adsorbed from  the 
im m une serum by affinity chrom atography. The adsorbed 
antiserum  was analysed by w estern blotting w hich dem onstrated 
that it now  recognised only one protein from  rat liver cytoplasm  
w hich corresponded to the ribonuclease inhibitor. Polyclonal
antiserum  also contains antibodies w hich b ind  to antigens 
produced by E.coli. This binding activity m ay result in  a h igh  
background when screening the library w hich m ay m ake the 
identification of positive clones difficult. These E.coli antibodies 
w ere rem oved from  the im m une serum  by adsorption against an 
E.coli crude cell lysate. To further reduce the possibility  o f a high 
background, IgG  was purified from  the im m une serum  and used to 
screen the library.
The rat liver cD N A  library in the phage expression vector, A,gtl 1 
was kindly provided by R ichard Hynes. The cD N A  inserts are 
cloned into the E coR l site o f the B-galactosidase gene and, w hen 
in  the correct fram e and orientation, give rise to fusion proteins 
com prising a large portion o f B-galactosidase fused to protein 
sequences encoded by the cDNA insert. Thus, cD N A  clones m ay 
be isolated by screening large num bers o f recom binant phage w ith 
antibodies raised against the protein o f interest. In itial plaque 
screening of 300,000 recom binants w ith the purified  IgG 
identified  five putative ribonuclease inhibitor clones. The clones 
w ere taken through several rounds of purification and only three 
o f the original five positives continued to  produce a positive 
signal. To characterise the fusion proteins from  the three clones 
(denoted ARLRI 3, ARJLRI 7 and ARJLRI 8), lysogens were 
prepared and IPTG -induced crude cell lysates w ere analysed by 
SDS polyacrylam ide gel electrophoresis. The relative m olecular 
m ass (M r) of the fusion proteins was approxim ately 127,000 
D altons, although the fusion protein o f ARLRI 7 appeared to be 
slightly larger. The fusion proteins w ere further characterised by
w estern blotting o f the crude cell lysates. This revealed that
ARLRI 7 and XRJLRI 8 produced im m unopositive fusion proteins 
whereas XRLRI 3 did not.
A t this stage in  the project, there was no  published am ino acid 
or nucleotide sequence data of ribonuclease inhibitor and hence a 
com parison of the nucleotide sequence o f the cD N A  inserts w ith 
know n sequence was im possible. To prove that the clones encoded 
ribonuclease inhibitor, peptide m apping o f purified ribonuclease 
inhibitor and the fusion proteins was carried out and the resultant 
peptides analysed by w estern blotting. It was hoped that sim ilar 
peptide m aps would be obtained w hich w ould suggest that the 
clones encoded ribonuclease inhibitor. H ow ever, the results 
obtained were irreproducible and hence inconclusive.
To aid in  the characterisation o f the clones, som e am ino acid 
sequence data o f ribonuclease inhibitor was obtained. Tryptic and 
chym otryptic digests o f the inhibitor w ere subjected to  H PLC 
analysis and six o f the resultant peptides w ere taken to A berdeen 
U niversity to be sequenced on their facilities. Only one o f the 
peptides provided sequence data and a polypeptide o f eleven am ino 
acids was obtained.
M eanwhile, the cD N A  inserts o f ARLRI 7 and ARLRI 8 were 
subcloned into the plasm id vector, pT Z  and nucleotide sequence 
was obtained using the dideoxy chain term ination m ethod of 
Sanger. The sequence o f the two inserts was identical w ith pR L R I 
7 being approxim ately 65 nucleotides longer than pR L R I 8. This 
corresponds to the previous data w here the fusion pro tein  for 
ARLRI 7 was slightly larger than that fo r ARLRI 8.
A t this tim e, nucleotide and amino acid sequence data for the 
hum an placental ribonuclease inhibitor was published. W hen 
com pared to the nucleotide and predicted am ino acid  sequences o f 
pR L R I 7 and pRLRI 8, there was no apparent hom ology. The full- 
length  hum an placental cD N A  clone was kindly sent by Professor 
B ert V allee and Southern blot analysis revealed that there was no 
cross-hybridisation betw een the rat liver clones and the hum an 
placental clone. N orthern blotting analysis show ed that the hum an 
clone does not cross-hybridise w ith rat liver R N A  w hich suggests 
that there m ay be little hom ology betw een the hum an ribonuclease 
inh ib ito r and the rat liver inhibitor.
Prelim inary data on the expression o f the isolated rat clones 
show ed that they are expressed in rat liver, k idney, brain  and 
heart.
C H A PT E R  O N E  
IN T R O D U C T IO N
TH E R EG U LA TIO N  OF mRNA D EG R A D A TIO N
1.1 INTRO DUCTIO N
The steady state level o f cytoplasm ic m RN A  is dependent upon its 
rate o f synthesis and degradation. U ntil recently, studies on the 
m echanism s regulating the levels o f m RNA have concentrated on the 
transcriptional control o f m R N A  synthesis (reviewed by M aniatis et 
al., 1987). How ever the m etabolism  of m RNA, w hich includes the 
processing of nuclear RN A , export from  the nucleus and m RN A  
degradation, has emerged as a m ajor control m echanism  in regulating 
the level o f m RN A  in  the cytoplasm  and is probably as im portant as 
transcription in  the control o f gene expression. The factors controlling 
the rate o f degradation of m RN A  are now beginning to  be elucidated 
(for review s see Raghow, 1987; Brawerm an, 1987; C leveland, 1988; 
H unt, 1988; M arzluff and Pandey, 1988 and B raw erm an, 1989) and are 
described in  some detail in  this introduction. O f obvious im portance are 
the ribonucleases w hich carry out the degradation of R N A  and how  they 
are regulated w ithin the cell. This introduction describes the m am m alian 
ribonucleases and their association w ith the endogenous ribonuclease 
inhibitor and how  the ribonuclease:inhibitor com plex m ay play a role in 
the regulation o f m RN A  turnover.
1.2 m RNA TURNO VER IN  EUKARYOTES!
U ntil recently, the rate o f synthesis o f m RN A  was assum ed to be  the 
m ajor determ inant of the steady state level o f m RN A  in  the eukaryotic 
cell. How ever, when the transcription rates of several constitutively 
expressed (housekeeping) genes in m ouse L  cell fibroblasts were
m easured  (Cam eiro and Schubler, 1984), it was found that although 
som e genes were transcribed at relatively low  rates, their m R N A s w ere 
abundant whereas some genes w ith a high rate o f transcription had 
m R N A s w hich were rare. In  each case, the steady state level o f a 
m R N A  correlated with its stability i.e. the m ore stable the m R N A , the 
m ore abundant it was. Cellular m RN A  levels actually represent a 
balance betw een rates o f synthesis o f nuclear RNA, processing and 
export from  the nucleus and rates o f cytoplasm ic m RN A  turnover 
(stability/degradation o f m RN A ).
The rates of m RN A  turnover vary to a w ide extent in  eukaryotes.
The half-lives o f some m RN A s are extrem ely short e.g. the p ro to­
oncogene, c-fos is degraded at a very high rate w ith a half-life o f 30 
m inutes (Greenberg et al., 1986) whereas other m RNAs are m ore 
stable w ith half-lives that span several hours or even days e.g. g lobin  
m R N A  (Bastos et al., 1977). The rate at w hich a m R N A  m olecule is 
degraded controls the speed w ith w hich changes in the transcrip tion rate 
are reflected in its cytoplasm ic level e.g. a m R N A  w ith a  short half-life 
responds rapidly to a change in  the rate o f transcription w hereas a 
m R N A  w ith a longer half-life responds m ore slowly to a  change in  
transcription rate.Thus the turnover of m R N A  is now  considered to be a 
m ajor control point in the regulation of gene expression.
1.2.1 CONTROL OF mRNA TURNOVER BY 
ENDOGENOUS AND EXOGENOUS FACTORS
The rates at w hich individual genes are transcribed and 
the rate o f turnover o f specific m RNAs can be altered in 
response to certain endogenous and exogenous stim uli e.g.
changes in  the cell-cycle or induction by horm ones and 
grow th factors.
Several constitutively expressed ’housekeeping' genes undergo 
changes in  their degradation rate in  response to changes in  the cell 
cycle e.g. the mRNAs encoding thym idylate synthase (A yusaw a et 
al., 1986) and histones (G raves et al., 1987). The rates of 
transcription are observed to rem ain constant whereas the steady state 
levels o f the m RNA vary considerably. The regulation o f histone 
m R N A  turnover is considered in  m ore detail in  Sections 1.2.3 to
1.2.6 inclusive.
Studies have been carried out to determ ine the effects of 
exogenous stim uli (horm ones and growth factors) on the turnover o f 
m R N A  (for review see Shapiro et al., 1987). O estrogen is observed 
to have a  dram atic effect on the stability o f the m R N A  encoding the 
egg-yolk precursor protein, vitellogenin (Brock and Shapiro, 1983).
In  oestrogen-treated cells, the half-life is 480 hours w hich  represents 
a 30-fold change in the rate o f m RN A  turnover as com pared to 
untreated cells. O estrogen-stim ulated stabilisation of vitellogenin 
m R N A  appears to be selective as the half-life o f the to tal m R N A  in 
both  treated and untreated cells is 16 hours (Baker and Shapiro, 1977)
The turnover of type 1 procollagen m RN A  is affected by treatm ent 
w ith  glucocorticoids and grow th factors (Shapiro et al., 1987). 
A ddition o f dexam ethasone, a synthetic glucocorticoid, increases the 
degradation rate o f this m R N A  whereas transform ing grow th factor B 
(TGF-B) stabilises type 1 procollagen m RN A  (Raghow  et al., 1987).
Specific stabilisation o f cellular m RNAs by  horm ones and grow th 
factors m ay be the result o f covalent m odifications of the m RN A  
during synthesis and processing in  the nucleus w hich render the 
m RN A s resistant to degradation in the cytoplasm . The presence or
absence o f a particular horm one or growth factor m ay cause the 
m odifications to  be irreversibly rem oved, thus altering the stability of 
the m RN A . Alternatively, the stability o f m R N A  m ay be regulated 
through reversible protein-RN A  interactions in  the cytoplasm . Initial 
studies carried out on oestrogen-stabilised vitellogenin m R N A  (Brock 
and Shapiro, 1983) first revealed that there are sequences w ithin the 
m RN A  m olecule which m ay confer a particular secondary structure on 
the m olecule or act as recognition sites for nucleases and thus regulate 
its stability. The follow ing sections describe the techniques w hich 
have been  used to elucidate these regulatory sequences and outline in  
detail the know n sequences within the m RN A  m olecule w hich are 
thought to play a role in  the regulation of m R N A  turnover.
1.2.2 TEC H N IQ U ES U SED TO STU D Y  m RNA T U R N O V E R
Several techniques have been influential in  determ ining how  m R N A  
is regulated. The im portance of a particular region of the m R N A  
m olecule in  RN A  turnover has been dem onstrated by the use o f 
transfection experiments. Constructs o f D N A  are m ade in  w hich regions 
o f the m R N A  are deleted, m odified or transferred to o ther genes. The 
constructs are then transfected into cultured cells and the D N A  
transcribed into the m odified mRNAs. The stability o f the m odified  
m RNAs are com pared to the unm odified m R N A  e.g. Fort et al.,
(1987) deleted 130bp from  the 3 'non coding region o f c-fos, 
transfected the m odified gene into ham ster fibroblasts and show ed that 
the deletion stabilised the m RN A  transcript. In this w ay sequences 
involved in  the regulation of m RNA turnover are beginning to be 
elucidated.
A  cell-free system has been devised by Ross and Kobs (1986) to
study the turnover of h istone m RN A . In this system , m R N A  turnover is 
studied by incubating m R N A  w ith polyribosom es isolated from a cell 
lysate. This seems to be a valid  m ethod of studying m R N A  turnover as 
the half-lives and degradation o f m RNAs studied to date in both the 
cell-free system  and in vivo appear to be sim ilar. U sing this system , 
the structural features w hich regulate the turnover o f histone m RN A s 
are now  beginning to be understood.
1.2.3 THE ROLE OF THE POLYfAl TATL IN mRNA TURNOVER
The degradation of m R N A  m ay be affected by the absence or 
presence o f the poly (A) tail at the 3' end o f the m R N A  m olecule. 
Rem oval o f the poly(A) tail from  certain m R N A  species causes them  
to be degraded rapidly (Huez et al., 1981) w hereas addition o f a 
poly  (A) tail to other m RN A s increases their stability (Peltz et al.,
1987). Certain horm ones w hich are know n to stabilise specific 
m R N A s also induce elongation o f the poly(A ) tail (Paek and Axel,
1987) thus providing further evidence that there m ay be a correlation 
betw een the presence o f a poly(A ) tail and m R N A  stability.
The absence of a poly(A ) tail has been im plicated in  the regulation 
o f histone mRNA. M ost h istone m RNAs do no t possess a poly(A) tail 
(A desnick and Darnell, 1972) and in  m any cell types are regulated as a 
function o f the cell-cycle i.e. they are present at low levels during G   ^
phase, accumulate during S phase and are degraded at the end of S 
phase (Robbins and Borun, 1967, Heintz et al., 1983). A m phibian 
oocytes contain histone m RN A s w hich possess poly(A ) tails 
(Levenson and M arcu, 1976). These m RNAs are stable during the 
period betw een oocyte developm ent and fertilisation. The histone
m R N A  loses its poly(A) tail during m aturation o f the oocyte to an egg 
and during em bryogenesis and is then rapidly degraded (H ym an and 
W orm ington, 1988). A lso, histone m RN A s lacking poly(A ) tails are 
rapidly degraded w hen injected into oocytes (Huez et al., 1978). 
H ow ever, i f  a poly(A) tail is added to the histone m RNAs prior to 
m icro-injection, then the m RN A s are stabilised (Huez et al., 1978). 
These observations suggest that there is a correlation betw een the 
degradation of histone m R N A  and the absence o f a poly(A ) tail.
In vivo, the poly(A) tail exists as a com plex w ith a  protein, the 
poly (A) binding protein (PABP) (Bergm ann and Brew erm an, 1977). It 
is thought that the PA BP helps to stabilise m R N A  by protecting the 
poly(A ) segm ent from  attack by  nucleases. How ever, PA B P does not 
protect every polyadenylated m R N A  to the same extent w hich suggests 
that other sequences on the m RN A  m olecule m ay affect how  
efficiently PA BP binds to the poly(A) tail (Brawerm an, 1987). W ilson 
and Treism an (1988) dem onstrated that in c-fos m RN A  constructs 
lacking the AU -rich signal (see section 1.2.4), the poly (A) segm ent is 
m ore stable. Thus the destabilising effect o f A U -rich sequences could 
be due to an interaction w ith the poly(A) tail/PA BP com plex.
Experim ents carried out in  a cell-free system  by B rew er and Ross
(1988) have shown that c-myc m R N A  loses its poly(A) tail before the 
rest o f the m olecule is degraded. Thus it is possible that degradation 
o f m R N A  in eukaryotic cells is initiated by cleavage at the 3' term inus 
o f the m RNA, resulting in  deadenylation and consequent degradation 
o f the m olecule in a 3 ’ to 5 ’ direction.
1.2.4 3'N O N  CO DING  R EG IO N  OF m RNA
Specific sequences in  the 3 'non coding region of certain  m R N A s
seem  to be im portant in determ ining their rates o f degradation. Shaw 
and K am en (1986) fused a 51 nucleotide A T-rich sequence from  the 
3 ’non coding region o f a hum an lym phokine gene (GM -CSF) to a 
rabbit beta (B) globin gene and found that the hybrid globin m RN A  
w as degraded 10-30 tim es faster than a norm al B globin transcript. 
E xam ination o f the 3 'non-coding regions o f m any transiently 
expressed genes, such as c-myc, c-fos and interferon, show ed that 
they also contain this A T -rich sequence and therefore the degradation 
o f these unstable mRNAs m ay be regulated by a com m on mechanism . 
A t present the m anner in w hich AU-rich sequences prom ote RN A  
degradation is unclear. It is possible that an endoribonuclease (or 
other binding protein that facilitates ribonuclease activity) cleaves 
specifically at AU-rich regions, thus leaving the m R N A  susceptible to 
3' exonucleolytic attack. H ow ever, it appears that this A U -rich 
sequence is not the only signal recognised by  this putative AU- 
specific endoribonuclease as it is also present in  the 3 'non coding 
region o f the m RNA of B globin, a transcript w hich is know n to be 
h ighly stable. Also, w hen the A T-rich sequence o f the G M -C SF gene 
w as fused to  a reporter m RN A , the transcript was stable in  a 
m onocytic tum our whereas an oncogene with a sim ilar A T-rich region 
was rapidly degraded (Shyu et al., 1989). This suggests that the A U - 
rich  sequence of the 3 'non coding region m ay in teract w ith  other 
sequences or structural elem ents o f the m RN A  to prom ote degradation 
o f these m RN A s (see previous section for the interaction o f A U -rich 
sequence and the poly (A) tail/PAPB complex).
The m R N A  of c-fos contains an AU -rich sequence in  the 3 'non 
coding region (Van Straaten, 1983). However, w hen this sequence is 
deleted, the m RNA is still relatively unstable w hich suggests that the
turnover o f c-fos m RNA is determ ined by m ore than one degradation 
signal. W hen the coding region o f c-fos is substituted fo r the coding 
region o f B globin m RNA, the hybrid transcript is unstable (Kabnick 
and H ousem an, 1988). Thus, a further degradation signal appears to 
be  present in  the coding region fo r c-fos m RN A . Experim ents carried 
out recently  by Shyu et al., (1989) show that, rather than  acting in  
concert, the degradation processes initiated by  the tw o putative 
signals are different. The degradation o f a transcript containing the c- 
fo s  A U -rich signal is decreased w hen transcription is inhibited 
w hereas the degradation o f a m R N A  w ith the c-fos coding region is 
unaffected.
One approach to determ ine how  the 3 'non coding region affects 
the turnover of some m RN A s involves com paring the half-lives o f 
closely-related, naturally ocurring m RNAs in  the same cell type. The 
m R N A s of hum an B globin and delta (3) globin code fo r the protein  
com ponents of two types o f haem oglobin. The 5 'non coding and 
coding regions of the m RN A s are very sim ilar bu t the 3 'non coding 
. regions differ greatly. In hum an bone m arrow  cells, the m R N A  o f 3 
g lobin is degraded 4-6 fold faster than the m RN A  of B globin (Ross 
and Pizzaro, 1983). As the two m olecules differ m ainly in  the 3 'non 
coding region, the difference in turnover is probably due to sequences 
in  the 3 'non coding region o f the 3 globin m R N A  being m ore 
susceptible to degradation than those o f the B globin m RN A .
As m entioned previously, cell cycle regulated histone m RN A s are 
degraded w hen DNA synthesis is arrested e.g. in phase o f the cell 
cycle. H istone mRNAs are term inated by a highly conserved stem- 
loop sructure at the 3 'non coding region and it has been show n that 
the presence of this structure is required to couple the degradation o f 
the m R N A  with cessation o f D N A  replication (Levine et al., 1987).
D egradation o f H4 m RN A  is apparently initiated by cleavage near the 
stem -loop structure and upon cessation of D N A  replication, histone 
m R N A  m olecules lacking betw een 5 and 12 nucleotides at the 3' end 
are observed (Ross et al., 1987). It is possible that during S phase, 
w hen there is a  high dem and fo r histones, a factor m ay bind  to this 
stem -loop structure thus protecting it from  nucleolytic attack. A  
sim ilar stem -loop structure is also present in the 3 'non coding region 
o f the m R N A  of the transferrin  receptor and it is thought to prom ote 
degradation o f this m R N A  in  the presence of iron (M uller and Kuhn,
1988).
1.2.5 PR O TEIN  SY N TH ESIS AND m RNA TU R N O V ER
Studies on the regulation o f histone m RN A s (Graves et al.,
1987) and on the autoregulated stability o f tubulin m R N A  (Cleveland,
1988) have provided evidence that the regions o f the m R N A  w hich are 
translated into proteins contain signals for the regulation o f m R N A  
degradation
The norm al regulation o f histone m RN A  requires progression o f 
the ribosom es to the correct term ination codon. Graves et al., (1987) 
m utated histone genes such that translation was initiated at the correct 
site but term inated prem aturely. The half-lives o f the m utated m RN A s 
were increased approxim ately 2-fold relative to norm al histone m R N A  
transcripts. They also observed that the regulation of histone m R N A  
degradation requires that the distance betw een the highly conserved 3' 
stem -loop structure of histone m RN A  and the translational term ination 
codon m ust be no m ore than 300 bases. This suggests that the decay 
o f the m RN A  is initiated by a nuclease w hich m ay be associated w ith
the  ribosom es and recognises som e structural feature(s) o f the 3’ 
reg ion  o f the histone m RNA. Term ination o f translation at the correct 
site w ould thus bring the nuclease to the target at the 3' term inus. 
A lternatively, the ribosom e m ay in some w ay unw ind the stem -loop 
structure thus exposing the recognition site to the nuclease.
In  contrast to the situation outlined above, where prem ature 
term ination o f translation increases the stability o f the histone m RN A , 
the absence o f translating ribosom es beyond a certain region o f the 
coding segm ent (due to prem ature term ination) results in  the rapid 
degradation o f triosephosphate isom erase m R N A  (Daar and M asquat,
1988). In  this case, there does no t appear to be a direct relationship 
betw een the length o f the untranslated RN A  and destabilisation. It is 
possible that prem ature term ination of the triosephosphate m RN A  
causes a nuclease-sensitive site to be exposed to som e nucleolytic 
activity and hence rapid degradation ensues.
R ecently, it has been show n that there is a  link betw een protein 
translation and m RN A  turnover in the autoregulated decay o f tubulin 
m R N A  (Cleveland, 1988; H unt, 1988 and references therein). The 
stability o f tubulin m RN A  is regulated by  the level o f unassem bled 
tubulin  subunits. Interestingly, the sequence or structure of the 
m R N A  m olecule itself is not necessary for autoregulation. Instead, the 
instability recognition elem ent is the first four amino acids (M et-A rg- 
G lu lie) o f the new ly synthesised (nascent) tubulin polypeptide chain. 
Furtherm ore, autoregulation requires that the tubulin m R N A  m ust be  
bound to the polysom e. A  m odel for this autoregulated control has 
been proposed: as the level o f unpolym erised tubulin subunits 
increases, tubulin interacts w ith the amino term inal o f the nascent 
polypeptide chain after it em erges from  the ribosom e. In  som e w ay, as 
yet unknown, this protein-protein interaction m ediates the subsequent
degradation of the m RN A  m olecule by either activating a ribosom e- 
associated ribonuclease o r by  stalling the polysom e, thus exposing a 
section o f the RN A  m olecule to cytoplasmic ribonucleases.
Further evidence that translation of m RN A  is linked to m RN A  
turnover comes from  the observation that cyclohexim ide, an inhibitor 
o f polypeptide chain elongation, causes stabilisation o f m any unstable 
m RN A s (Fort et al., 1987). It has been suggested that this effect is 
due to loss o f an unstable ribonuclease but there is no  direct evidence 
to support this hypothesis. It is perhaps m ore likely that translational 
inhibitors m odify the interaction between the ribosom e and m RN A  
thus altering the susceptibility o f the m RN A  to degradation by 
nucleases.
1.2.6 5'N O N  C O P IN G  R EG IO N
It is also understood that sequences in  the 5 'non coding region 
can affect the stability o f m RNA. U nder norm al circum stances, the 
m RN A  o f the proto-oncogene, c-myc is relatively unstable w ith  a 
half-life o f approxim ately 10 minutes (Dani et al., 1984). H ow ever, in  
cancerous lym ph node cells, the 5'non coding region o f the c-myc 
m RN A  is deleted. This truncated m RNA contains the entire coding 
region and the translated protein displays norm al biological activity. 
How ever, deletion o f the 5 ’non coding region increases the stability 
o f the m RN A  by 3 to 5-fold (Piechaczyk et al., 1985; R ay et al., 
1987). A t present, the m echanism  by w hich the 5 ’non coding region 
affects the half-life o f c-myc m RN A  is unknow n. It is possible that 
deletion of this region m ay affect the translation rate o f the m R N A  or 
it m ay affect the secondary structure of the m RNA. A lthough rem oval
o f the 5 'non coding region increases the stability o f c-myc m RNA, 
fusion o f this region w ith the chloram phenicol acetyl transferase 
(CAT) gene does not affect the stability o f the CA T gene (Piechaczyk 
et al., 1987). Thus, it seem s likely that the destabilising 5 'non 
coding region interacts w ith other regions o f the c-myc m R N A  (Saito 
et al., 1983).
Further evidence that the 5'non coding sequence can  affect the 
stability o f m RN A  comes from  experiments carried out on the 5’non 
coding region of the hum an histone H3 m RN A . W hen the 5 ’non 
coding region of histone H3 m RNA is fused to B globin m RN A , the 
hybrid  R N A  is destabilised w hen DNA synthesis is blocked, thus 
suggesting that the 5 'non coding region plays a role in  histone H3 
stability (M orris et al., 1986). W hen the 5 'non coding region  of 
histone m R N A  is replaced by that from the Drosophila heat shock 
protein 70 (hsp70) m RN A  , the histone m R N A  rem ains stable in  the 
absence o f D N A  synthesis (M orris et al., 1986). H ow ever, the 5 ’non 
coding region is not involved in the regulation of all o f  the histone 
. m RN A s. The sequence that links m RN A  stability to D N A  synthesis in  
the histone H4 appears to be located in the 3 'non coding region 
(Luscher et al., 1985).
In  general, m ost m RNAs are protected from  degradation in  a 5' to 
3' direction by the presence of a cap at their 5' term ini (Shatkin, 
1976). In the absence of a cap or bound protein  at the 5' end, m RNAs 
are degraded rapidly. It is unlikely, however, that the nuclease which 
degrades in  a  5' to 3' direction is a m ajor nuclease in  selective m RN A  
degradation as m ost m RN A  species are protected by a  cap and also, 
m ost m RN A s are thought to be degraded from  the 3’to the 5' end 
(Ross and K obs, 1986; Ross et al., 1987).
1.2.7 m R N A  T U R N O V E R  W IT H IN  T H E  N U C L E U S
The previous sections have outlined the m echanism s which 
control the rate of degradation o f m ature m R N A  m olecules w ithin the 
cytoplasm ic fraction of the cell. There is also some evidence that 
degradation o f pre-m RNA occurs w ithin the nucleus (V aessen e t al.,
1987). There are several stages in  the processing o f pre-m R N A  to 
m ature m R N A  at which R N A  degradation m ay occur e.g. the splicing 
o f introns and polyadenylation. C affarelli et al., (1987) reported that 
the accum ulation of m ature R N A  of Xenopus laevis ribosom al L I  
protein is controlled at the level o f splicing. In  this case, w hen an 
excess o f free L I protein is present, an incom pletely spliced precursor 
R N A  accumulates. The two introns w hich have not been spliced out 
are specifically cleaved and the resultant truncated m olecules are 
degraded. Similarly, two introns o f the Drosophila suppresor-of- 
white-apricot gene are not rem oved after cellular blastoderm  
developm ent, thus preventing the production o f a  functional m R N A  
(Chou et al., 1987)
It is also possible that degradation o f R N A  m ay occur during 
transportation from  the nucleus to the cytoplasm  (Pena and Zasloff,
1987). H ow ever, as yet there have been no reports to support this 
possib ility .
1 2.8 E N Z Y M E S IN V O L V E D  IN  m R N A  D E G R A D A T IO N
Know ledge about the nucleases and other factors involved in the 
degradation of m RNA is lim ited. The cell-free system  for 
investigating the turnover o f histone m R N A  (see Section 1.2.2)
revealed that a  polysom e-associated nuclease initiated degradation of 
h istone m RN A  by cleavage o f the stem -loop structure at the 3' end o f 
the RN A . The histone m R N A  was then degraded in  a 3' to 5' direction 
(Ross et al., 1987). H opefully, the establishm ent of this system  w ill 
be  furthered by the developm ent o f sim ilar systems to investigate the 
degradation of other m R N A  species and the role, if  any, o f non­
polysom e associated nucleases.
T he presence of discrete, interm ediate-sized products o f m R N A  
breakdow n suggests that a com bined action of exo- and endonucleases 
m ay be responsible for com pleting the process o f m R N A  turnover e.g. 
an endonuclease which specifically recognises the A U -rich sequence 
o f certain m RN A  m olecules could expose the 3’ term inus o f such 
m R N A s thus rendering them  susceptible to degradation by  a 3' 
exonuclease. However, no A U -rich sequence specific endonuclease 
has been identified as yet.
There is also very little inform ation concerning the nature of 
possible factors which m ay regulate the action o f the nucleases 
involved in  m RNA degradation. Evidence that such factors m ay be 
intracellular molecules that are activated by appropriate signals is 
provided by  studies carried out on interferon. Interferon induces the 
synthesis o f several proteins, including 2 -5 ' oligoadenylate (2-5A) 
synthetase w hich synthesises the m olecule 2-5A. This m olecule 
activates an endoribonuclease w hich selectively degrades viral m R N A s 
(B aglioni et al., 1984). Infection by Herpes simplex virus leads to 
non-specific degradation of m ost cellular m RNAs (Kwong and 
Frenbel, 1987). This degradation could result from  the action of a 
viral gene product or by activation of a cellular nuclease.
M any questions have still to be answ ered concerning the 
nucleases and factors responsible for the degradation o f m R N A  e.g.
do m RNA-degrading ribonucleases act only on specific m RN A s or do 
they degrade non-specifically? Also, how  are the ribonuclease 
activities regulated? Use o f the cell-free system  developed by Ross 
and Kobs (1986) will hopefully  provide the answers to these 
questions in  the near future.
1.3 C LA SSIFICA TIO N O F M A M M A LIA N  R IB O N U C L E A SE S
It is evident from the preceding sections that one o f the m ajor 
functions o f ribonucleases is the degradation o f m R N A  m olecules. 
Ribonucleases are also required for a variety o f other functions w ith in  
the eukaryotic cell. R ibonucleases are necessary for processing o f 
R N A  molecules i.e. where one R N A  m olecule is converted to another 
e.g. the processing of heterogenous nuclear (hn) RN A  to  m ature 
m RN A . This involves the addition of a cap ,M ^G(5')ppp(5')-N at the 
5 ’ term inal end of the R N A  (Shatkin, 1976; Shatkin, 1987), the 
addition o f a poly (A) tail at the 3' term inus of the R N A  m olecule and 
the rem oval o f intron transcripts (splicing).
Thus, there are m any different types of ribonucleases to be found 
w ithin the eukaryotic cell and they were classified by Sierakow ska 
and Shugar in 1977 into two m ain types: endoribonucleases w hich act 
at specific sites within the R N A  m olecule yielding oligonucleotide 
fragm ents and exoribonucleases which digest RN A  sequentially from  
the 3' or 5 ’ term inus. Endogenous ribonuclease inhibitor is thought 
no t to affect exoribonucleases and these enzym es are therefore om itted  
from  the rem ainder o f this discussion.
The endoribonucleases are further sub-divided into tw o groups: 
type I and type II endoribonucleases. Type I ribonucleases are
optim ally active at alkaline or neutral pH  and digest R N A  via the 
form ation o f products w ith term inal pyrim idine nucleoside 2’,3 - 
cyclic phosphates. Type I  ribonucleases are sensitive to the 
ribonuclease inhibitor and are discussed in  m ore detail in  the 
follow ing section. Type II endoribonuleases show optim al activity at 
pH 5.0-6.0, digest RN A  non specifically, are theim olabile and are 
found exclusively in the lysosom al fraction o f m am m alian cells. Type 
II endoribonucleases are also insensitive to the endogenous 
ribonuclease inhibitor (Blackburn and M oore, 1982)
O ther nucleases w hich fall into neither the type I no r type II 
categories and are insensitive to  the ribonuclease inhibitor are those 
w hich are involved in  the processing o f ribosom al RNA , heteronuclear 
R N A  and transfer RNA, nucleases active towards double-stranded 
RNA, ribonuclease H  which digests the RN A  m oiety o f D N A :RN A  
hybrids and an endonuclease activated in  response to interferon 
(Sierakow ska and Shugar, 1977)
1.3.1 TYPE I EN D O R IBO N U C LEA SES
Sierakow ska and Shugar (1977) divided the type I 
endoribonucleases into two further subgroups: secretory and 
nonsecretory ribonucleases. The pancreatic ribonucleases are typical 
o f the secretory class. In  particular, bovine pancreatic ribonucleases A  
and B (RNase A  and RNase B) have been w ell-characterised and the 
am ino acid and nucleotide sequences are know n (review ed by 
B lackburn and M oore, 1982). A  num ber o f o ther secretory 
ribonucleases have been isolated from  several sources e.g. the 
pancreas o f hum an (Beintem a et al., 1984) and the pancreas o f turtle 
(Beintem a et al., 1985a) and their amino acid sequences determ ined.
Com parison o f these amino acid sequences w ith  that o f RNase A  has 
revealed that they are all related. Also, a secretory ribonuclease has 
been  isolated from  bovine brain  (W atanabe et al., 1988) and shown to 
be  78%  hom ologous to RN ase A. Ribonucleases o f the pancreatic type 
are secreted by the pancreas and salivery glands o f all m am m als and 
are found in  the duodenal contents, kidney, serum  and urine.
The other class o f type I ribonucleases are the non  secretory 
ribonucleases. These enzym es cleave m ost effectively a t pH 6.5-7.0 
and occur predom inantly in liver, lung, spleen and leucocytes (M orita 
et al., 1986) . R ibonucleases o f this class have also been  isolated 
from  lysosom e-rich sources (Niwata et al., 1985). A  non  secretory 
ribonuclease has been isolated from  hum an urine and its amino acid 
sequence determ ined (Beintem a et al., 1988). C om parison of this 
sequence w ith  that o f non secretory ribonucleases from  hum an liver 
(Sorrentino et al., 1988) and bovine kidney (Irie et al., 1988) shows 
that they are very closely related. Both the hum an urine and bovine 
kidney non secretory ribonuclease show approxim ately 30% hom ology 
w ith  secreted m am m alian ribonucleases. O n the basis o f  this am ino 
acid sequence data, m am m alian secretory ribonucleases, hum an urine 
non secretory ribonuclease, turtle pancreatic ribonuclease and hum an 
angiogenin (see Section 1.4.6 for a b rief discussion o f this 
vascularising protein) have been grouped into a ribonuclease 
" superfam ily".
The precise function o f the non secretory ribonucleases is 
unclear. H ow ever, among these ribonucleases are a group of 
intracellular enzym es for which a regulatory role in  R N A  m etabolism  
has been proposed. This hypothesis is based on the association o f 
these ribonucleases with the endogenous ribonuclease inhibitor
(review ed by Blackburn and M oore, 1982). B riefly, the ribonuclease- 
inhibitor com plex m ay determine the rate o f R N A  degradation and thus 
the rate o f protein biosynthesis. Tissues characterised by  high rates o f 
R N A  synthesis have an excess o f inhibitor p resent w hereas tissues 
w ith  h igh  levels o f R N A  catabolism  have an excess o f free 
ribonuclease present. A lso, "latent" ribonuclease activity, i.e. w here 
the ribonuclease is bound to the inhibitor, can be activated depending 
on the physiological state o f a particular cell. A  detailed discussion o f 
the ribonuclease inhibitor and its possible role in  regulating RN A  
m etabolism  is presented in Section 1.4
1.3.2 A S S O C IA T IO N  O F  R IB O N U C L E A S E S  W IT H  T H E  
IN H IB IT O R  IN  V IV O
The intracellular ribonucleases associated w ith the endogenous 
inhibitor have not been thoroughly characterised due to the sm all 
quantities available within the cell. How ever, studies w hich were 
carried out revealed that m ore than one ribonuclease activity is bound 
to the inhibitor e.g. tw o peaks o f latent ribonuclease activity  were 
observed after anion-exchange chrom atography o f intact ribonuclease- 
inhibitor com plexes from  rat reticulocyte (A oki et al., 1981) and from  
m ouse skeletal m uscle (Little and W hittingham , 1981). A  variety of 
cytoplasm ic ribonucleases were partially purified from  porcine thyroid 
and separated by gel filtration (Button et al., 1982). The m ajor 
ribonuclease activity was attributed to a species w ith a relative 
m olecular m ass (Mr) of 51,000 Daltons. The rem ainder o f the activity 
corresponded to several species w ith M r ranging from  13,000-28,000 
Daltons. A ll of the ribonuclease activities w ere inhibited by  the 
endogenous inhibitor. B lackburn et al., 1982 proposed that the
ribonucleases associated w ith the inhibitor in vivo should resem ble 
pancreatic RNase A  in  order to interact w ith  the inhibitor and 
therefore it is surprising that the inhibitor inactivated the high 
m olecular w eight species purified  by Button et al., 1982.
M ore recently, several groups have purified ribonucleases that 
associate w ith  the inhibitor in vivo. A n inhibitor-associated 
cytoplasm ic type I ribonuclease was first purified to hom ogeneity 
from  rat liver by K um agai et al., (1983). The enzym e was isolated by 
obtaining the ribonuclease-inhibitor com plex, inactivating the 
inhibitor w ith CdCl2 , then purifying the enzym e using ion-exchange 
chrom atography. Sufficient am ounts o f the ribonuclease were obtained 
to  allow characterisation o f the enzym e. It w as found to be  a  heat- 
stable protein w ith a M r of 16,000 Daltons and a pH  optim um  o f 7.5-
8.0. The enzym e was found to be different from  rat pancreatic 
ribonuclease in  that it preferentially cleaved poly(C) over poly(U ).
The authors also reported the presence o f a second, m inor species o f 
ribonuclease at an early stage in  the purification procedure but this 
species w as no t further characterised.
K now ledge of the intracellular endoribonucleases was further 
enhanced w hen Brockdorff and K now ler (1987) purified two 
inhibitor-associated ribonuclease activities from  rat liver and three 
activities from  rat utem s using a m ore rapid purification procedure 
than  K um agai et al., (1983). The m ain peak of activity from  the rat 
liver (RLC I) was purified to hom ogeneity and characterised by 
determ ining its substrate preference and pH  optima. This revealed that 
it is sim ilar to the ribonuclease purified by K um agai et al.,(1983).
T he other activity purified from  rat liver (RLC II) by B rockdorff and 
K now ler differed from  RLC I in  that R LC II preferred yeast R N A  to
poly(C) and the pH  optim a was different. Tw o of the activities 
purified  from  the rat uterus also preferentially degraded poly(C). The 
th ird  activity (RUC HI) degraded poly(U) preferentially.
U sing a technique sim ilar to that o f B rockdorff and Know ler, tw o 
m ajor and a  num ber of m inor species o f ribonuclease activities were 
isolated from  the hum an placenta by B lackburn (personal 
com m unication). The two m ajor activities w ere purified to 
hom ogeneity and characterised. One activity was determ ined to  be 
sim ilar to hum an pancreatic ribonuclease while the other resem bled the 
ribonuclease isolated from  hum an liver.
1.4 TH E CY TO PLASM IC RIBONT TCI .EASE IN H IB IT O R
In  general, 90-95% of the type I endoribonucleases are present in  
the cell cytoplasm  in an inactive 'latent' form  due to their association 
w ith  an endogenous inhibitor. The presence o f this inhibitor in  the 
h igh  speed supernatant fraction prepared from  guinea pig liver w as 
first reported by Pirotte and D esreux in  1952. M ost m am m alian 
tissues have since been found to contain sm all am ounts o f the 
ribonuclease inhibitor in the cytoplasm . The inhibitor appears to be  an 
alm ost ubiquitous feature in nature as in  addition to m am m alian , it 
has been reported in am phibian (M alicka-Blaskiewicz, 1978), avian 
(Kraus and Scholtissek, 1974) and insect (Aoki and N atori, 1981) 
tissu es.
Prelim inary studies w ere carried out on partially purified inhib itor 
from  rat liver by Roth (1956, 1962) and Shortm an (1961, 1962) w ho 
dem onstrated that it was a heat- and acid- labile protein. The activity 
o f the protein was dependent upon the integrity of one or m ore SH  
groups as it was inactivated by either sulphydryl blocking reagents
e.g. p-hydrom ercuribenzoate (pHM B) or by heavy m etals e.g. 
m ercury and lead. In  addition, inactivation o f the inhib itor by 
sulphydryl blocking reagents resulted in  the release o f  active 
ribonuclease w hich had  been  bound to the inhibitor in  a  latent form. 
The partially  purified inhibitor did not inhibit acid lysosom al 
ribonuclease bu t was specific Tor neutral ribonucleases o f the 
pancreatic type.
1.4.1 PU R IFIC A T IO N  O F TH E R IB O N U C L E A SE  
IN H IBITO R
The ribonuclease inhibitor was initially purified from  rat liver by 
a com bination of am m onium  sulphate precipitation o f the high speed 
supernatant fraction o f isotonic extracts o f tissue, ion-exchange 
chrom atography and gel filtration (Gribnau et al., 1969). Purification 
to  hom ogeneity was achieved w ith the introduction o f an affinity 
chrom atography step (RNase A  coupled to CM -cellulose) as the final 
stage o f purification (G ribnau et al., 1970). This procedure was 
sim plified by  rem oving the ion-exchange chrom atography and gel 
filtration steps which resulted in the rapid purification o f an alm ost 
hom ogenous preparation o f inhibitor (Gagnon and de Lam irande, 
1973). B lackburn et al. (1977) obtained a hom ogenous preparation o f 
inhibitor from  the hum an placenta using ion-exchange chrom atography 
and affinity chrom atography on RNase A -Sepharose 4B. This 
purification procedure was sim plified by utilising only am m onium  
sulphate precipitation and affinity chrom atography (B lackburn, 1979) 
and high yields of hum an placental ribonuclease inhibitor were 
obtained (40-60% ). Using a sim ilar approach to that o f B lackburn
(1979), the inhibitor has been purified to hom ogeneity from  bovine 
brain  (Burton, 1980), the livers o f various m am m alian species 
(Burton and Fucci, 1982) and rat testes (Fom inaya et al., 1988a).
The ribonuclease inhibitor is generally assayed by  its ability to 
inhibit bovine pancreatic RN ase A. One unit o f activity  is usually 
defined as the quantity required to inhibit the digestion o f 5ng R N A  
w ith  RN ase A  by 50%.
1.4.2. G EN ER A L C H A R A C TER ISTIC S O F TH E  
R IB O N U C L E A SE  INH IBITO R
U sing purified preparations o f the inhibitor, fu rther 
characterisation o f the protein has been carried out and  it appears that 
the ribonuclease inhibitor from  different species and tissues show 
several com m on characteristics. The inhibitor is an acidic protein 
(Blackburn, 1977; Fom inaya et al., 1988a) w ith  an isoionic poin t (pi) 
ranging from  4.6 for the hum an placenta to 5.1 for the rat testes. 
O ptim al activity o f the inhibitor occurs at pH 7.5-8.0 and  the activity 
is greatly decreased at pHs above 8.5. The relative m olecular m ass 
(M r) o f the inhibitor is circa 50,000 D altons, as determ ined by bo th  
SDS polyacrylam ide gel electrophoresis and gel filtration which 
indicates that it is a single polypeptide chain. W hen a com plex o f 
ribonuclease inhibitor and bovine pancreatic RN ase A  is subjected to 
gel filtration, the M r o f the com plex is approxim ately 64,000 D altons 
w hich suggests a 1:1 com bination of the com plex w ith RNase A  on a 
m olar ratio (Blackburn, 1977; Burton and Fucci, 1982). Native bovine 
brain  ribonuclease com plexed to its inhibitor gave a sim ilar result 
(Burton et al., 1980) thus indicating that the intracellu lar 
ribonuclease has a relative m olecular m ass sim ilar to that of
R N ase A  (about 14,000 Daltons).
The inhibitor has also been detected in non-m am m alian sources 
e.g. chick em bryo cells (Kraus and Scholtissek, 1974), rooster liver 
(D ijkstra et al., 1978), the insect Ceratitis capitata (G arcia-Segura 
et al., 1985) and am phibian liver (M alicka-Blaskiew icz, 1978). 
H ow ever, it has not been characterised as extensively as that from  
m am m alian sources. A ll o f the inhibitors from  the non-m am m alian 
sources appear to depend upon the m aintenance o f free sulphydryl 
groups, a characteristic shared by  their m am m alian counterparts. The 
inhibitor from  chicken liver has no inhibitory activity against 
m am m alian ribonucleases but it  does inhibit chicken type I 
ribonuclease (Dijkstra et al., 1978) w hich suggests that the inhibitor 
m ay be species specific.
Studies have been carried out to determ ine the K^ value o f the 
inhibitor and its m ode of inhibition (Turner et al., 1983; Fom inaya et 
al., 1988b and references therein). T urner utilised the m ethods of 
D ixon to determ ine the type of inhibition and also to determ ine the 
approxim ate K j values fo r the interactions o f porcine thyroid  and liver 
inhibitors w ith RNase A. The D ixon plot show ed com petitive 
inhibition w ith K j values o f 0.4nM  for liver and 0. In M  for thyroid. 
Analysis o f the steady state velocities by the m ethods o f H enderson 
and Bacci also showed that the porcine thyroid and liver ribonuclease 
inhibitors in teract with RNase A  by tight binding kinetics. In 
addition, Turner et al. showed that the inhib itor is o f the slow 
binding type as the initial rate depended upon  w hether the enzym e or 
the substrate was used to start the reaction. M ore recently, Fom inaya 
et al., (1988b) described a general treatm ent w hich descim inates 
betw een the different types o f inhibition and allows the calculation of
inhibition  param eters, using ribonuclease inhibitor purified from  rat 
testes as an exam ple o f a tight-binding inhibitor. They obtained a K j 
value o f 3.22x10"-^ M  w hich is several orders o f m agnitude low er 
than  tha t obtained by B lackburn et al., (1977), B urton et al., (1980) 
and T urner et al., (1983). The discrepancy in  results betw een Turner 
et al. and Fom inaya et al. (who both analysed the kinetics of 
ribonuclease inhibitor w ith procedures designed for tight binding 
inhibitors) m ay be explained as Turner et al. em ployed m uch higher 
concentrations of inhibitor and their protein preparations were im pure. 
Thus, the K j values fo r porcine inhibitor m ay be m uch low er than 
reported.
The inhibition o f R N ase A  by  the ribonuclease inhibitor has been  
w ell-studied (Blackburn et al., 1977; B urton et al., 1980) and the 
m echanism  has been defined by  M ichaelis-M enten kinetics as pure, 
linear, non-com petitive inhibition. H ow ever, inspection of the 
pertinent literature shows that the kinetic analyses o f the 
ribonuclease:inhibitor system  was carried out w ith an 
. enzyme-.inhibitor m olar ratio o f 1 i.e. the m ajority  o f the inhibitor 
m olecules were present as a com plex w ith RN ase A. A lso, the K m  
values w ere several orders of m agnitude greater than the K j values 
and, under these conditions, L inew eaver-Burke plots invariably 
indicate non-com petitive inhibition, although the inhibition m ay be 
otherw ise. Further, studies carried out on the residues present at the 
active site o f RNase A  (Blackburn and Jailkhani, 1979; B lackburn and 
G avilanes, 1980) show ed that m odification o f only one am ino acid, 
Lys-41, altered the binding of inhibitor to the enzym e and this was 
in terpreted to support the idea o f non-com petitive inhibition. T urner 
et al., (1983) proposed that this data was m ore suggestive of 
com petitive inhibition as com petitive inhibition involves the binding
o f the inhibitor to the enzym e in such a way that catalysis is prevented 
through the active site being entirely or partially blocked. Sim ilar 
kinetics result if  binding o f the inhibitor produces a conform ational 
change w hich alters the positioning o f the residues involved in either 
catalysis or binding o f substrate. In  addition, Turner states that if  the 
inhibition of RNase A  by the inhibitor is non com petitive then, in 
theory, the inhibitor should be able to com bine w ith both  free enzym e 
and enzym e:substrate com plex. In  practice, the RNase A :inhibitor 
com plex is readily available whereas a com plex of RNase 
A :inhibitor:RN A  has not been  isolated.
Recently, Fom inaya et al., (1988b) suggested that to describe the 
regulation o f inhibitory activity in  terms o f com petition w ith 
cytoplasm ic RNA for ribonuclease binding is not biologically 
m eaningful. Instead they suggest that the activity o f the inhibitor in 
vivo m ay be regulated through som e m odulation system w hich 
controls the reversibility o f the inhibition equilibrium . They further 
propose that such a m odulation system  could be the G SSG /G SH  
(oxidised/reduced glutathione) w hich is know n to be a cytoplasm ic 
th io l buffer. This proposal is based upon the observation that all 
ribonuclease inhibitor proteins contain essential free th iol groups and 
all are inactivated by thiol blocking reagents.
1.4.3 AM INO ACID AN A LY SIS OF R IB O N U C L E A SE  
IN H IBITO R
The amino acid com position has been determined from  hum an 
placenta (Blackburn et al., 1977), bovine brain  (Burton et al.,
1980), the livers o f five m am m alian species (Burton and Fucci, 1982)
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TABLE 1.1 AMINO ACID COMPOSITION OF MAMMALIAN 
RIBONUCLEASE INHIBITORS
This table illustrates the degree of conservation o f amino acid 
com position am ong m am m alian ribonuclease inhibitors. The data was 
obtained from  the follow ing sources:
1. Fom inaya et al., 1988a
2. B urton and Fucci, 1982
3. B urton et al., 1980
4. B lackburn  et a\., 1977
RESID U ES/M O LECU LE
1 2 3  14-
A M IN O  ACID Rat testis R at liver Bovine brain H um an placenta
A sx 55 59 43 47
Thr 25 23 20 16
Ser 42 43 40 45
G lx 61 60 65 64
G ly 40 33 53 36
A la 30 29 38 34
V al 20 22 22 24
M et 2 2 2 2-3
Be 13 10 9 12
Leu 66 89 88 85
T yr 8 5 5 4
Phe 7 5 3 6
His 7 6 5 6
Lys 18 20 15 17
A rg 23 20 20 23
Cys 31 31 30 30
Trp n.d. 5 5 5
and rat testes (Fom inaya et al., 1988a). As can be seen from  Table
1.1, all ribonuclease inhibitors from  these different sources have a 
very sim ilar am ino acid com position. O f special note is the high 
content o f hydrophobic residues, especially leucine. It is also 
apparent that the inhibitor proteins contain a h igh  level o f cysteine and 
1/2 cyst ine residues (31 per m olecule). Initially, it w as calculated 
that 8 o f these were present as free sulphydryl groups (B lackburn et 
al., 1977). H ow ever, this figure has since been am ended to 
approxim ately 25 (Blackburn, personal com m unication).
The data obtained from  the amino acid com position suggests that 
there has been  a degree of evolutionary conservation, at least in  
m am m als. The data also predict : that the prim ary sequence of the 
inhibitors w ould be hom ologous. However, B urton and Fucci (1982) 
raised antiserum  against hum an placental ribonuclease inhibitor and, 
using this antiserum , show ed that the im m unological cross reactivity 
betw een hum an placental inhibitor and a variety o f m am m alian liver 
inhibitors w as relatively low. This suggests that either there m ay be 
significant variations in  the prim ary structure o f ribonuclease 
inhibitors from  different species or the hum an placental inhibitor 
differs from  the liver inhibitors.
Very recently, and tow ards the end o f the study described in  the 
results section o f this thesis, the nucleotide sequence o f  hum an 
ribonuclease inhibitor (Schneider et al., 1988; Lee et al., 1988) and 
the amino acid sequence of inhibitor from  both hum an p lacenta and 
porcine liver becam e available (Lee et al., 1988; H ofsteenge et al.,
1988). H ofsteenge et al., (1988) determ ined the am ino acid  sequence 
o f ribonuclease inhibitor purified from  porcine liver. D igestion  o f  the 
protein w ith cyanogen brom ide resulted in  the isolation o f three 
peptides (CB1, CB2 and CB3). Sequence analysis o f CB1 revealed
that the N  term inus of the inhibitor is b locked w ith an acetyl group. 
Overlapping sequence was obtained by  digesting each o f the peptides 
w ith  either trypsin or V8 protease from  S. aureus and also by 
digesting the whole protein w ith the sam e enzym es. Thus, the to tal 
am ino acid sequence was obtained.
The prim ary amino acid sequence of porcine liver ribonuclease 
inhibitor revealed that the protein exhibits a  considerable am ount o f 
internal hom ology. Two different types o f in ternal repeat were 
apparent w hich occurred alternatively. The type A  repeat was 29 
am ino acids long whereas the type B repeat w as 28 am ino acids. B oth 
repeats w ere rich in leucine residues w hich w ere present at constant 
positions.
The am ino acid sequence o f inhibitor from  hum an placenta has 
also been determ ined (Lee et al.,1988) by sequencing o f tryptic 
digests o f the protein. The ribonuclease inhib itor from  hum an placenta 
has a stretch o f 5 amino acids m ore at the N  term inus than the pro tein  
isolated from  pig. The placental inhibitor also has a  blocked N  
term inal and has seven direct internal repeats, each 57 am ino acids in  
length.
The prim ary structure o f ribonuclease inhibitor is sim ilar to six 
other proteins o f diverse function w hich contain leucine-rich repeats: 
a subunit o f hum an platelet glycoprotein lb  (T itani et al., 1987;
Lopez et al., 1987); hum an leucine-rich glycoprotein of unknow n 
function (Takahashi et al., 1985); hum an fibroblast proteoglycan core 
protein  (Krusius and Ruoslahti, 1986; Patthy, 1987);yeast adenylate 
cyclase, a mem brane-bound enzyme that converts ATP into cAM P 
(K ataoka et al., 1985); Drosophila Toll p ro tein  (H ashim oto et al.,
1988) and Drosophila chaoptin (Reinke et al., 1988). The
ribonuclease inhibitor appears to be  unique as it is the first 
cytoplasm ic protein w ith such a repeat. It has been suggested that this 
leucine-rich repeat is im portant in m em brane binding (Takahashi et 
al., 1985; H ashim oto et al., 1988). H ow ever, early  studies on the 
inhibitor (Roth, 1956) have show n that little  inhib itor activity is 
associated w ith  m em brane fractions. Thus, the leucine-rich repeats 
m ay form  structures that have other functions e.g. protein-protein 
interactions. Adenylate cyclase, glycoprotein lb  and inhibitor are all 
know n to b ind  to other proteins.
It is interesting to note that ribonuclease inhibitor binds w ith a 
1:1 stoichiom etry which suggests that the binding site fo r 
ribonuclease does not correspond to  a single leucine-rich repeat b u t is 
form ed by a structure resulting from  an interaction o f the repeats in 
the protein. O ther proteinase/proteinase inhibitor interactions show  a 
relationship betw een the stoichiom etry and the num ber o f domains 
e.g. adzuki bean inhibitor I  binds to two m olecules o f trypsin and the 
inhibitor has two homologous repeated dom ains (Y oshida and 
Y oshikaw a, 1975; K iyohara et al., 1981).
1.4.4 IN TER A C TIO N  OF TH E IN H IBITO R  W IT H  RN ASE A
The interaction o f the inhibitor w ith RN ase A  has been well- 
studied. Specific proteolytic cleavage o f R N ase A, w hich rem oved 
parts o f the active site, was perform ed and the resultant derivatives 
assayed for inhibitor binding by com petition binding assays 
(B lackburn and Jailkhani, 1979). The results dem onstrated that the 
active site residues, H is-112 and H is-119, and the auxiliary residues 
Lys-7, Phe-120, A sp-121 and Ser-123 are no t essential for the
TABLE 1.2 CONTACT POINTS OF RNASE A  W ITH 
RIBONUCLEASE INHIBITOR
The three regions on RNase A  w hich are thought to  interact w ith the 
inhibitor are shown. The data was obtained from  B lackburn and 
G avilanes, 1982.
G roup A
G roup B
G roup C
Lys-7, Lys-41, Pro-42, V al-43,Lys-91, Tyr-92 and 
Pro-93
L ys-31 and Lys-37
Lys-61 and surrounding residues
interaction o f RNase A  w ith the inhibitor. A lso, the rem oval o f the 
residues 1 to 20 inclusive did no t affect the binding w ith  inhibitor.
Specific chem ical m odifications o f amino acid side chains on the 
enzym e show ed that four arginine residues are not involved in b inding 
R N ase A  to the inhibitor (B lackburn and G avilanes, 1980). H ow ever, 
m odifications m ade to lysines indicated that these residues are 
im portant for the interaction. W hen the inhibitor is bound to R N ase A, 
the enzym e is protected from  inactivation by reagents w hich are 
know n to inactivate RN ase A  by  reaction at Lys-41. M oreover, 
specific m odifications of Lys-41 decreased the in teraction w ith the 
inhibitor by  90%. Thus this residue appears to be involved in  the 
interaction w ith the inhibitor.
The ability o f the chem ically-m odified derivatives to  bind 
placental inhibitor was also m onitored by circular dichroism  (CD).
The CD m easurem ents suggested that at least one tyrosine residue o f 
R N ase A  is involved in  binding the enzym e to the inhibitor. A  
com parison of the ability o f several different m am m alian pancreatic 
ribonucleases to bind hum an placental inhibitor was carried  out to 
determ ine w hich tyrosine residue(s) was involved. The binding o f the 
different ribonucleases w ith inhibitor were very sim ilar and, as Tyr- 
92 is the only tyrosine residue to be retained in  all o f the species 
studied, it was concluded that this residue m ay play an im portant role 
in  the interaction. Carboxym ethylation of the active site residue H is- 
119 increases the binding o f enzym e to inhibitor (B lackburn and 
G avilanes, 1980) and it is thought that this m odification renders Tyr- 
92 m ore accessible for interaction of RNase A  w ith inhibitor.
From  X -ray analysis o f R N ase A and from  the above data, the 
contact points with the inhibitor can be placed into 3 groups (Table 
1.2). Groups A  and B are adjacent, whereas group C lies distal to
both groups. It is proposed that there is extensive contact betw een the 
inhibitor and RNase A  w ith  the inhibitor m olecule w rapping around 
the R N ase A  molecule, leaving the active site cleft exposed.
As m entioned in  the previous section, am ino acid analyses has 
show n that there are 31 cysteine and 1/2 cyst ine residues per 
m olecule of ribonuclease inhibitor. A ddition o f reagents w hich react 
w ith sulphydryl groups results in  both inactivation o f inhibitor and 
dissociation of the ribonuclease:inhibitor com plex. These observations 
suggest that free sulphydryl groups m ay play an essential role in  the 
binding o f inhibitor to ribonuclease. W ork carried out by  B lackburn 
(personal com m unication) show ed that o f the 25 free sulphydryl 
groups o f hum an placental inhibitor, at least 12 are exposed to the 
solvent and react readily w ith alkylating reagents. O f 4-6 of the m ost 
rapidly reacting sulphydryl groups, 2 appear to be m ost im portant for 
fu ll inhibitor activity.
1.4.5 FU N C TIO N  O F TH E R IBO N IIC LEA SF IN H IB IT O R
It is clear that cellular ribonucleases cannot be catalytically 
unrestrained or all rRNA, tRN A  and m RN A  w ould be subject to 
uncontrolled degradation. The two known classes o f m am m alian 
cellular ribonucleases (described in Section 1.3) are kept under 
control either by com partm entation, as w ith the localisation o f type II 
enzym es in  lysozom es, or by the ribonuclease inhibitor protein. 
H ow ever, this raises the question what controls the release o f type I 
ribonuclease from  its inhibitor or for that m atter the entry o f RN A  
and/or RNA-containing subcellular particles into lysozom es? There are 
tw o m ain possibilities neither o f which are m utually exclusive. On the
one hand, changes to the structure, com partm entation or 
m acrom olecular associations o f RN A  m olecules could m ake them  m ore 
vulnerable to low  levels o f unrestrained enzym e. A lternatively, the 
levels o f available enzym e could be controlled fo r instance by changes 
in  the relative levels o f the enzym e and its inhibitor.
There are several lines o f evidence w hich suggest that the 
interaction betw een ribonuclease inhibitor and ribonuclease m ay play 
an im portant role in the control o f RNA m etabolism  and the regulation 
o f cell grow th and differentiation. In  general, tissues w hich are 
characterised by high rates o f RN A  synthesis and accum ulation have 
increased ratios o f inhibitor to ribonuclease activities i.e. there is an 
excess o f unbound inhibitor in  these system s. T he ribonuclease 
inhibitoniibonuclease ratio is increased in regenerating rat liver 
(M oriyam a et al., 1969), in thyroid-stim ulating horm one (TSH) 
treated rat thyroid relative to norm al glands (G rief and Eich, 1972), in  
developing and lactating rat m am m ary gland (Liu et al., 1975), in  
oestrogen-stim ulated rooster liver (Djikstra et al., 1978) and in  
m itogen-stim ulated lym phocytes (Kyner et al., 1979).
The aforem entioned tissues i.e. liver, thyroid and m am m ary gland 
are associated with the synthesis o f m ajor abundant proteins e.g. 
album in and other serum  proteins are synthesised in  the liver and the 
m ajor m ilk  proteins are synthesised in  the lactating m am m ary gland. 
O ther exam ples of tissues involved in synthesising m ajor abundant 
proteins are reticulocytes (Aoki et al., 1981) w here globin proteins 
are synthesised, calf lens (Ortworth and Byrnes, 1971) w here alpha- 
crystallin is synthesised and skeletal m uscle (Little and W hittingham , 
1981) w here the m ajor m uscle proteins are synthesised. A ll of these 
tissues have been shown to contain high levels o f unbound inhibitor 
and this is further evidence that the ratio o f inhibitor to ribonuclease
m ay be im plicated in the m etabolism  of RNA.
Conversely, tissues w ith decreased levels o f protein  synthesis and 
increased catabolic activity dem onstrate low er inhibitor and elevated 
ribonuclease activities. Exam ples o f this phenom ena include the 
m uscle o f dystrophic m ice com pared to norm al m ice (Little and M eyer, 
1970), the liver o f rats after adrenalectom y (Lui and M atiisian, 1977) 
and several tissues of the rat during aging (Chesters and W ill, 1978). 
T issues w hich are not associated w ith the synthesis o f m ajor abundant 
proteins e.g. lung, spleen and kidney have low  levels o f ribonuclease 
activity  (Brockdorff, PhD thesis, 1985).
Studies carried out by Sajdel-Sulkow ska and M arotta (1984) 
suggested that there is an increase in  free alkaline ribonuclease 
activity and a  corresponding decrease in  the level o f inhibitor in  the 
brains o f A lzheim er's-diseased (AD) patients relative to norm al brain. 
A n increase in ribonuclease activity m ay result in  an increase in  the 
rate  of degradation o f R N A  w hich w ould lead to a decrease in protein  
synthesis, a know n sym ptom  o f A lzheim er's disease. H ow ever, Jones 
and K now ler (1989) m easured the activity o f total and free 
ribonuclease and ribonuclease inhibitor from  various pathologically 
affected and unaffected regions o f both AD brain and age-m atched 
controls and dem onstrated that there are no observable differences in  
the levels o f ribonuclease and inhibitor betw een the brains of patients 
suffering from  AD and control brains. The results o f Jones and 
K now ler are in agreem ent w ith those o f two other groups who w ere 
also unable to demonstrate any differences in ribonuclease levels in 
A D  and norm al brains (Guillem ette et al., 1986; M orrison et al.,
1987)
There are deviations from  the general rule that increased protein
synthesis results in an increased ratio of inhibitor to ribonuclease e.g 
hepatom as of the rat liver. In  general, hepatom as are characterised by 
increased growth and cellular proliferation and it w ould  be expected 
that this m ay result in an increased ratio of inhibitor to  ribonuclease. 
Indeed the level o f free inhibitor in  Dunning hepatom a and the M orris 
7288C hepatom a is h igher than that found in norm al ra t liver (Roth, 
1967). How ever, the level o f free inhibitor in N ovikoff hepatom a 
(Gauvreau et al., 1974) and the M orris 4123D hepatom a (Roth, 1967) 
is reduced com pared to norm al liver. Thus, there does n o t appear to 
be a clear cut relationship betw een the level o f free inhib itor and 
increased growth in rat liver hepatom as.
A nother exception to the rule that tissues w ith increased levels o f 
protein synthesis have a h igh  ratio o f inhibitor to ribonuclease is the 
rat uterus. In the uterus o f the im m ature rat, the level o f free inhibitor 
is sim ilar to that in rat liver i.e. the inhibitor is present in excess over 
ribonuclease. Treatm ent w ith oestrogen (M cGregor et al., 1981; 
B rockdorff and Knowler, 1986) or during the course o f norm al 
developm ent (Munro and Know ler, 1982) results in  the loss o f 
inhibitor activity. These effects are due to the action o f oestrogen as 
ovariectom y of m ature anim als results in the partial restoration of 
inhibitor activity (Zan-Kow alszew ska and Roth, 1975). The 
m echanism  by which oestrogen decreases ribonuclease inhibitor 
activity was determined by B rockdorff and K now ler (1986) by  raising 
anti-serum  to purified rat liver ribonuclease inhibitor to  quantitate the 
total levels o f this protein in  uterine preparations. They found that 4  
days after treatm ent w ith oestrogen the total level o f inhib itor had  
increased approxim ately 1.5 fold whereas cytoplasm ic ribonucleases 
increased approxim ately 7 fold. Thus the free inhibitor becom es 
saturated w ith ribonuclease and inhibitor activity is observed to
decrease.
A t present, the reasons for these deviations from  the general rule 
are no t fully understood. The horm one-stim ulated uterus and 
hepatom a cells are undergoing rapid growth and cell differentiation.
In  this situation, increased ribonuclease activity m ay be required to 
degrade the m RN A  of transiently expressed proteins w hich are 
involved in  the cell cycle. The other system s in  w hich ribonuclease 
has been  studied have been  fully differentiated tissues e.g. brain, 
k idney and liver. As m entioned, these tissues are involved in  the 
synthesis o f m ajor abundant proteins and the m R N A  encoding these 
proteins has been found to be relatively stable and therefore 
ribonuclease activity m ay not be required. K raft and Shortm an 
(1970 ) suggested that the heterogeneity o f cell types w ithin  a given 
tissue m ay account fo r the deviations from  the general rule. This is 
exem plified by the rat kidney (Lui and M atrisian, 1977) w here there is 
no  observable inhibitor activity in  total kidney or k idney cortex 
preparations. How ever, free inhibitor is observed in  red  or white 
m edulla preparations.
Further evidence that the inhibitor plays an essential role in the 
control o f R N A  m etabolism  and protein synthesis includes the 
observation that ribonuclease inhibitor stabilises m R N A  in  cell-free 
translation system s, thus increasing the size o f the polypeptides 
synthesised (Robbi and Lazarow , 1978; Scheele and B lackburn,
1979). A lso, addition o f ribonuclease inhibitor to in vitro 
transcription system s im proves the synthesis o f RN A  (E ichler et al.,
1981) and improves the yield o f high m olecular w eight cD N A  obtained 
in  reverse transcription system s (de M artinoff, 1980). M oreover, 
polysom e stability is enhanced in the presence o f inhibitor. Isolation
o f intact polysom es is easier from  tissues w ith high endogenous levels 
o f  inhibitor (Blobel and Potter, 1966; Takahashi et al., 1966) and can 
be im proved in  m any tissues by exogenous addition o f inhibitor 
(B urghouts et al., 1970).
As m entioned in Section 1.4.2, it has been proposed that the 
ribonucleaserribonuclease inhibitor system  m ay be regulated through a 
m odulation system  in vivo (Fom inaya et al., 1988b) w hich m ay 
control the reversibility o f the inhibition equilibrium . The authors 
propose that the GSSG /G SH system  (oxidised/reduced glutathione), a 
know n cytosolic thiol group buffer, m ay be involved in  the regulation 
o f the system . It has been show n that oxidised glutathione reversibly 
inactivates the inhibitor from  hum an placenta (B lackburn, personal 
com m unication). A  relationship betw een inhibitor and oxidised 
glutathione has been im plied in vivo as calf lens cataractogenesis is 
accom panied by decreased inhibitor and increased ribonuclease 
activity (M aione et al., 1968), together w ith increased levels o f 
oxidised glutathione (Reddy et al., 1976). As yet, there is no 
. evidence that a sim ilar system  is operative in  other tissues.
R ibonuclease and ribonuclease inhibitor activities are associated 
w ith  free m R N P particles of the hum an p lacenta (G ileadi et al., 1984) 
and it is possible that a function o f the com plex m ay be to  control the 
expression and turnover o f mRNPs. H ow ever, less than  1% of the 
to tal inhibitor o f placental cytoplasm  is associated w ith m RN P 
particles a finding which raises some doubt about the significance o f 
this data. A t present, it is unknow n if  the ribonuclease:inhibitor 
com plex is also associated with polyribosom e m RN Ps.
A n alternative hypothesis as to the function of the ribonuclease 
inhibitor is that it possibly acts as a scavenger protein, inhibiting type 
I ribonucleases that m ay be taken up into cells from  serum  or released
from  intracellular organelles. This hypothesis results from  the finding 
that there are a num ber o f endo- and exoribonucleases w hich occur in 
the ribosom al fraction o f eukaryotic cells w hich are thought to be 
involved in  the degradation o f m RN A  in eukaryotes bu t which are 
insensitive to the inhibitor (Reboud et al., 1976; K um agai et al., 
1985a,b).
1.4.6 A SSO C IA TIO N  OF R IBO N IICLFASK  IN H IBITO R  
W ITH  ANOTOOENTN
R ecently it has been suggested that, in addition to controlling 
cytoplasm ic ribonucleases, the inhibitor m ay also be involved in the 
regulation o f angiogenesis (Shapiro and V allee, 1987). A ngiogenin is 
a protein that induces b lood vessel grow th (Fett et al., 1985) and has 
been isolated from  tum our cell conditioned m edium  and from  hum an 
plasm a (Fett et al., 1985; Shapiro et al., 1987). The prim ary 
structure o f angiogenin is approxim ately 35%  identical w ith hum an 
pancreatic ribonuclease (Strydom  et al., 1985). A ngiogenin exhibits 
relatively low  ribonucleolytic activity, w ith a specificity different 
from  that o f pancreatic ribonuclease. A ngiogenin catalyses the lim ited 
cleavage o f 28S and 18S rR N A  into products o f 100-500 nucleotides 
long and its prim ary function is probably not as a ribonuclease. A lso, 
the role o f angiogenin as an angiogenic factor has also been 
questioned (M arx, 1987).
On the basis of angiogenin's structural and catalytic sim ilarity 
w ith  pancreatic ribonucleases, the interaction o f angiogenin w ith 
hum an placental ribonuclease inhibitor was investigated. A ngiogenin 
was found to bind tightly to the inhibitor and this results in the
inhibition o f both its angiogenic and ribonucleolytic activities 
(Shapiro and Vallee,1987). Angiogenin and placental ribonuclease 
inhibitor form  a very tight 1:1 com plex and the value has been 
calculated to be 7.1x10" -^M , w hich is approxim ately 60 tim es low er 
than  that fo r bovine pancreatic RNase A  (Lee et al., 1989). As w ith 
bovine pancreatic RNase A, the inhibition o f angiogenin is reversible 
as addition o f pHM B dissociates the com plex to yield active 
angiogenin.
As described in Section 1.4.4, B lackburn and coworkers 
suggested that there are 3 contact regions fo r ribonuclease inhibitor in  
the 3-D structure of RNase A: 1) Lys-7, Lys-41, Pro-42, V al-43, 
Lys-93, T yr-92 and Pro-93; 2) Lys-31 and Lys-37 and 3) Lys-61 and 
adjacent residues. In these regions RNase A  and angiogenin are very 
sim ilar and therefore it m ay be expected that both  enzym es w ill b ind 
p lacental inhibitor w ith com parable avidity. As m any o f these residues 
are outw ith the active centre, the conservation o f residues necessary 
fo r enzym atic activity alone cannot account for the strength of the 
interaction. This implies that the capacity o f angiogenin to bind 
p lacental inhibitor has been m aintained independently during 
evolution. Notwithstanding doubts about the true function of 
angiogenin, it would therefore seem  plausible that binding of inhibitor 
reflects a physiologically relevant control m echanism .
C H A PTER  TW O  
M A TER IA LS AND M E T H O D S
2.1 L IST  OF SU PPLIE R S
A ll chem icals used were o f analytical grade and w ere obtained from  
B D H  Chemicals Lim ited , Form achem  (Research International) L im ited 
or Fisons Scientific Apparatus. W here chem icals and equipm ent were 
obtained from  other sources, this is indicated in  the text. A  list o f the 
suppliers is given below .
Am ersham  International pic, W hite Lion Road, A m ersham , Bucks HP7 
9LL
BD H  Chemicals Lim ited, Poole, Dorset, England.
Boehringer-M annheim , BCL, Boehringer M annheim  House, B ell Lane, 
Lew es, East Sussex.
Jam es B urrough Lim ited, 70 Eastw ays Industrial Park, W itham , Essex. 
Cam bridge B iotechnology Labs., 12-14 St. A nn’s Crescent, L ondon 
SW18
D ifco Laboratories, D etroit, M ichigan, U .S.A .
Fisons Scientific Apparatus Ltd., Loughborough, Leics., U .K .
Fluka Fluorochem  Ltd., Peakdale Road, G lossop, D erbyshire SK13 
9XE
Form achem . Ltd., Strathaven, Scotland, U .K.
FSA  Lab Supplies, B ishop M eadow Road, Loughbough, Leics., LE11 ORG 
G IBCO -BRL Lim ited, P.O. B ox 35, Paisley, Scotland.
Genetic Research Instrum entation Ltd., G ene House, D unm ow  R oad,
Felsted, Dunmow, Essex CM 6 3LD
M ay and Baker Limited, Dagenham, England.
Pharm acia LKB Biotechnology, Pharm acia House, M idsum m er 
Boulevard, M ilton Keynes, M K9 3HP
Schleicher and Schuell, D assel, W . Germ any.
S c o ttish  A n tib o d y  P ro d u c tio n  u n it, L aw  H o sp ita l, C a rlu k e , 
Lanarkshire, Scotland.
Siem ens Ltd., 26-28 N apier Court, W ardpark North, Cum bernauld. 
S igm a Chem ical Com pany, Fancy Road, Dorset, E ngland BH17 7NH. 
Technical Photo System s Ltd., 34 Telford Road, L enziem ill Industrial 
Estate, Cum bernauld G67 2A X  
W hatm an L td., M aidstone, K ent, U .K.
2.2 S T E R IL E  P R E C A U T IO N S
To prevent contam ination of glassw ear and solutions by  ribonucleases, 
the follow ing precautions w ere taken:
(i) disposable protective gloves were w orn during all procedures;
(ii) all solutions and glassw are were autoclaved at 15 p.s.i. fo r 20 
minutes;
(iii) disposable plasticw are was treated w ith Repelcote 
(dim ethyldichlorosilane in 1,1,1-dichloroethane, BD H ) before being 
autoclaved as described above.
2.3 E X P E R IM E N T A L  A N IM A L S
A ll anim als were supplied by the departm ental anim al house. The 
anim als w ere given free access to food and water.
The adult rats used were o f the W istar strain and w eighed 
approxim ately 250g. These anim als were killed by concussion and 
cervical dislocation.
The rabbits used for the production of antiserum  w ere o f the W hite 
N ew  Zealand breed.
2.4 G E N E R A L  P R O T E IN  M E T H O D S
2.4.1 Protein Assays
In  general, pro tein  concentrations w ere m easured  using  the dye-
binding m ethod of Bradford (1976) as m odified by  M acart and G erbaut 
(1982).
The Bradford dye reagent was prepared as follows: 
lOOmg Coomassie Brilliant Blue G  (Sigma) and 30mg SDS were 
dissolved in  50m l 95% (v/v) ethanol and then 100ml 85%  (v/v) 
phosphoric acid was added. The solution was diluted to  a final volum e 
o f 1000ml and filtered to rem ove particulate m atter. This reagent was 
found to be stable for several m onths w hen stored at 4 °C in the dark.
lm l o f the dye reagent was added to lOOpl o f each sam ple to be 
assayed. A fter 15 m inutes, the absorbance at 595nm  w as m easured 
against a reagent blank prepared from  lOOpl o f the appropriate buffer 
and lm l o f dye reagent. Standard curves w ere prepared using various 
amounts o f a lm g/m l solution o f BSA (Sigma).
The protein concentration of fractions from  chrom atographic colum ns 
was estim ated by m easuring the absorbance at 280nm. One absorbance 
unit at 280nm  was taken to be equivalent to approxim ately lm g/m l 
protein.
A  Cecil 272 spectrophotom eter was used to m easure absorbance at 
280nm  and 595nm.
2.4 .2 Concentration of Protein Samples
Proteins w ere concentrated by tw o m ethods, depending upon  the 
initial volum e o f the protein solution to be concentrated.
For sam ples o f lm l or less, the protein was precipitated by the 
addition of 4  volumes o f acetone at -20°C overnight. The proteins w ere 
recovered by centrifugation at 3,000 rpm  (l,500xgav) in  a B eckm an 
benchtop centrifuge for 10 minutes. Residual acetone w as evaporated in 
a stream  o f N 2  gas.
Sam ples o f proteins in larger volumes were concentrated by 
lyophilisation in  a Flexi-Dry freeze dryer attached to a vacuum  pum p.
2.4.3 Polyacrylam ide Gel Electrophoresis
E lectrophoresis in  the presence o f 0.1%  (w/v) SDS was carried out 
using the discontinuous system  described by  L aem m li (1970), utilising 
the procedure o f Le Sturgeon and Beyer (1977).
The follow ing stock solutions were prepared:
A. 30% (w/v) acrylamide, 0.8%  (w/v) bisacrylam ide;
B. 1.5M  Tris.H C l, pH 8 .8 ;
C. 1.5M  Tris.H C l, pH 6 .8 ;
D. 10% (w/v) SDS;
R eservoir Buffer: 0.025M  Tris, 0.192M  glycine, 0.1%  (w/v) SDS. The 
approxim ate pH  of this buffer was 8.3.
The percentage of the resolving gel varied from  7.5%  to 15% 
depending upon  the m olecular w eight of the proteins under analysis. In  
all cases, a  3%  stacking gel was used. The gel m ixtures were prepared 
using the volum es indicated in  Table 2.1. In  each case, the gel m ixture, 
except fo r TEM ED (NN N'N '-tetram ethylethylenediam ine, BDH), w as 
prepared in  a Buchner flask and degassed for 2 m inutes using a w ater 
suction pum p. Polym erisation was initiated by  the addition of TEM ED  
to the gel m ixture. The resultant slab gels (15x18cm , 1mm thick) were 
electrophoresed using a BRL V161 vertical gel electrophoresis system  
at a constant current of 40-50m A  until the tracking dye reached the 
bottom  o f the gel.
2 .4 .4  Preparation of protein samples for electrophoresis
Sam ples to be resolved by SDS polyacrylam ide gel electrophoresis
TABLE 2.1 COMPOSITION OF SDS POLYACRYLAMIDE GELS
This table shows the com position of SDS polyacrylam ide gels used 
as outlined in  Section 2.4.3. The stock solutions A ,B ,C  and D are 
described in  the tex t o f the aforem entioned section.
SO LU TIO N RESO LV IN G  G EL STA CK IN G  GEL
(% (w/v) polyacrylam ide)
7.5%  10% 15% 3%
A  (ml) 10 13 20 2
B (ml) 10 10 10
C (ml) - - 5
D (ml) 0 .4  0.4 0.4 0 .2
W ater 19.6 15.6 9.6 12.8
Am m onium
persulphate
(mg) 30 40 50 20
TEM ED (pi) 20 20 20 10
w ere diluted with an equal volum e of Laem m li sam ple buffer (0.0725M  
Tris.H C l pH 6 .8 , 3% (w/v) SDS, 10% (v/v) glycerol, 5%  (v/v) B- 
m ercaptoethanol, 0.002%  (w/v) brom ophenol blue, ( Sigm a), then 
boiled  for 2 minutes at 100°C.
2.4.5 Staining of polvacrvlam ide gels
A. Staining with Coom assie Brilliant Blue R
Gels w ere stained for protein  in 0.25%  (w/v) Coom assie B rilliant 
B lue R  (Sigma), 25% (v/v) m ethanol, 10% (v/v) acetic acid at room  
tem perature for 2 hours. Occasionally, if  a gel had  to be stained 
quickly, the gel was placed in  stain at 37°C for 30 m inutes. The 
background was destained by diffusion in 50%  (v/v) m ethanol, 10% 
(v/v) acetic acid for several hours at room  tem perature w ith several 
changes o f buffer.
. B . Staining with silver.
W hen greater sensitivity was required, proteins were stained w ith 
silver using the m ethod o f W ray et al., 1981.
Gels w ere soaked overnight at room  tem perature in 50%  (v/v) 
m ethanol. Staining solution was prepared by adding solution A  (0.8g 
silver nitrate in 4m l H 2O) to solution B (1.4m l 14.8M am m onia plus 
21m l 0.36%  (w/v) NaOH) dropw ise and stirring vigorously. The 
solution was then m ade to 100m l w ith double deionised distilled water, 
The gel was incubated at room  tem perature in staining solution for 8 
m inutes, then rinsed for one hour w ith 6 changes o f water. The stain  
was developed by im m ersing the gel in a solution com prising 2.5m l 1%
(w/v) citric acid and 0.25 m l 38% (v/v) form aldehyde in  500m l Wpter 
Staining w as stopped by  w ashing the gel in w a te r
2.4.6 Preparative SDS gel electrophoresis
Preparative slab gels w ere prepared and run exactly as described in 
Section 2.4.3, except that 3m m  spacers w ere used and a single 
continuous w ell was form ed in the stacking gel for the application of 
sample.
2.4.7 Peptide m apping
Peptide m apping was perform ed on fusion protein and ribonuclease 
inhibitor essentially as described by C leveland et al. (1977)
Crude cell lysate (Section 2.11.2) containing induced fusion protein  
was electrophoresed on a 7.5%  SDS polyacrylam ide preparative gel 
(Section 2.4.6). The gel was stained and destained as described in  
Section 2.4.5.A . The band corresponding to the fusion protein  w as 
excised and cut into strips o f gel of approxim ately 5m m . G el slices 
containing ribonuclease inhibitor were obtained in  a sim ilar fashion 
except that the inhibitor was electrophoresed on a 10% SDS 
polyacrylam ide preparative gel. The gel slices were soaked for 30 
m inutes in  a solution containing 0.125M  Tris.H C l pH 6 .8 , 0.1%  (w/v) 
SDS, Im M  EDTA. The slices could be stored in  this buffer at -20°C  
until required.
A  15% SDS polyacrylam ide gel was prepared as described in Section
2.4.3 w ith the additional inclusion of 1mm EDTA. The gel was cast 
w ith a longer than usual stacking gel (approxim ately 1cm  longer) and a
w ider-toothed comb w as used.
The gel slices, prepared as above, were pushed to the bottom  o f a 
w ell w hich had  been filled w ith the above buffer. A ny spaces around 
the gel w ere filled by  overlaying the gel w ith the sam e buffer m ade 
20%  (v/v) w ith  glycerol. Finally, lOjil o f buffer containing 10% (v/v) 
glycerol and an am ount o f protease that varied experim entally was 
overlaid into each well. Electrophoresis was perform ed in  the usual 
m anner except that the current was sw itched off fo r 1 h ou r w hen the 
tracking dye neared the bottom  o f the stacking gel.
A fter electrophoresis, the resolved peptides were transferred  to 
nitrocellulose m em brane and analysed by w estern blotting as described 
in  Section 2.7.3.
2 .4 .8  D eterm ination o f the relative m olecular w eigh t o f  a p ro tein  bv 
SDS PAGE.
Relative m olecular m ass (Mr) values were obtained from  SDS 
polyacrylam ide gels after staining for protein by determ ining the 
electrophoretic m obility (Rf) values as follows:
distance m igrated by protein
R f  =  ------------------------------------------ -----
distance m igrated by tracker dye
A  p lo t o f  R f values versus log M r o f a set o f s tandard  p ro teins 
enabled the M r of the protein under analysis to be determ ined.
The standard proteins were obtained from  Sigm a and consisted o f 
m yosin (200,000 Da), phosphorylase B (97,000 Da), a lbum in (68,000 
Da), ovalbum in (45,000 Da) and carbonic anhydrase (30,000 Da).
2.5 P U R IF IC A T IO N  O F  R IB O N U C L E A S E  IN H IB IT O R  F R O M
R A T  L IV E R
2.5.1 Preparation o f the RN ase A -Sepharose 4B affinity colum n
T he a ffin ity  colum n w as p repared  b y  the  m eth o d  ou tlined  in 
"Principles o f affinity chrom atography" (Pharm acia).
1.5g o f freeze-dried CN Br-activated Sepharose 4B (Sigma) was 
sw ollen in  300m l Im M  HC1 for 15 m inutes. The acid solution was 
rem oved using a sintered glass filter (porosity G3) fitted  to a vacuum  
pum p. The gel slurry was w ashed w ith 10ml coupling buffer (0.1M  
sodium  bicarbonate pH8.3, 0.5M  NaCl) and im m ediately transferred to 
a solution o f the ligand i.e. lOmg bovine pancreatic RN ase A (Sigm a) 
in  5m l coupling buffer. The suspension was then m ixed on an end-to- 
end rotating wheel for either 2  hours at room  tem perature or for 16 
hours at 4°C. A fter the coupling reaction, any rem aining active groups 
w ere blocked by m ixing w ith blocking buffer (0.2M  glycine p H 8) at 
room  tem perature for two hours. Excess adsorbed protein was rem oved 
by  w ashing w ith 200m l coupling buffer, then w ith 200m l w ash buffer 
(0.1M  acetate buffer pH4, 0.5M  N aC l ) and then finally with 200m l 
coupling buffer.
lm l o f the gel slurry was poured into the barrel o f a 2m l sterile 
disposable syringe w hich had been stoppered w ith glass w ool and a 
nitrocellulose (Schleicher and Schuell) filter. The colum n was then  
equilibrated w ith 0.045M  potassium  phosphate pH 6.4, 0.01M  13- 
m ercaptoethanol, 0 .001M EDTA at 4°C.
2.5 .2 Purification procedure
R ibonuclease inhibitor was purified from  rat liver using the affinity 
chrom atography procedure o f B urton et al. (1980). A ll steps w ere 
carried ou t a t 4°C, unless otherw ise stated.
Livers from  20 m ale W istar rats were excised and hom ogenised in  3 
volum es o f ice-cold hom ogenisation buffer (0.05M  Tris.H C l pH 7.6, 
0.35M  sucrose, 0.025M  K C 1, 0.01M  M g(C H 3 CO O )2 , 0 .01M  £- 
m ercaptoethanol) in an U ltraTurrax hom ogeniser. The hom ogenate was 
then  centrifuged for 2 hours at 25,000 rpm  (105,000xgav) in  the 
SW .27 sw ing-out rotor o f a B eckm an L5-50 ultracentrifuge
The supernatant fraction obtained from  the high speed spin was 
brought to 35%  (w/v) saturation w ith the gradual addition of 
am m onium  sulphate (free from  heavy m etals), stirred fo r 3 0  m inutes 
and centrifuged at 12,000 rpm  (25,000xgav) in  the G SA  rotor o f a 
Sorvall RC-5 centrifuge for 15 m inutes. The supernatant fraction was 
brought to 6 0 %  (w/v) am m onium  sulphate saturation, then stirred and 
centrifuged as described above. The resultant pellets w ere used 
im m ediately or stored at -2 0 °C until required.
The pellets were resuspended in  a m inim al volum e o f starting buffer 
(0.045M  potassium  phosphate pH6.4, 0.01M  B-m ercaptoethanol,
0 .001M E D TA  ) and dialysed against 2 x 2 0  volum es o f the same buffer 
fo r 4 hours. The dialysate was centrifuged at 17,000 rpm  (70,000xgav 
) in  a B eckm an SW .27 rotor for one hour to rem ove particulate m atter. 
The supernatant fraction was then loaded onto a RN ase A -Sepharose 
affinity colum n (Section 2.5.1) at a flow  rate o f 25m l/hour. The run- 
through fraction containing the proteins that had  not bound to the 
colum n was retained for use at a later stage (see Section 2.7.5). The 
colum n was washed with starting buffer m ade 0 .5 M  w ith N aC l until all
non-specifically  bound proteins were eluted. R ibonuclease inhibitor 
was then eluted with elution buffer (0.05M  borate buffer pH 6 , 4M  
N aCl, 0 .0 1M B-mercaptoethanol 0 .001M EDTA, 15% (v/v) glycerol) at 
a  flow  rate o f lOm l/hour. A ll fractions w ere assayed fo r ribonuclease 
inhib itor (Section 2.5.4) and for protein by  m easuring absorbance at 
280nm . Fractions containing inhibitor w ere pooled and dialysed against 
2 x 2 0  volum es of dialysis buffer (0.02M  Tris.H C l pH  7.5, 0.15M  
N aC l, 0 .001M  EDTA, 0.01M  B-m ercaptoethanol, 15% (v/v) glycerol) 
fo r 4  hours, then stored at -20°C .
2.5.3 FPLC  fractionation of ribonuclease inhibitor
W hen required, ribonuclease inhibitor w as further purified by ion- 
exchange chrom atography on the FPLC system  (Pharm acia) using the 
M ono Q  anion-exchange column. Fractions from  the affinity 
chrom atography column w hich contained ribonuclease inhibitor w ere 
dialysed fo r 16-20 hours at 4°C against lOOmM Tris.H Cl pH7.4, 
lOmM B-mercaptoethanol, Im M  EDTA, w ith several changes of 
buffer. The M ono Q colum n was equilibrated with the sam e buffer 
and the protein loaded onto the column. R ibonuclease inhibitor was 
eluted w ith a 0-0.5M  linear N aCl gradient over a period of 30 m inutes 
at a flow  rate of lm l/m inute and lm l fractions were collected.
2.5.4 A ssay of ribonuclease inhibitor activity
The assay used to detect ribonuclease inhibitor activity was 
described by Brockdorff and K now ler (1986) and is based  upon the 
ability o f the ribonuclease inhibitor to prevent the digestion of
transfer R N A  by RNase A.
Sam ples were incubated at 37°C for 30 m inutes in  a to tal assay 
volum e o f 150JJ.1 consisting o f 0.025%  (w/v) B SA  (fraction V,
Sigm a), 0.25ng bovine pancreatic RN ase A  (Sigma) and 125pg tRN A  
(Sigm a) in  lOOmM Tris.HCl pH7.5 w ith Im M  EDTA. The reaction 
w as initiated  by the addition o f tRN A  to the sam ples and stopped by  
the addition o f 50jil ice-cold 24%  (v/v) perchloric acid in 40m M  
lanthanum  acetate (Ventron). U nder these conditions, the digestion of 
tR N A  by RN ase A was linear. The sam ples w ere incubated on ice for 
20 m inutes and centrifuged in  an A nderm an 5415 m icrofuge for 5 
m inutes. lOOpl of supernatant fraction, containing acid-soluble 
nucleotides, was diluted to 1m l w ith w ater and the absorbance read at 
260nm  on a Cecil CE 272 spectrophotom eter. The assay was carried 
out in  sterile 1.5ml polypropylene m icrotubes (Eppendorf tubes) 
w hich had  been treated with Repelcote (dim ethyldichlorosilane in 
1 ,1, 1-dichloroethane)
One un it o f inhibitor activity is defined as the am ount required to 
inhibit by 50%  the degradation o f R N A  by  5ng of RN ase A. As this 
assay uses 0.25ng RNase A, the quantity o f inhibitor resulting in  50% 
inhibition  was taken to be 0.05 units.
2.6 P R E P A R A T IO N  O F  P E P T ID E S  F O R  A M IN O  A C ID  
S E Q U E N C IN G
2.6.1 Preparation of ribonuclease inhibitor fo r digestion bv  proteases.
In  general, proteins in  their native state are digested only to a lim ited 
extent by proteases. This is probably due to the conform ation o f the
protein w hich renders susceptible peptide bonds inaccessible to the 
protease. A lso, the presence o f covalent intrapolypeptide crosslinks 
e.g. disulphide bonds m ay obstruct the action o f the protease. Thus, to 
render the protein m ore accessible to the action of proteases, the 
protein m ust be fully denatured, the disulphide bonds cleaved and the 
resultant sulphydryl groups alkylated.
A  preparation of FPLC-purified ribonuclease inhibitor (Section 
2.5.3) was dialysed against distilled w ater fo r 48 hours at 4°C  w ith 
several changes of water. The sam ple was then transferred to an  acid- 
w ashed round bottom  flask and lyophilised overnight. The precipitate 
was resuspended in  4m l de-gassed 6M  guanidine hydrochloride (Sigma) 
in  lOOmM Tris.HCl pH8.5. A  five times m olar excess o f dithiothreitol 
(DTT) over protein cysteine residues was added and the solution stirred 
under N 2  for 3 hours at room  tem perature. A  five tim es m olar excess of 
iodoacetic acid (IAA) over D T T  was then added and the solution stirred 
in  the dark for 3 hours over N 2  at room  tem perature. This alkylating 
reaction was quenched w ith ten times m olar excess B-m ercaptoethanol 
over IAA. The protein was then dialysed against distilled w ater fo r a 
further 3 days and then lyophilised overnight
2 .6 .2 Proteolytic digestion o f ribonuclease inhibitor
The lyophilised protein, obtained as described in  Section 2.6.1, was 
resuspended in 4ml 50m M  am m onium  bicarbonate pH8.5. The sam ple 
w as then divided into two: one ha lf o f the sam ple was digested w ith  
trypsin (Sigma); the other h a lf digested w ith chym otrypsin (Sigm a).
The ratio of proteinrprotease w as 50:1 and the digest was carried out 
fo r four hours at 37°C. A  second, equivalent am ount o f protease was 
added and the solutions digested as before. The reaction was then
stopped by  lyophilisation o f the digested protein.
2.6.3 Purification o f peptides using H PLC
The lyophilised digested protein, obtained as described in  Section 
2 .6 .2 , w as resuspended in  2 0 0 p l sterile double deionised distilled 
water, transferred to acid-w ashed glass test tubes and centrifuged at 
1000xgav fo r 2 m inutes to  rem ove particulate m atter. The sam ple was 
then applied to the C l 8 reverse phase colum n of the high  pressure 
liquid chrom atography (HPLC, Beckm an) system  using a pH 2 
trifluoroacetic acid buffering system. The peptides w ere eluted w ith  a 
gradient o f 0-70% acetonitrile over 60 m inutes. Only the peptides 
w hich appeared as w ell-defined, distinct peaks on the trace obtained 
were collected, then lyophilised and stored at -20°C until required.
The lyophilised peptides w ere redissolved in 500pl double deionised 
distilled water. The purity o f the peptides was checked by applying a 
sam ple o f each individual peptide to the sam e HPLC colum n as used  
previously w ith a Im M  sodium  phosphate pH 6.2 buffering system . The 
peptide was again eluted from  the colum n w ith a 0-70%  acetonitrile 
gradient. The peptides on the trace w hich appeared to be greater than  
90% pure were lyophilised and then taken to A berdeen U niversity to be 
sequenced by Mr. B. D unbar on the SERC funded protein sequencing 
facility .
2.7 IM M U N O L O G IC A L  M E T H O D S
2.7.1 Preparation of antiserum
250p.g ribonuclease inhibitor was resolved on a preparative 10% 
(w/v) polyacrylam ide slab gel (Section 2.4.6), then stained fo r protein 
using Coom assie B rilliant B lue R  (Section 2.4.5.A ). A fter destaining, 
the gel was washed with distilled w ater fo r 30 m inutes to rem ove 
excess acid. The protein band corresponding to ribonuclease inhibitor 
was excised from  the gel w ith  a  scalpel, diced, frozen in  liquid N 2  and 
ground to a fine pow der using a m ortar and pestle.
The pow dered m aterial was sonicated w ith 0.5m l 0.9%  (w/v) N aC l 
and 1ml Freunds complete adjuvant and this m ixture w as injected 
subcutaneously at m ultiple sites on the back o f a N ew  Zealand w hite 
rabbit. A dditional booster injections were adm inistered in Freundfc 
incom plete adjuvant 2  weeks before each bleeding.
A ntiserum  was collected by bleeding the rabbit from  a m arginal ear 
vein. A fter allowing the blood to clot overnight at 4°C , the antiserum  
w as rem oved w ith a pasteur pipette, clarified by centrifugation at 2 ,000  
rpm  (l,0 0 0 x g av) in a Beckm an benchtop centrifuge fo r 10 m inutes, 
aliquoted into 1ml fractions and stored at -20°C.
2.7 .2 Isolation of IgG  from  im m une sem m
IgG  was purified from  antiserum  as described by Johnstone and Thorpe 
(1982).
20m l im m une serum was w arm ed to 25°C in a w ater bath. Solid 
sodium  sulphate was added to m ake a 18% (w/v) solution w ith stirring
to allow the salt to dissolve. The solution was incubated at 25°C for 30 
m inutes, then centrifuged at 4,000 rpm  (2,500xgav) fo r 30 m inutes at 
25°C in the HB4 rotor o f a Sorvall RC-5 centrifuge. The supernatant 
fraction was discarded and the protein precipitate redissolved in  10m l 
water. This solution was w arm ed to 25°C and sodium  sulphate added to 
m ake a 14% (w/v) solution, allowing for the salt carried  over in the 
first precipitate. The solution was again incubated and centrifuged as 
described above. The resultant precipitate was resuspended in  5m l 
w ater and dialysed overnight against 0.07M  sodium  phosphate buffer 
pH6.3 at room  tem perature.
The dialysate was then applied to a 10ml D EA E-anion exchange 
colum n (W hatman DE52) w hich had been equilibrated w ith 0.07M  
sodium phosphate buffer pH 6.3. 1ml sam ples w ere collected and the 
absorbance at 280nm  m onitored. The starting buffer w as used to elute 
IgG  in a single assym etric peak  of which the earliest fractions 
contained the purest IgG.
2.7.3 W estern blotting
Im m unoblots were perform ed using a m odification o f T ow bin et al. 
(1979).
Proteins were resolved on SDS PAGE (Section 2.4.3) and 
electrophoretically transferred onto nitrocellulose paper (Schleicher and 
Schuell) at 70V for 3 hours using the B io-Rad T r a n s - b l o t ^ M  apparatus. 
The transfer buffer consisted o f 0.025M  Tris, 0 .192M  glycine, 0.02%  
(w/v) SDS, 20% (v/v) m ethanol w ith an approxim ate pH  o f 8.3.
A fter transfer of the proteins to nitrocellulose m em brane, additional 
binding sites on the paper w ere saturated by incubating the filters 
overnight at 4°C in buffer A  (TBS (Table 2.4 ) and 3% (w/v)
reconstituted dried skim med m ilk) supplem ented w ith 0 .5 % (v/v) 
T w een 20 (Sigma). Im m une serum , at a dilution o f 1:200 in buffer A  
supplem ented with 2% (v/v) heat inactivated goat serum  (SAPU), was 
incubated w ith  the filters fo r 2  hours at room  tem perature w ith shaking. 
Excess free antibody was rem oved by w ashing the nitrocellulose filters 
w ith  TBS fo r 15 minutes, then TBS m ade 0.05%  w ith Tw een 20 for 15 
m inutes, follow ed by a further 15 m inutes w ash w ith  TBS. In  general, 
antibody-antigen complexes were detected using donkey anti-rabbit IgG  
conjugated to  horseradish peroxidase (SAPU) by incubating the filters 
w ith  a solution o f the conjugate diluted l in  100 w ith  buffer A. A fter 2 
hours, the m em brane filters were w ashed as previously described. The 
im m unoblot was then allowed to develop in  developing solution (TBS 
containing 2.2m M  4-chloro-l-naphthol (Sigm a) and 0.03%  (v/v) H 2 O 2 ) 
fo r 15-20 m inutes, rinsed in  distilled w ater and allow ed to dry.
O ccasionally, when greater sensitivity w as required, a w estern b lo t 
w as developed w ith the biotdn-streptavidin detection system  
(A m ersham ). Briefly, after incubation w ith  im m une serum , the filters 
w ere incubated with a 1 in 500 dilution o f donkey anti-rabbit IgG  
conjugated to biotin for 2  hours at room  tem perature, then w ashed as 
described above. The biotin was then detected by incubating the 
m em branes w ith a 1 in 400 dilution o f streptavidin-horseradish 
peroxidase for 30 minutes, follow ed by 6x5 m inute washes in  TBS.
The b lo t w as then developed as described above.
2.7.4 Enzvm e linked im m unosorbent assay 6ELISA1
A ntibody levels in samples o f serum w ere m easured using the E LISA  
system  as described by Cam pbell (1984)
A ntigen, in  lOOjil PBS (Table 2.4) was bound to the w ells o f a  
D ynatech m icrotitre plate by incubating overnight at 4°C. Excess 
antigen w as removed by  w ashing the plate w ith PBS containing 0.05%  
(v/v) T w een 20 (Sigma). R esidual binding sites w ere b locked fo r 2 
hours at room  temperature w ith 10 m g/m l B SA  (fraction V , Sigm a) in  
PBS. The plate was rinsed w ith  buffer as before, then  serial dilutions 
o f antiserum  (1/100 to 1/100,000) in 100p.l PBS w ere placed in  the 
wells. A fter incubating fo r 2 hours at room  tem perature, the p late was 
w ashed w ith  PBS containing 0.05%  (v/v) Tw een 20. The plates w ere 
then incubated for 1 hour at room  tem perature w ith lOOpl donkey anti­
rabbit IgG  conjugated to horseradish peroxidase (SAPU) w hich had  
been diluted l in  1000 w ith PBS containing 0.5%  (v/v) Tw een 20. 
Excess conjugate was rem oved by  washing the plate w ith  PBS 
containing 0.05% (v/v) Tw een 20. The quantity of peroxidase activity 
bound to each well was determ ined by incubating w ith  lOOpl substrate 
solution (0.04%  (w/v) o-phenylenediam ine (Sigma) 0.04%  (v/v) H 2 O 2 , 
36m M  citric acid, 128mM N aH 2PC>4 pH 6) in  the dark for 30 m inutes at 
room  tem perature. The reaction was term inated by the addition o f 50jil 
2M  H 2SO 4 . The absorbance at 492nm  was determ ined using a T itertek 
m ultiscan spectrophotometer.
The titre o f immune serum  was determined by  finding the dilution at 
w hich im m une serum and pre-im mune serum from  the sam e anim al gave 
an equal absorbance at 492nm .
2.7.5 Im m unoadsorption
The anti-serum  raised against ribonuclease inhibitor was found to 
recognise other liver proteins in  addition to inhibitor. To im prove the 
specificity of the anti-serum , the contam inating antibodies were
adsorbed from  the serum by passing it through an affinity  colum n 
w hich consisted of liver proteins depleted in ribonuclease inhibitor 
bound  to Sepharose 4B.
Approxim ately 20 m g of protein from  the run-through fraction o f the 
R N ase A-Sepharose affinity colum n (Section 2.5.2) w as covalently 
bound per m l o f activated Sepharose 4B (Sigm a) as described in  
Section 2.5.1. lOmls im m une serum  was passed through a 10ml bed  of 
conjugated resin at a flow rate o f lOm l/hour at room  tem perature. 1ml 
fractions w ere collected and m onitored for specificity by ELISA  
(Section 2.7.4) and w estern blotting (Section 2.7.3). T he colum n was 
regenerated by  eluting bound antibody w ith 0.5M  am m onium  hydroxide 
containing 3M  potassium  thiocyanate.
2.7.6 Rem oval of E.Coli antibodies from  im m une serum
Im m une serum often contains antibodies w hich b ind  to  E.Coli 
antigens and this m ay cause a  high background w hen screening an 
expression library w ith im m une serum. These contam inating E.Coli 
antibodies can be rem oved by incubating the im m une serum  with a 
bacterial lysate bound to a nitrocellulose filter (H uynh et al., 1985).
A  crude cell lysate was prepared from a non-recom binant
A ,gtll/Y 1089 lysogen as described in Section 2.11.2. This cm de cell 
lysate contains m any E. Coli proteins, including that fo r B- 
galactosidase. All of the follow ing steps w ere carried out at room  
tem perature. The lysate was incubated with 140m m  diam eter 
nitrocellulose filter discs (Schleicher and Schuell) for 15 m inutes to 
allow  the proteins to bind to the nitrocellulose. The filter discs w ere 
then w ashed for 5 m inutes w ith TBS (Table 2.4). IgG , purified from
im m une serum  (Section 2.7.2), was incubated with 2 separate filters 
fo r 10 m inutes to rem ove contam inating E. Coli antibodies.
2.8 C L O N IN G  M E T H O D S
The follow ing section describes the library w hich w as screened in  
this project, the plasm id w hich was used in  the generation of subclones 
and the bacterial strains w hich w ere required.
2.8.1 R at L iver Xgtl 1 L ibrary
The library which was screened in  this project was a  rat liver cD N A  
library in the expression vector X g tll. The preparation o f this library 
is described by Schwarzbauer et al. (1983) and was k indly  donated by  
R. H ynes.
The structure o f the expression vector Xgtl l  (lac 5, c l8 5 7 , nin 5, 
S100) is show n in  Figure 2.1. X g tll  contains a tem perature sensitive 
repressor o f lytic growth (c l8 5 7 ) that is inactive at 42°C  and active at 
32°C allowing a selection against lysogenic growth. The am ber 
m utation S100 renders the phage induced lysis defective in  E.Coli 
hosts w hich lack the suppresor sup F. Foreign D N A  is inserted  in to  a 
unique EcoRI cleavage site located w ithin the lac Z  gene, near the 
CO O H  term inus of B-galactosidase. Foreign DNA in this vector can be 
expressed as a fusion protein w ith B-galactosidase, assum ing the 
inserted D N A  is in the correct fram e and orientation. R ecom binant 
libraries in Xgtl 1 can thus be screened w ith antibodies as an antibody 
m ay detect the foreign antigen encoded by the DNA insert w hich is 
fused  to B-galactosidase.
There are m any problem s associated w ith the expression of foreign
FIG U R E 2.1 STRUCTURE OF EXPRESSION VECTOR XGT11
The structure o f the expression vector X g tll (lac 5, c l 857, n in  5, 
S100) is outlined. A lso shown is the position of the unique E coR I site 
in  the lac Z  gene into which foreign cD N A  sequences are inserted.
T he transcriptional orientation o f lac Z  is indicated by the horizontal 
arrow  and the size o f the vector is show n in kilobase pairs.The salient 
features are described in detail in  Section 2.8.1
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D N A  in  E.Coli e.g. the foreign protein is often unstable and the 
presence o f these novel proteins m ay be toxic to the host cell. 
H ow ever, these problem s have been m inim ised by  the use of bacterial 
hosts w hich allow the expression and accum ulation o f  foreign proteins. 
These host strains are described m ore fully in  Section 2.8.3
2.8 .2  Plasm id. pTZ
The positive clones obtained from  the ? ig tll cD N A  library were 
subcloned into the m ulti-functional vector pTZ  (Pharm acia) to perm it 
dideoxy D N A  sequencing and also for preparative grow th to obtain 
probes fo r northern blotting. A  diagram  o f pT Z  is show n in  Figure 2.2.
pT Z  vectors contain the lac Z  gene and within this gene is the 
polylinker region from  pU C  18 or 19 into w hich a cD N A  insert can be 
cloned. W hen pTZ is introduced into lac Z  ~ E.Coli strains, the 
plasm id gives rise to blue colonies on agar plates supplem ented w ith 
IPT G  (isopropyl B-D thiogalactopyranoside, Sigm a) and X  gal (5- 
brom o-4-chloro-3-indolyl-B-D galactoside, BRL) i.e. B-galactosidase 
activity is restored to the bacterial strain by  a process know n as a -  
com plem entation. The active B-galactosidase converts the colourless 
substrate X  gal to a blue pigm ent w hich gives the characteristic blue 
colour to the bacterial colonies. W hen DNA fragm ents are cloned into 
the polylinker region, the lac Z  gene is disrupted and w ill thus fail to 
com plem ent lac Z  ~ E.Coli strains. The recom binant plasm id 
transform ants rem ain lac Z~ and therefore cannot m etabolise X  gal to a 
b lue colour. Resulting colonies, grown on agar plates supplem ented 
w ith X  gal and IPTG, will rem ain white. To distinguish these colonies 
from  untransform ed host, the transform ation m ix is grow n in the
FIGURE 2.2 STRUCTURE OF PLASMID. pTZ
The features o f the m ultifunctional plasm id pTZ (Pharm acia) are 
outlined and are described in detail in  Section 2.8.2.
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presence o f ampicillin as this prevents growth o f untransform ed host. 
pT Z  transform ed colonies are able to grow  as the plasm id contains an 
am picillin  resistance gene. Thus, a white colony obtained from  an agar 
plate containing ampicillin and supplemented w ith IPTG  and X  gal 
should contain recom binant p lasm id carrying the insert o f interest.
T he plasm id pTZ contains both  the bacteriophage f  1 and the pBR322 
origins o f replication for generation o f single and double stranded 
D N A . Single stranded D N A  can be used for dideoxy D N A  sequencing. 
T he production of single stranded DN A  requires the pT Z  transform ed 
cells to be superinfected w ith M 13K 07 helper phage. These phages 
provide the replication enzym es and packaging proteins to synthesise 
and package the single stranded pTZ DNA. The M 13K 07  itself is not 
efficiently replicated and packaged w hen com peting w ith  pTZ, so that 
the ratio o f single stranded D N A  isolated from  pTZ and M 13K 07 co­
transfected cells is at least 50:1.
2.8.3 B acterial Strains
The bacterial strains utilised in this project are outlined in Table 2.2. 
E. Coli Y1088, Y1089, Y1090 were the strains required for cloning in  
£ g t l l  and are described by Young and D avis (1983) .
The features which m ake these strains suitable for screening Xgtl 1 
cD N A  expression libraries include the follow ing:
Y 1088 is hsd R ' and hsd + i.e. it is defective for host-controlled 
restriction  and m odification. Thus, this strain is suitable for 
am plification of the library and also for determ ining the titre of 
bacteriophage stocks (Section 2.10.4)
Y 1089 contains a m utation in the hfl A  gene w hich favours the 
production of lysogens (Section 2.11.2). A lso, Y1089 lacks the sup F
TABLE 2.2 GENOTYPE OF BACTERIA UTILISED IN  CLONING. 
SUBCLONING AND SEQUENCING PROCEDURES
This table describes the genotype o f the various bacteria used 
w hile carrying out this project and are described in m ore detail in  
Section  2.8.3
ST R A IN  G EN O TY PE R EFER EN C E
Y 1088 supF, supF, metB, trpK, hsdRT hsdWL+ Young and
ton A2A, strA , A/<zcU169, pr<9C::Tn5(pMC9) D avis (1983b)
Y1089 proA +, araD139, strA, hflA, 150[chr::Tnl0] Young and
A/<zcU169, A Ion, (pM C9) Davis (1983b)
Y1090 proA +, araD139, strA, supF, [rr/?C22::TnlO] Young and
A/<zcU169, A Ion, (pM C9) Davis (1983b)
DS941 A B1157, rec F", lac Z  M 15, lac W Sherratt,D .
D ept, o f Genetics, 
G lasgow  University
MV1190 A(lac-pro), thi, supF,
A(srl-recA)::TnlO(tetT) , 
F':traD36, proAB, laclQ ZAM15 B io-R ad
gene w hich is required to supress the am ber m utation in  the S gene of
Xgtl 1 and hence this bacterium  is unable to lyse until the addition of 
chloroform . Therefore, preparative amounts o f the induced fusion 
pro tein  can be produced from  lysogens.
Y 1090 is the plating host fo r screening X g tll  libraries (Section 2.10.1) 
It contains the sup F  gene and therefore the bacterium  w ill lyse in  the 
presence o f bacteriophage. Thus X g tll libraries are screened as plaques 
w ith antibody probes.
Y1089 and Y1090 lack the Ion protease , an enzym e w hich degrades 
foreign proteins in E. Coll. Thus the stability o f the induced 
recom binant fusion protein is increased.
Finally, all three strains contain the plasm id pM C9. This is a plasm id 
derived from  pBR322 w hich contains the lac IQ gene. This gene codes 
fo r the repressor protein w hich binds to the operator region of the lac 
operon thus preventing transcription and hence expression o f B- 
galactosidase. Therefore, the B-galactosidase fusion protein  need  not 
be  expressed during infection and early grow th o f the phage. This is 
advantageous as the presence o f foreign proteins can be toxic to the 
bacterial cell. W hen required, this repression can be overcom e by the 
addition of IPTG, a gratuitous inducer o f the lac operon w hich induces 
the expression of the B-galactosidase fusion protein.
DS941 was the recom m ended bacterial strain for transform ation w ith  
recom binant pTZ subclones.
M V 1190 was the bacterial strain used to produce single stranded 
D N A  for use in dideoxy D N A  sequencing. This bacterium  has the F' 
plasm id w hich is required for the superinfection o f a defective M 13 
phage (M 13K 07). The plasm id also carries a gene coding for an 
enzym e involved in proline synthesis w hich is defective in  the host
cell. Selection by growth on m inim al m edium  agar p lates can thus be 
used to ensure that the plasm id encoding the m ale pilus is m aintained.
2.9 G E N E R A L  C L O N IN G  P R O C E D U R E S
2.9.1 Storage o f plasm id and lam bda DNA
Plasm id D N A  was stored in  TE buffer (Table 2.4) at -20°C in 
E ppendorf tubes. Lam bda D N A  was stored at 4°C  in  T E  buffer.
2.9.2 Storage o f bacterial strains
For short term  storage, the bacterial strains w ere streaked out onto 
an agar plate containing the appropriate antibiotic. The plates w ere 
grown overnight at 37°G, then sealed w ith N escofilm  and stored at 4°C 
fo r 1-2 weeks.
For long term  storage, 0.15m l glycerol was added to  0.85m l o f an 
overnight culture grown in  LB m edium  plus the correct antibiotic. The 
culture was then snap frozen in a dry ice-m ethanol ba th  and stored at - 
20°C or -70°C. Bacteria stored in this m anner rem ained viable fo r the 
duration o f this project.
2.9.3 Com position of growth m edia
The com position o f growth m edia is shown in  Table 2.3. A ll m edia  
w ere autoclaved at 15 lb p.s.i. for 20 m inutes. I f  required, antibiotics 
were added aseptically to the m edium  w hen it had cooled to 
approxim ately 50°C.
TABLE 2.3 COMPOSITION OF GROWTH MEDIA
The com positions o f  the different m edia used throughout the project 
are shown. A ll m edia  w ere autoclaved prior to use (Section 2.2) and 
antibiotics, if  required, were added aseptically w hen the m edia  had 
cooled to approxim ately 50°C (Section 2.9.4)
A. LIQ U ID  M EDIA
LB: lOg bacto tryptone (Difco), 5g yeast extract(D ifco), 5g N aC l per 
1000ml.
2xTY: 16g bacto tryptone, lOg yeast extract, 5g N aC l per 1000ml. 
Minimal Medium
The follow ing reagents were autoclaved separately and cooled before 
m ixing aseptically:
900m l water
100ml 10xM9 salt (337mM N a2H P 0 4 , 220mM  KH2P 0 4 , 187mM
N H 4C1, 85m M N aCl)
lm l 1M M gS 04
lm l 0.1M  CaCl2
lm l 1M thiamine HC1
10m l 20% (w/v) glucose
B . M e d ia  co n ta in in g  a g a r
LB agar: m edium  as for LB m edium  plus 1.5% (w/v) Bacto agar 
(D ifco).
Top agar: m edium  as for LB m edium  plus 0.5%  (w/v) Bacto agar.
M inim al agar: medium as for m inim al m edium  plus 1.5% (w/v) Bacto 
agar.
2.9.4 Supplem ents to growth m edia
Stock solutions were m ade up in  sterile w ater to the appropriate 
concentration, filter sterilised using a M illipore filter (0.2pm ) and 
stored at -20°C.
A m picillin (Sigma) and Kanam ycin (Sigma) were m ade at stock 
concentrations of 50mg/ml. The working concentration of A m picillin 
w as lOOpg/ml whereas the working concentration o f K anam ycin was 
70pg/m l.
2.9.5 Com m only used solutions for nucleic acid procedures
The solutions used m ost frequently in cloning procedures are listed  
in  Table 2.4. A ll solutions used in  the follow ing sections were 
autoclaved at 15 lb p.s.i. for 20 m inutes before use.
2.9.6 O rganic reagents
C rystalline phenol was redistilled at 160°C and stored in  aliquots a t - 
20°C. W hen required, aliquots were m elted and m ade 0.1%  (w/v) w ith 
respect to 8-hydroxy quinoline, an antioxidant. The m elted phenol was 
extracted w ith an equal volum e of 0.1M  Tris.H Cl pH 7.5 and stored 
saturated in  the same buffer in  the dark at 4°C. Phenol was also 
extracted and stored saturated w ith TE buffer (Table 2.4) and w ith  
cloroform risoam yl alcohol (24:1).
TA B LE 2.4 COM M ONLY USED SOLUTIONS
The solutions used m ost frequently are outlined in this table. A ll 
solutions w ere sterilised by autoclaving as described in Section 2.2. 
Solutions w hich were used in procedures involving R N A  w ere first 
treated w ith  diethylpyrocarbonate (DEPC, Sigma) and then autoclaved 
to preven t contam ination w ith ribonucleases.
Phage buffer (SM)  50m M  Tris.HCl pH7.5, lOOmM N aCl, lOmM 
M g S 0 4 , 0.01%  (w/v) gelatin.
Phosphate buffered saline (PBS1 140mM NaCl, 2 .7m M  KC1, 1.5mM  
K H 2P 0 4 , 1.8mM N a2H P 0 4 pH7
TE lOmM Tris.HCl pH 8, Im M  EDTA.
Tris buffered saline (TBS) 50m M  Tris.H Cl pH 7.5, 150mM  N aC l
IPX  SSC 1.5M NaCl, 0 .15M  trisodium  citrate pH 7
5OX Denhardt's solution 1% (w/v) BSA, 1% (w/v) F icoll type 400 
1% (w/v) polyvinylpyrrolidone pH7
20X  SSPE 3.6 M  NaCl, 200m M  NaH2P 0 4 pH7, 20m M  ED TA  
IPX  TBE 0.89M  Tris-borate, 0.89M  boric acid, 0 .02M  ED TA
I o
2.9.7 A garose gel electrophoresis
D N A  fragm ents were separated by horizontal gel electrophoresis 
using a  TBE buffering system  as described by M aniatis et al., 1982. 
The electrophoresis buffer contained 0.089M  tris-borate, 0.089M  boric 
acid 0.002M  EDTA.
1.5% (w/v) agarose gels were routinely used for visualising the 
cD N A  inserts from  restriction digestion of recom binant lam bda or 
plasm id DNA. 1% (w/v) agarose gels were used for m onitoring lam bda 
or plasm id D N A  during their purification.
A garose gels were prepared by autoclaving fo r 5 m inutes at 51b p.s.i. 
the correct am ount o f agarose in the desired quantity o f electrophoresis 
buffer. The agarose solution was cooled to 55°C, ethidium  brom ide 
(lOm g/m l) added to a final concentration o f 0 .5pg/m l and the gel 
poured on a flat surface.
D N A  samples were prepared by the addition o f 0.1 volumes of 
sam ple buffer containing 0.25%  (w/v) brom ophenol blue in 40% (w/v) 
sucrose.
Electrophoresis was perform ed using either BRJL H5 or H6 
apparatus. The gel was im m ersed in  the electrophoresis buffer 
containing 0.5pg/m l ethidium brom ide. The D N A  sam ples were applied 
to  the pre-form ed wells and electrophoresed until the tracking dye had  
reached the bottom  of the gel. D N A  was visualised by ethidium  
brom ide fluorescence on a transillum inator. Gels w ere photographed 
w ith a Polaroid CU-5 cam era using a 665 positive/negative film.
2.10 ISO LA TIO N  OF CLO NES FR O M  A cDNA EXPRK SSIO N
LIBRARVTN A.GT11
2.10.1 Preparation of plating bacteria
E. Coli strains Y1088, Y1089 and Y 1090 w ere prepared for plating 
bacteriophage by isolating a single colony o f E. Coli from  an LR agar 
plate supplemented with lOOpg/ml Am picillin (Sigma), inoculating 
10ml LB containing 0.2% (w/v) m altose (Sigma) and incubating at 37°C 
overnight. Bacteria grown in  the presence o f m altose absorb 
bacteriophage lam bda m ore efficiently as the sugar induces the m altose 
operon w hich contains the gene coding fo r the lam bda receptor. The 
bacteria were then harvested in a Beckm an benchtop centrifuge at 3000 
rpm  (l,5 0 0 x g av) for 10 m inutes at room  tem perature. The m edium  was 
decanted and the bacterial pellet resuspended in 5m l lOmM MgSC>4 .
2.10.2 Screening of a cDNA expression library with polyclonal 
antibodies
The library screened in this project was a rat liver cD N A  library in 
the expression vector X g tll. The library is described in  m ore detail in  
Section  2.8.1.
For the initial screen, 0.6m l o f Y1090 plating bacteria (Section
2.10.1) was m ixed with 3x10^ p.f.u. o f the library and incubated at 
37°C for 15 minutes to allow the phage to adsorb to the bacteria. 7m l 
top agar (Table 2.3) was added and the culture poured onto a w ell-dried 
140mm LB plate supplemented w ith lOmM MgSC>4 . The agar was 
allow ed to harden, the plate was inverted and incubated at 42°C until 
the plaques were just visible (approxim ately 2 hours). The plate was
then  overlaid with a dry nitrocellulose filter (Schleicher and Schuell) 
w hich had been previously soaked in lOmM isopropyl B-D 
thiogalactopyranoside (IPTG, Sigma) and the plate w as incubated for a 
further 3 hours at 37°C. The plate was rem oved to room  tem perature 
and the position of the filter on the plate was m arked using a needle. If  
a  duplicate filter was required, a second filter was overlaid after the 
first had been rem oved and the plate returned to incubate at 37°C for a 
further 3 hours. The filter, w hich had been carefully rem oved from  the 
plate, was placed in a petri dish containing 15ml TBS (Table 2.4) .
This and all subsequent steps were carried out at room  tem perature.
The filter was incubated w ith 15ml TBS containing 2%  (w/v) BSA  
(fraction V, Sigma) for 15 m inutes. It was then incubated overnight 
w ith  IgG  purified from  im m une serum  (Section 2.7.2) from  w hich E. 
Coli antibodies had been rem oved (Section 2.7.6), at a concentration 
o f 50 pg  IgG /m l in 15ml TBS containing 2% (w/v) B SA  and 0.05%  
(v/v) Tw een 20 (Sigma). The antibody-antigen com plexes were detected 
using the donkey anti-rabbit IgG  conjugated to horseradish peroxidase 
(S APU) system  and the filters developed as described in  Section 
2 .7 .3 .
D ue to the high density of the plaques in this initial screen, it w as 
im possible to unam biguously identify the plaques giving rise to 
candidate positive signals on the filter. Hence, it was necessary to 
isolate the plaques from  the general area o f the positive signal. 
Bacteriophage were then isolated from  these plaques (described in  
Section 2.10.3) and then taken through two successive rounds o f 
antibody screening at progressively low er plaque densities. The second 
round of screening was perform ed with 1x10^ p.f.u. o f  purified phage 
and 200pl of Y1090 which were plated onto 90mm LB, lOmM MgSC>4
plates using 3ml top agar. The plaques obtained from  the second round 
o f screening were discrete and thus it was possible to isolate individual 
positive plaques. The third and final round o f screening utilised 500 
p.f.u. o f bacteriophage w ith 200 jj1 Y1090 as described for the second 
round o f screening. Each plaque gave rise to a positive signal, hence 
further purification was unnecessary.
2.10.3 Purification of bacteriophage from  a positive plaque
Plaques o f interest were isolated using the broad end o f a sterile 
pasteur pipette which was stabbed through a plaque into the agar 
below . The agar plug containing a plaque was rem oved from  the end of 
the pasteur pipette with the aid o f a sterile toothpick into an E ppendoif 
tube containing 1ml SM  buffer (Table 2.4) and 1 drop of chloroform . 
The bacteriophage particles w ere allowed to diffuse out o f the agar for 
12-16 hours at 4°C. The E ppendorf was then centrifuged in an 
A ndeim an 4515 m icrofuge for 2 m inutes. The supernatant fraction 
containing the bacteriophage particles was transferred to  a fresh sterile 
E ppendorf tube and stored at 4°C. The titre o f phage particles was 
determ ined as described in  Section 2.10.4. In  general, a single plaque 
yielded approxim ately 10^ p.f.u./m l.
2.10.4 Determ ination o f the titre of bacteriophage lam bda
Y1088 plating cells were prepared as described in  Section 2.10.1. 
200jil o f plating cells were m ixed with 3m l top agar (Table 2.3) and 
poured onto a 90mm LB plate (Table 2.3). W hen the top agar had  set, 
the plate was inverted and grown at 37°C until a law n o f bacteria was 
visible. The bacteriophage to be titred were diluted in SM  buffer (Table
2.4) and 25p l o f the diluted phage was dropped onto one quarter of the 
LB plate containing the law n of Y 1088, thus four separate dilutions 
w ere applied to a single plate. The drop o f SM  buffer containing the 
bacteriophage was allow ed to dry, then the plates w ere inverted and 
incubated overnight at 37°C. The following m orning, the num ber of 
plaques present in each quarter could be counted and thus the num ber 
o f plaque form ing units (p.f.u.) per m illilitre could be calculated.
2.10.5 Preparation o f a high titre lvsate
H igh titre lysates w ere prepared from  plate stocks o f the purified 
positive phage obtained from  the third round o f screening (Section
2.10.2) as described by  M aniatis et al (1982). A  single positive plaque 
was picked using a sterile toothpick and w ashed into a test tube 
containing 200p l o f plating bacteria Y1088 (Section 2.10.1). The phage 
and bacteria were incubated for 15 m inutes at 37°C, 3m l o f top agar 
w ere added and the culture poured onto a 90mm LB plate supplem ented 
w ith lOmM MgSC>4 . The plate was then incubated at 42°C  until plaques 
w ere visible. A t this stage, 2m l SM  buffer (Table 2.4) was added to the 
plate w hich was then incubated overnight at 4°C. The SM  buffer 
containing the high titre lysate was rem oved from  the plate and 
centrifuged in the H B4 rotor o f the Sorvall centrifuge at 8,000 rpm  
(10,000xgav ) for 15 m inutes at 4°C to rem ove bacterial debris. The 
supernatant fraction was transferred to sterile universals w ith the 
addition o f a few  drops o f chloroform.
Bacteriophage stored in this m anner are stable fo r m any years w ith 
the titre o f phage dropping by a factor of 10 per year. In general, a 
h igh titre lysate yielded approxim ately 10*0 p.f.u./m l.
2.11 C H A R A C TER ISA TIO N  OF LAM BDA cDNA CLO NES
The m ethods described in  this section are described by H uynh et al. 
(1985).
2.11.1 Preparation of lvsogens
E. Coli strain Y1089 (Section 2.8.3) was infected w ith each clone 
at a m ultiplicity  o f infection of 5. The correct proportion of phage and 
bacteria w ere incubated at room  tem perature fo r 1 hour. The culture 
was then diluted 1:100, 1:1000 and 1:10,000 in  TBS (Table 2.4 ) and 
100p i of each dilution was spread onto 90m m  LB plates w hich were 
incubated at 30°C overnight. The plate w hich contained discrete 
colonies w as then replica-plated w ith the aid o f a pedestal and sterile 
W hatm an filter discs as follows: the plate containing the discrete 
colonies w as pressed onto the top filter on the pedesta l thus 
transferring the colonies to the filter. A  fresh LB plate  w as then placed 
on top of the filter and thus a replica of the original p late was obtained 
on the new  plate. This procedure was repeated so that tw o plates w hich 
were replicas o f the original plate were obtained. The first plate was 
incubated at 42°C while the second plate was incubated at 30°C until 
colonies were visible. Colonies which grew at 30°C (a tem perature at 
w hich the tem perature-sensitive phage repressor is functional) but not 
at 42°C were considered to be lysogenic. To ensure that individual 
colonies w ere lysogenic, a single colony was streaked out onto a fresh 
LB plate, incubated at 30°C and then replica-plated. I f  this colony 
continued to grow at 30°C but not at 42°C then  lysogeny was assured.
2.11 .2 Preparation of a crude lvsate from a X,gtl 1 recombinant lvsogen
10ml LB m edium  (Table 2.3) was inoculated w ith a single colony of 
Y1089 recom binant lysogen (Section 2.11.1) and incubated at 30°C 
overnight. 100ml o f pre-w arm ed LB m edium  was inoculated with 1ml 
o f overnight culture and incubated at 30°C until an optical density o f 
0.5 at 600nm  was obtained. The cells were then heat-shocked for 20 
m inutes at 45°C and isopropyl B-D thiogalactopyranoside (IPTG,
Sigm a) was added to a final concentration of lOmM to induce lac z - 
directed production o f the fusion protein. The cells were incubated at 
37°C  for a further 3 hours and then harvested by centrifugation at
8,000 rpm  (10,000xgav) in a Sorvall G SA  rotor for 15 m inutes. The 
cell pellet was resuspended in  2m l TBS (Table 2.4), transferred to a 
sterile Corex tube and the cells lysed by  repeated freezing in a dry ice- 
m ethanol bath and thawing in  a 37°C w ater bath. Bacterial DNA was 
digested by the addition o f lOpg D N ase I and the suspension 
centrifuged at 8,000 ipm  (10,000xgav) fo r 15 m inutes in a Sorvall H B 4 
rotor. The resulting supernatant fraction contained the fusion protein.
2 .12 IS O L A T IO N  O F  LA M B D A  AND P L A S M ID  DNA
A ll the procedures in the follow ing section are described in M aniatis 
et al (1982).
Purified DN A  was analysed by agarose gel electrophoresis (Section 
2.9.7) and the concentration of DN A  was determ ined by  m easuring the 
optical density at 260nm  (Section 2.12.5)
2.12.1 Preparation o f lambda D N A  from lvsogens
A  lysogenic colony was isolated (Section 2.11.1) and used to 
inoculate 10ml LB m edium  (Table 2.3) in a universal and grown 
overnight at 30°C. A  two litre flask, containing 400m l pre-w arm ed LB 
m edium , w as inoculated w ith 4m l o f the overnight culture and grow n at 
30°C until an optical density o f 0.5 at 600nm  was reached. A t this 
point, the culture was heat-shocked at 45 °C for 20 m inutes and then 
incubated at 37°C for a further 3 hours. The bacterial cells w ere then 
harvested by  centrifugation at 8,000 ipm  (10,000xgav) in a Sorvall 
GS A  rotor fo r 15 m inutes at 4°C. The bacterial pellet was resuspended 
in 10ml lOmM Tris.HCl pH  7.4, 50mM  NaCl, 5m M  M gCl2 and 
transferred to sterile Corex tubes. The cells were lysed by the addition 
o f 5 drops o f chloroform  to the bacterial suspension and incubated at 
room  tem perature for 30 m inutes. Cell lysis was evident due to the 
appearance o f bacterial D N A  which m ade the suspension viscous. To 
rem ove bacterial nucleic acids, DNase I (Sigma) and RNase A  (Sigm a) 
w ere added to a final concentration of lp g /m l and the cell lysate w as 
incubated fo r 30 minutes at room  tem perature. Solid N aC l and PE G  
6000 were added to the lysate to a final concentration of 1M and 10% 
(w/v) respectively. The cell lysate was then incubated overnight at 4°C  
to allow  the phage to precipitate. The phage w ere recovered by
i
centrifugation at 8,000 ipm  (10,000xgav) for 10 m inutes at 4°C  in  a 
Sorvall H B 4 rotor. The supernatant fraction was discarded and the 
pellet resuspended in 5m l SM  buffer (Table 2.4). An equal volum e o f 
chloroform  was added, vortexed for 30 seconds and centrifuged in  a 
Sorvall H B 4 rotor at 3,000 rpm  (l,500xgav) fo r 15 m inutes at 4°C . The 
aqueous phase was recovered and the volum e m easured. Caesium  
chloride was added to a concentration of 0.75 m g/m l, the solution
gently m ixed and transferred to Beckm an SW .50 tubes. The rem ainder 
o f the tube was filled w ith SM  buffer containing 0.75m g/m l caesium  
chloride. This suspension was centrifuged at 45,000 rpm  
(137,000xgav) at 4°C overnight. A fter centrifugation, a  pale band was 
visible w hen the tube was placed in  front o f a dark background. The 
band, containing intact phage particles, was isolated using a G ilson 
p200 pipette, transferred to dialysis tubing and dialysed at room  
tem perature for 3 hours against lOOOx volum es 50m m  Tris.H Cl pH 8, 
lOmM  N aCl, lOmM M gCl2 w ith  several changes of buffer. The phage 
w ere transferred to Eppendorf tubes and ED TA  was added to a final 
concentration of 20mM. A t this tim e, proteinase K (Sigm a) and SDS 
w ere also added to final concentrations o f 50pg/m l and 0.5%  
respectively. The solution was m ixed gently by inverting the tube 
several tim es and was incubated for 1 hour at 65°C. This results in  the 
digestion of the protein coat surrounding the lam bda D N A . The D N A  
was extracted with phenol tw ice, w ith phenolrchloroform  once, w ith  
chloroform risoam yl alcohol (24:1) once and then finally ethanol 
precipitated  (Section 2.12.4) 1
In  general, a lam bda purification resulted in  a yield of 
approxim ately 100-150 Jig DNA.
2.12.2 Large scale preparation o f plasm id D N A
This procedure was used to obtain large amounts o f plasm id pTZ. A  
single colony of E.coli DS941 transform ed w ith pTZ was used to 
inoculate 10ml LB m edium  (Table 2.3) supplem ented w ith lOOpg/ml 
A m picillin (Sigma) and the m edium  incubated overnight at 37°C. 5m l of 
overnight culture was used to inoculate 500m l LB m edium  containing
the same concentration of A m picillin as above. This culture was 
incubated at 37°C until an optical density of 0.4 at 600nm  was 
obtained. 2.5m l of a 34m g/m l solution of chloram phenicol (Sigm a) in 
ethanol was added to the culture and the incubation continued for 
approxim ately 12 hours. Chloram phenicol is an inhibitor o f bacterial 
pro tein  synthesis and thus stops genom ic D N A  synthesis, bu t no t 
plasm id D N A  replication. Therefore, the num ber o f plasm id copies/cell 
is increased.
A fter the incubation, the bacterial cells were harvested by 
centrifugation at 8,000 rpm  (10,000xgav) for 10 m inutes at 4°C in  the 
G SA  rotor of a Sorvall RC-5 centrifuge. The supernatant fraction w as 
discarded and the bacterial pellet washed in  100ml ice-cold STE 
(lOOmM NaCl, lOmM Tris.H Cl pH7.8, Im M  EDTA). The pellet w as 
resuspended in 10ml o f buffer containing 50m M  glucose, 25m M  
Tris.H Cl pH8, lOmM EDTA and 5m g/m l lysozyme (Sigma). The 
suspension was then transferred to Beckm an SW .27 polyallom er tubes 
and incubated at room  tem perature for 5 m inutes, after w hich 20m l of 
freshly prepared 0.2M  N aO H , 1% (w/v) SDS was added and the 
solution incubated on ice fo r a further 10 m inutes. 15m l ice cold 5M  
potassium  acetate pH4.8 was then added to the lysate and the contents 
o f the tube m ixed and left on ice for 10 m inutes before centrifugation at
20,000 rpm  (84,000xgav) fo r 20 m inutes at 4°C to pellet the cellu lar 
D N A  and the bacterial debris. T he resultant supernatant fraction 
containing the plasm id was transferred to Corex tubes, 0.6 volum es 
isopropanol added and incubated at room  tem perature fo r 15 m inutes. 
The DN A  was recovered by centrifugation at 8,500 rpm  (12,000xgav) 
fo r 30 m inutes at room  tem perature. The supernatant fraction w as 
discarded and the pellet w ashed w ith 70% (v/v) ethanol. The pellet was 
dried for 3 minutes in a vacuum  desiccator and resuspended in 8m l TE
buffer (Table 2.4)
To obtain closed circular D N A, the plasm id was centrifuged in  a 
caesium  chloride-ethidium  brom ide gradient, lg  o f solid caesium  
chloride was added per m l o f resuspended pellet and m ixed gently until 
all the caesium  chloride was dissolved. 0.8m l o f ethidium  brom ide 
(lOm g/m l) was added per m l o f caesium  chloride solution. The 
resultant solution was transferred to Beckm an SW .50 tubes and 
centrifuged at 45,000 rpm  (137,000xgay) for 36 hours at 20°C. Closed 
circular plasm id DN A binds less ethidium  brom ide m olecules than 
linear chrom osomal, open circular and linearised plasm id D N A  and 
hence has a higher buoyant density. It can therefore be seen as a 
separate band on the gradient and isolated.
Yields o f approxim ately lOOOpg of plasm id were routinely prepared 
by  this m ethod.
2.12.3 Small scale preparation o f plasm id DN A
A  single colony o f E.Coli transform ed with recom binant p lasm id 
was inoculated into 5m l LB m edium  (Table 2.3) supplem ented w ith 
lOOpg/ml Am picillin (Sigma) and grown overnight at 37°C. 1.5ml was 
transferred to an Eppendorf tube and centrifuged for 1 m inute in  an 
Anderm an 4515 microfuge. The m edium  was rem oved and the pellet 
drained. The bacterial pellet was resuspended by vortexing in lOOpl 
ice-cold 50m M  glucose, lOmM EDTA, 25m M  Tris.HCl, pH 8.0 
containing 5mg/ml lysozym e (Sigma) and was incubated at room  
tem perature for 5 m inutes. 200p i of freshly prepared 0.2M  N aO H , 1% 
(w/v) SDS was added, the contents of the tube m ixed by  inversion and 
the E ppendorf incubated on ice for 5 minutes. 150pl o f ice-cold 3M
potassium  acetate pH4.8 was then added, the solution vortexed for 10 
seconds and stored on ice for 5 m inutes. The E ppendorf was 
centrifuged at 4°C and the supernatant fraction, w hich contained the 
plasm id D N A, was transferred to a fresh tube. The D N A  was then 
phenol extracted and ethanol precipitated as described in  Section
2.12.4. The resultant pellet was resuspended in  50p l T E  buffer (Table
2.4) containing 20pg/m l D N ase-free RNase.
2.12.4 Phenol extraction and ethanol precipitation o f D N A
Proteins were rem oved from  D N A  solutions by sequential extraction 
w ith phenol, phenol: chloroform  and finally w ith chloroform :isoam yl 
alcohol (24:1)
A DNA-containing solution was phenol extracted by  the addition o f 
an equal volum e of TE saturated phenol, vortexed fo r 30 seconds and 
centrifuged in an A nderm an 4515 m icrofuge for 5 m inutes at room  
tem perature. The upper aqueous phase was carefully rem oved and 
transferred to a fresh E ppendorf tube. Extraction w ith 
phenol:chloroform  and chloroform :isoam ylalcohol (24:1) was 
perform ed in  the same m anner as for a phenol extraction.
D N A  was precipitated w ith Burrough's absolute alcohol as follow s: 
The volum e of the D N A  solution was estim ated and the final 
concentration of m onovalent ions adjusted to 0.25M  by  the addition o f 
2.5M  sodium  acetate pH5.2. Two volumes o f ice-cold absolute alcohol 
were added and the solution m ixed well. The D N A  was allowed to 
precipitate at -20°C for at least one hour, then centrifuged fo r 10 
m inutes in a m icrofuge at 4°C. The alcohol was discarded and the pellet 
was dried in  a vacuum  desiccator for 2 m inutes. F inally, the D N A  was 
redissolved in  TE buffer (Table 2.4).
2.12.5 Determination of D N A  concentration
The concentration of a D N A  solution was estim ated by obtaining the 
absorbance at 260nm. A n optical density o f 1 corresponds to 
approxim ately 50jig/m l fo r double stranded D N A  and 40jig/m l for 
single stranded DNA.
2.13 S U B C L O N IN G  L A M B D A  cDNA IN S E R T S  IN T O  
P L A S M ID  n T Z
The plasm id vector pTZ  (Section 2.8.2 and Figure 2.2) was used  in 
the construction o f all subclones in this project. The D N A  to be 
subcloned was inserted into the EcoRI site in  the polylinker region o f 
the vector.
2.13.1 Restriction digestion w ith EcoRI
B oth plasm id and recom binant lam bda D N A  w ere digested w ith 
EcoRI (BRL) and agarose gel electrophoresis was perform ed to ensure 
that digestion of the plasm id was com plete as undigested plasm id 
m olecules m ay result in a h igh background o f b lue colonies upon 
transform ation.
Restriction enzyme digests w ere generally carried out in  a final 
volum e of 20pl. A  typical digestion m ix contained the appropriate 
am ount of DN A  and EcoRI (1 unit o f restriction enzym e digests lp g  
D N A  in 1 hour), 2\il xlO high salt buffer (lOOmM NaCl, 50m M  
Tris.HCl pH7.4, lOmM MgSC>4 , Im M  DTT) and the volum e m ade up to 
20p l w ith sterile water. The m ix  was incubated fo r 2 hours at 37°C  and
the reaction term inated by heat denaturation. The digestion products 
w ere m onitored by  electrophoresis o f a sm all aliquot on an agarose gel 
o f the appropriate percentage (Section 2.9.7) B oth plasm id and lam bda 
D N A  were extracted twice w ith phenol and then precipitated w ith 
ethanol as described in  Section 2.12.2.
2.13.2 A lkaline phosphatase treatm ent of plasm id D N A
A fter digestion with EcoRI, the vector D N A  was treated with alkaline 
phosphatase to rem ove the 5' phosphate groups, thus preventing 
recirculaiisation o f the vector during the ligation reaction. Failure to do 
this m ay result in  a high background of blue colonies upon 
transform ation.
The digested plasm id DNA was resuspended in  20p l alkaline 
phosphatase buffer (lOm M  Tris.HCl, pH 9.2, O .lm M  EDTA) and 0 .5p l 
calf intestinal phosphatase (70 units/pl, B oehringer M annheim ) was 
added, m ixed w ell and incubated at 37°C for 30 m inutes. A fter 
incubation, the volum e o f sam ple was increased to  lOOpl w ith TE  
buffer (Table 2.4 ) and extracted w ith phenol:chloroform  3 tim es, w ith 
ether tw ice and finally precipitated w ith ethanol as described in  Section
2.12.4. The DN A  was redissolved in  TE buffer.
2.13.3 Ligation of DN A fragm ents
The ligation reactions were carried out using a vector:insert m olar 
ratio o f 3:1. The ligation m ix contained 2 .2pg lam bda DNA, 0 .3pg 
vector DNA, 3p i 5mM  ATP, 1 unit ligase (BRL), 3p i x  10 ligase buffer 
(400m M  Tris.HCl pH7.6, lOOmM M gCl2 , lOOmM D TT) and the 
volum e m ade up to 30pl with sterile distilled water. T he ligation m ix
w as incubated at 15°C for 16 hours.
2 .13.4 Preparation o f com petent cells
The tw o E.Coli strains w hich were required to be com petent fo r the 
uptake o f plasm id were DS941 (for the propagation and characterisation 
o f recom binant plasmids) and M V 1190 (for DN A sequencing ). B oth o f 
these strains are described in  detail in  Section 2.8.3.
DS941 was streaked out onto an LB agar plate (Table 2.3) to  obtain a 
stock plate o f bacterial colonies. A  single colony of DS941 was 
transferred to 10ml LB m edium  (Table 2.3) and grow n overnight at 
37°C. 100ml LB m edium  supplem ented w ith 0.2% (w/v) glucose was 
inoculated w ith 1ml of the overnight culture and incubated at 37°C w ith 
good aeration until the optical density at 600nm  was 0.3. The culture 
w as incubated on ice for 10 m inutes, then harvested at 6,000  rpm  
(6,000xgav) in the Sorvall G SA  rotor for 5 m inutes at 4°C. The 
m edium  was decanted and the bacterial pellet gently resuspended in  6m l 
ice-cold CaCl2  in  lOmM Tris.H Cl pH 8 . The resuspended pellet w as 
incubated on ice for 30 m inutes, then centrifuged at 3,000 rpm  
(l,5 0 0 x g av) for 5 m inutes at 4°C in  the Sorvall H B4 rotor. The 
supernatant fraction was decanted and the bacterial pellet very gently 
resuspended in 2ml ice-cold lOOmM CaCl2 - The bacterial cells w ere 
now  com petent and ready for transform ation. Fresh com petent cells 
w ere prepared for each transform ation.
M V 1190 bacterial cells w ere m ade competent as described for DS941 
bacteria  w ith  the following exceptions: a single colony o f M V 1190 was 
p icked from  a stock grown on m inim al agar (Table 2.3) and the colony 
w as then propagated in 2xTY m edium  (Table 2.3)
2.13.5 Transformation o f competent E. Coli bv plasm id D N A .
3 p l and 15 |il o f ligation m ix (Section 2.13.3) was added to lOOpl of 
com petent cells (Section 2.13.4) and then incubated on ice for 30 
m inutes. T he cells were heat-shocked at 42°C for 3 m inutes, 1ml of LB 
m edium  (Table 2.3) was added and the cells incubated at 37°C for 45 
m inutes to allow  the transform ed bacteria to express the antibiotic 
resistance gene. A t least 5 m inutes before use, 0.5%  (w/v) 5-brom o-4- 
chloro-3-indolyl-B D galactoside (Xgal, BRL) in  dim ethyl form am ide 
and 0.5%  (w/v) isopropyl B-D thiogalactopyranoside (IPTG, Sigm a) in  
w ater w ere spread over the surface of LB agar plates supplem ented 
w ith 100 jig/m l Ampicillin (Sigma). D ifferent amounts o f transform ation 
m ix  (one tenth  and half o f the m ix) were spread onto the 
LB/A m picillin/X gal/IPTG  plates. W hen the liquid had  been adsorbed, 
the plates w ere inverted and incubated at 37°C for 16 hours. A fter this 
tim e, positive (white) colonies were subcultured onto sim ilar plates as 
above and again incubated overnight at 37°C to ensure that they were 
no t false positives. Colonies w hich continued to be w hite after several 
rounds o f screening were isolated and used to purify plasm id D N A  
(Sections 2.12.2 and 2.12.3) or to prepare single stranded D N A  for use 
in  D N A  sequence analysis (Section 2.14.2)
2.14 S E Q U E N C IN G  DNA BY  T H E  SA N G E R  D ID E O X Y  
C H A IN  T E R M IN A T IO N  M E T H O D
The cD N A  clones, pRLRI 7 and pRLRI 8 w ere sequenced by the 
Sanger chain term ination m ethod as described in the "M13 Cloning and 
Sequencing Handbook" (Amersham International)
A  single stranded tem plate is required for synthesis o f the
com plem entary strand by the K lenow fragm ent of E.coli DNA 
polym erase I. The K lenow  fragm ent lacks the 5' to 3 'exonuclease 
activity o f the intact enzym e and requires a 3' OH  group to synthesise 
in  a 5' to 3' direction. A  prim er, i.e. a short region o f double stranded 
D N A , is annealed to the m ultiple cloning region and acts to direct the 
synthesis of the DN A  chain. D ideoxy sequence analysis depends on the 
random  incorporation of dideoxyribonucleotides into the growing 
chains. As these nucleotides lack  a 3' hydroxyl group, the K lenow  
fragm ent is unable to form  a phosphodiester bond w ith another 
deoxyribonucleotide and hence chain term ination results. To determ ine 
the sequence, four separate synthesis reactions are perform ed, each 
containing only one of the four dideoxyribonucleotides. The ratio o f 
deoxy NTP:dideoxy N TP is controlled so that chain term ination occurs 
random ly over the com plete sequence. The D N A  chains are then 
separated according to m olecular weight by  gel electrophoresis. The 
developm ent of high definition, thin polyacrylam ide gels has m ade 
possible the separation o f D N A  fragm ents differing in  size by a single 
nucleotide.
2.14.1 Propagation of M 13K Q 7 Helper Phage
The M 13K 07 helper phage were kindly donated by D r L.M  A nderson 
o f this departm ent and were propagated as follows:
Phage were streaked onto an LB agar plate (Table 2.3). 4m l o f top 
agar (Table 2.3) containing 0.5m l of an overnight culture of M V 1 190 
was poured across the plate and it was incubated overnight at 37°C.
The agar was scraped into a 250m l flask containing 50m l 2xTY m edium  
(Table 2.3) and 70pg/m l K anam ycin (Sigma), and grow n for 10 hours
w ith good aeration. The bacteria w ere harvested at 8,000 rpm  
(10,000xgav) in the Sorvall H B4 rotor and the supernatant fraction, 
w hich contained the M 13K 07  helper phage, saved. The supernatant 
fraction was recentrifuged at 8,000  rpm  to ensure that there w as no  
contam ination w ith bacteria. The supernatant fraction was then stored 
at 4°C.
2.14.2 Preparation of single stranded pT Z  DN A
M V 1190 transform ed w ith either pR LR I 7 or pR LR I 8 were grow n at 
37°C overnight in 10ml m inim al m edium  (Table 2.3) containing 
lOOpg/ml Am picillin (Sigma). 10ml 2xTY  m edium  (Table 2.3), also 
supplem ented w ith Am picillin, was inoculated with lOOpl o f the 
overnight culture and grown at 37°C until the OD at 660nm  w as 0.5. 
2m l of this culture was transferred to a 50m l Falcon tube and 
inoculated with M 13K 07  at a m ultiplicity o f 10, i.e. 10 plaque form ing 
units (pfu) M 13K 07 per M V 1190 cell (assuming an OD o f 1 is 8x10** 
cells/m l), and incubated at 37°C for 1 hour w ith good aeration. 10m l 
2xTY, supplem ented with 70ji.g/ml Kanam ycin, was inoculated w ith 
400p i of infected cells and incubated at 37°C overnight w ith vigorous 
shaking. The bacteria were harvested by centrifugation at 6,000 rpm  
(6,000xgav) in the Sorvall H B 4 rotor and the supernatant fraction 
retained. The supernatant fraction, w hich contains the packaged pT Z  
DN A, was recentrifuged until there was no evidence o f a bacterial 
pellet. The DN A was precipitated by the addition o f 1ml PEG  (25% 
(w/v) in 3M  NaCl) to the supernatant fraction and the solution 
incubated at room tem perature fo r 15 minutes. The precipitated phage 
w ere harvested by centrifugation at 8,000  rpm  ( 10 ,0 0 0xgav) in  the
Sorvall H B 4 rotor, resuspended in 350pl 20m M  T ris.H C l pH7.5, 
20m M  N aC l and Im M  ED TA  and transferred to an Eppendorf tube. The 
D N A  was then phenolxhloroform  extracted and precipitated as 
described previously (Section 2.12.4) and the D N A  pelle t resuspended 
in  50p i TE  buffer (Table 2.3).
2.14.3 Annealing tem plate to  prim er
The first step in the sequencing reaction was to anneal the prim er to 
the tem plate in  order to provide a double stranded prim ing region for 
the K lenow  catalysed elongation. The prim er used routinely was the 15 
base reverse sequencing prim er which anneals 3 ’ to the m ultiple 
cloning region (see Figure 2.2).
5 p i (approximately lp g  o f DNA) of single stranded D N A  tem plate 
(Section 2.14.2) was annealed to  lp l  o f reverse p rim er (1.2m g/m l) in a 
final volum e of lOpl containing 1.5pl o f 10X K lenow  reaction buffer 
(lOOmM Tris.HCl pH 8.0, 50m M  M g C ^ ). The sam ples were placed in a 
boiling w ater bath at 90°C, the heat turned off and the sam ples left fo r 
45 m inutes.
2.14.4 Chain elongation w ith Klenow polym erase
The annealed prim er/tem plate prepared as described in  the previous 
section (Section 2.14.3), was spun briefly to the bottom  o f the 
Eppendorf tube. 15pCi [ a - ^ S ]  dATP (Am ersham ) and 1 unit o f 
K lenow  fragm ent (Amersham) were added and the contents o f the tube 
m ixed carefully by pipetting in and out.
Four Eppendorf tubes, m arked A, C, G, and T, w ere p laced in  an 
A nderm an 4515 m icrofuge and into each was pu t 2.5 p i  o f the above
TABLE 2.5 COMPOSITION OF dNTP/ddNTP MIXES.
T he com position of deoxy (d) NTP/dideoxy (dd) N TP m ixes used in 
Section  2.14.4 are shown. Stock solutions were provided in  the 
A m ersham  sequencing kit and the m ixes were prepared as described by 
the m anufacturer in  the "M13 Cloning and Sequencing Handbook" 
(Amersham)
deoxy (d)/dideoxy (dd) nucleotide m ixes contained the following:
d/ddA  62.5J0.M of dCTP, dGTP, and dTTP, and 5 0 |lM  o f ddATP
d/ddC 82 |iM  o f dGTP and dTTP, 4pM  o f dCTP, and 50 |iM  of 
ddCTP
d/ddG  82 |iM  o f dCTP and dTTP, 4 |iM  o f dGTP, and 150|oM of 
ddGTP
d/ddT 82p.M of dCTP and dGTP, 4jtM  o f dTTP, and 250p.M ddTTP
prim er/tem plate/label/enzym e mix. 2 p i o f the relevant dNTP/ddNTP 
m ix  (Table 2.5) was added to the appropriate tube and the reactions 
started by  a b rief spin. A fter 20 m inutes, 2 p l o f chase m ixture (0.5m M  
o f all 4  dNTPs) was added and the sam ples incubated for a further 15 
m inutes. This elongates the DN A  chains no t term inated by a 
dideoxynucleotide and therefore helps to  reduce the appearance o f non­
specific bands on the sequencing gel. The sam ples w ere then split into 
two: one h a lf for imm ediate electrophoresis; the other ha lf was stored 
at -20°C until required. 2pl o f form am ide dye m ix  (0.1 % (w/v) xylene 
cyanol FF  (Sigma), 0.1% (w/v) brom ophenol blue (Sigma), 20m M  
ED TA  in  deionised form am ide (Fluka)) w as added to the sample to be 
electrophoresed immediately. The sam ple w as then heated for 2 m inutes 
at 90°C and loaded onto a polyacrylam ide gel apparatus (Shandon 
V ertical Slab U nit 400, Southern) for determ ination o f the D N A  
sequence (see following section for details).
2.14.5 Polyacrylam ide gel electrophoresis in  the analysis o f D N A  
sequence
The D N A  samples were separated by electrophoresis on 
polyacrylam ide/urea denaturing gels (containing 6 % acrylam ide 
/bisacrylam ide (19:1) and 7M  urea) using a TBE (Table 2.3) buffering 
system. T he gel plates were siliconised p rior to use w ith Repelcote 
(dim ethyldichlorosilane in 1,1,1, trichloroethane) and assem bled w ith 
0.4m m  spacers. The wells for loading the sam ples w ere prepared by  
inserting a 20  tooth comb.
The gel was pre-run at 30m A for 15 m inutes prior to sam ple 
application using an LKB 2197 pow er supply. The sam ples, prepared
as described previously (Section 2.14.4), w ere loaded im m ediately 
after boiling and subjected to electrophoresis fo r betw een 1 and 3 
hours. Electrophoresis fo r 1 hour at 30m A  was sufficient to resolve the 
first 200 bases from  the prim er region. Further resolution was obtained 
by  electrophoresing the second h a lf o f the reaction m ix  for 3 hours.
A fter electrophoresis, the gel was fixed in  10% (v/v) m ethanol, 10% 
(v/v) acetic acid for 20  m inutes at room  tem perature, then dried using a 
vacuum  gel diyer. The gel was then exposed using F uji RX  film  
overnight at room  tem perature.
2.15 P R E P A R A T IO N  O F  RNA
To prevent contam ination w ith ribonucleases, all solutions used  in 
the preparation of R N A  w ere treated w ith diethylpyrocarbonate (DEPC, 
Sigm a) before autoclaving (described in Section 2.2) and all g lassw ear 
w as treated w ith Repelcote as described in  the sam e section.
. 2.15.1 Isolation of total R N A
R N A  was isolated from  rat tissues using a m odification of the 
guanidine isothiocyanate m ethod o f Chirgwin et al.,(1919).
The tissue of interest was rem oved from  a freshly-killed rat and 
placed into an ice-cold solution o f saline (0.9% (w/v) N aCl) in  a sterile 
beaker. The saline was then poured off, the tissue chopped into sm all 
pieces and transferred to a chilled m ortar containing liquid N 2 , ground 
to a fine pow der and then stored in  a plastic universal container in 
liquid N 2  until required. 6m l of chilled G IT-m ercaptoethanol buffer 
(4M  guanidine isothiocyanate, 25m M  sodium acetate pH 6.0, 120m M  B- 
m ercaptoethanol) was pipetted into a glass hom ogeniser, lg  o f
pow dered tissue added and the tissue hom ogenised w ith a m otor-driven 
pestle (approxim ately 10 strokes). The resultant "slurry" was draw n 
into a  syringe and the D N A  sheared by passing through a G23 needle 
five tim es. The solution was transferred to sterile Corex tubes and 
centrifuged at 10,000 rpm  (16,000xgav  ^ in the H B 4 ro tor o f a Sorvall 
RC-5 centrifuge for 10 m inutes at 4°C to rem ove cellular debris. 6m l of 
caesium  chloride buffer (5.7M  caesium  chloride, 25m M  sodium  acetate 
pH 6.0) was pipetted into ultracentrifuge tubes and the guanidine-lysed 
sam ple layered on top. The tube was filled w ith G IT-m ercaptoethanol 
buffer and the sample centrifuged at 31,000 rpm  (116,000xgav) in  a 
SW .40 rotor o f a Beckm an LS-50 ultracentrifuge for 20 hours at 20°C. 
A fter this tim e, the centrifuge was stopped w ithout the use o f brakes to 
prevent disturbing the bands o f protein and DNA. The R N A  was 
observed as a gelatinous pellet at the bottom  o f the tube. The 
supernatant fraction was rem oved carefully w ith a sterile pasteur 
pipette and the tube inverted over a tissue to drain. The R N A  pellet was 
resuspended in  1ml G IT-m ercaptoethanol and transferred to a C orex 
tube. The ultracentrifuge tube was w ashed out w ith 2 x lm l aliquots o f 
the same buffer which was also transferred to the C orex tube. The 
volum e was then increased to 6m l w ith G IT-m ercaptoethanol and the 
R N A  extracted with an equal volum e of phenol: CHCL3 . The phases 
w ere separated by centrifugation at 10 ,000 rpm  (16,000xgav) in  the 
H B4 rotor o f the Sorvall fo r 20 m inutes. The upper aqueous phase was 
extracted w ith chloroform  as above and the R N A  precipitated as 
described in  Section 2.15.2.
A n aliquot o f resuspended R N A  was obtained and analysed by 
spectrophotom eter to determine the OD 260/280 ratio (a pure sam ple of 
R N A  has an OD 260/280 ratio o f 2) and the quantity o f R N A  (an
OD260 o f 1 is equivalent to 40pg/m l RNA). In general, lg  of rat tissue 
yielded approxim ately lOOOpg o f total RNA.
2.15.2 Ethanol precipitation o f RNA preparations
R N A  was precipitated by  estim ating the volum e o f the sam ple, 
adding 1/10 volum e of 3 .3M  N a acetate pH 5.5 and 2.5 volum es o f 
absolute alcohol (Burrough) and incubating overnight at -20°C.
In  general, the RN A  was stored as an ethanol precipitate at -20°C 
until required. W hen needed, the RNA was pelleted by  centrifugation at
10,000 rpm  (16,000xgav) in  the Sorvall H B4 ro tor at 4°C . The pellet 
was washed with 70% (v/v) absolute alcohol, dried under vacuum  and 
resuspended in an appropriate volume of D EPC-treated double 
deionised distilled w ater ("super Q" water).
2.16 P R E P A R A T IO N  O F  PR O B E S  F O R  U S E  IN  N O R T H E R N  
AND S O U T H E R N  B L O T T IN G
2.16.1 Purification o f cD N A  insert
To isolate the required cD N A  insert, 5pg  of recom binant plasm id 
(pRLRI 7, pRLRI 8 or pH PI) was digested w ith E coR I as described in 
Section 2.13.1 and the digested products subjected to electrophoresis 
on an 1% low m elting poin t agarose gel (Section 2.9.7) at 40V  until the 
tracking dye neared the end o f the gel. The gel was illum inated using a 
U V  transihum inator and the D N A  band corresponding to the cD N A  
insert was excised, diced into small pieces and transferred  to a sterile 
1.5ml Eppendorf tube. The tube containing the gel was heated to 65°C 
for 5 m inutes to m elt the agarose and the volum e m ade to 200pl w ith
TE buffer (Table 2.4). A  further 2 volum es o f TE buffer was added and 
the cD N A  insert was extracted with 1 volum e o f TE-saturated phenol 
(the phenol w as pre-equilibrated to 65°C). The resultant aqueous phase 
was extracted a further tw ice w ith phenol, once w ith phenolrchloroform  
at room  tem perature and once with chloroform . The cD N A  was 
precipitated as described previously (Section 2.12.4). The resultant 
pellet was resuspended in 10|il TE buffer and stored at -20°C until 
required. In  general, it was assum ed that, from  5pg  o f  recom binant 
plasm id, 250ng of pR LR I 7 and 8 insert and 800ng o f pH PI insert was 
obtained (assum ing the inserts from  pR L R I 7 and 8 w ere one tenth o f 
the total D N A , the insert from  pH PI was one third o f to ta l D N A  and 
50% of the D N A  was lost during phenol extraction and subsequent 
stages).
2.16.2 Labelling o f cD N A  inserts
The cD N A  inserts were labelled by the random  prim ing m ethod o f 
Feinberg and V ogelstein (1983). Denatured D N A  acts as a tem plate for 
the Klenow fragm ent o f DNA polymerase using random  
oligonucleotides as prim ers.
50ng o f insert cDN A , purified as decribed in  the previous section 
(Section 2.16.1), w as diluted to 35p i w ith T E  buffer (Table 2.3) in  a 
sterile Eppendorf tube, incubated for 5 m inutes in  a boiling w ater bath  
to  denature the D N A  and then plunged into ice for 2 m inutes to prevent 
the denatured DN A  from  reannealing. lOpl o f hexanucleotide solution 
(Table 2.6) and lp l  o f BSA  (20mg/ml, B oehringer M annheim ) were 
added and the contents o f the tube spun briefly. 30pC i [ a ^ P ]  dC TP 
(Am ersham ) was added, followed by 3 units o f K lenow  fragm ent
TABLE 2.6 COMPOSITION OF THE RANDOM PRIMER SOLUTION
The hexanucleotide random  prim er solution used in  Section 2.16.2 is 
outlined. The solution was prepared as described, aliquoted into 50jil 
lots and stored at -2 0 °C.
Solution A : 0.5m M  deoxytriphosphates (dATP, dG TP, dTTP) in  1.25M  
Tris.H Cl pH 8 , 0.125M  M g Cl2 ,10m M  B-m ercaptoethanol
Solution B : 2M  HEPES pH 6.6
Solution C : 50 units hexadeoxynucleotides (Pharm acia) resuspended in 
556p l distilled water.
The hexanucleotide solution was prepared by  m ixing together solutions 
A , B and C in  the ratio 100:250:150.
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(Boehringer Mannheim). The reaction m ix was then incubated at room  
tem perature for approxim ately 16 hours. To stop the reaction, 2JJ.1 0.5M  
E D T A  and 2jil 20% (w/v) SDS were added to the solution. A t this point 
lp.1 o f the reaction m ix was diluted to 50p l w ith TE buffer and 
processed as described in  the follow ing paragraph. The rem ainder of 
the labelled insert w as precipitated as described in Section 2.12.4 and 
resuspended in 10pl TE  buffer.
The am ount o f radioactivity incorporated into the cD N A  was 
determ ined by spotting 5jxl aliquots onto two separate W hatm an DE 81 
filters that were allowed to dry. One filter (A) was p laced  directly into 
a scintillation vial and 5m l Ecoscint added. The other filter (B) was 
w ashed w ith 0.5M  N a2H P 0 4  fo r 30 m inutes w ith 6 changes of buffer, 
then  several times w ith distilled w ater and finally w ith  absolute 
alcohol. These washes rem ove any label w hich has no t been 
incorporated into the cDNA. The filter was allowed to  dry and added to 
a  scintillation vial w ith 5m l Ecoscint. The two filters w ere then counted 
on an LKB 1209 Rackbeta scintillation counter. F ilter A  is a m easure of 
the to tal counts obtained whereas filter B is a m easure o f the label 
w hich has been incorporated into the cD N A  insert. In  general, the 
random  prim ing m ethod o f labelling the cD N A  inserts gave 
incorporation of betw een 70 and 85%.
2.17 NIJCTETC A C ID  H Y B R ID IS A T IO N
2.17.1 N orthern blotting
This technique involves the separation o f R N A  by electrophoresis on 
an agarose gel under denaturing conditions, transfer o f the R N A  onto a 
solid support i.e. a m em brane filter, and then detection o f specific
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R N A  species by hybridisation w ith a radioactive probe.
Sam ples of RNA were denatured by heating them  to  65°C for 5 
m inutes in 20mM  M OPS (3- [N]-m orpholinopropane sulphonic acid, 
Sigm a), 50% (v/v) deionised form am ide and 2.2M  form aldehyde. They 
w ere then rapidly cooled on ice and m ade 0.04%  (w/v) w ith respect to 
brom ophenol blue (Sigma).
A  1% agarose gel containing 2.2M  form aldehyde was prepared and 
the R N A  sample (prepared as described in  the above paragraph) applied 
to  the gel. Electrophoresis o f the RNA sam ples was carried out 
overnight at 25V using 20m M  MOPS as the buffering system.
A fter electrophoresis, the R N A  was transferred from  the agarose gel 
to a nylon m em brane (Hybond N, Am ersham ) as described by Thom as 
(1980). W hatm an 3M M  paper, saturated w ith 20X  SSC (see Table 2.3), 
w as laid  over a glass plate such that two o f its edges w ere dipping into 
reservoirs o f 20X SSC. The agarose gel was placed on the saturated 
3M M  paper and cling film  placed around all four edges. H ybond N  was 
laid  carefully over the gel to ensure that no air was trapped betw een the 
gel and filter. Three pieces o f dry 3M M  paper were then placed on top 
o f the gel, followed by a 6 cm thickness o f paper tow els and a glass 
plate. A  heavy w eight was then placed on top o f this and the assem bly 
left for 4 hours with the wet paper towels being replaced every 15 
m inutes. A fter this time, the m em brane filter was dried at room  
tem perature, wrapped in Saranwrap and the R N A  cross-linked to the 
filter by exposure to UV light fo r 1 m inute.
The m em brane filter was prehybridised by incubating at 42°C w ith 
10ml buffer 1 (30% (v/v) deionised form am ide (Fluka), 5X  D enhardt's 
(Table 2.3), 5X SSPE (Table 2.3), 0.1% (w/v) SDS and 100jxg/ml 
denatured salmon sperm DNA) for 4 hours in a perspex, w ater-tight
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box. Single stranded radioactive probe (labelled by the random  prim ing 
m ethod as described in Section 2.16.2) was added to 10 m l o f buffer 1 
at a concentration of 10^ cpm /m l and incubated with the H ybond N  
filter at 42°C for 16 hours. The filter was then rem oved from  the 
hybridisation cham ber into a plastic sandwich box and rinsed w ith 2X  
SSPE containing 0.1%  (w/v) SDS at 42°C. N on specifically bound 
probe was rem oved by incubating the filter w ith IX  SSC containing 
0.1%  (w/v) SDS for 15 m inutes at 65°C (m edium  stringency wash).
The filter was then w ashed w ith high stringency (0.1X  SSC, 0.1%  
(w/v) SDS) for 15 m inutes at 65°C. The hybridisation o f probe to 
blotted R N A  was visualised by  autoradiography i.e. the filter was 
exposed to Kodak-X-Om at film  using an intensifying screen (Cronex 
lighting) and left for an appropriate time period at -70°C. It should be 
noted that when a non hom ologous probe was used in  the northern b lo t 
technique, the filter was exposed after the m edium  stringency w ash, 
then subjected to a high stringency w ash and re-exposed.
The radioactive probe m ay be rem oved from  the northern b lo t by 
incubating the m em brane in  a solution containing 5m M  Tris.H Cl 
pH8.0, 2m M  EDTA and O .lxD enhardt’s (Table 2.4) fo r 2 hours at 
65°C. The blot m ay then be challenged w ith an alternative probe.
2.17.2 D eterm ination o f the size of RN A  transcripts
A n R N A  ladder (Boehringer M annheim) was electrophoresed in the 
last track of all RN A  gels and blotted w ith the other R N A  sam ples onto 
H ybond-N  as described in  Section 2.17.1. A fter cross-linking, the 
section o f filter containing the RNA ladder was rem oved, stained w ith 
m ethylene blue for 5 m inutes and destained in H 2 O until the R N A  
bands were visible (Section 2.17.3). R f values were then  calculated i.e:
distance m igrated by R N A  standard
R f =--------------------------------------------------------- ----
distance m igrated by  tracking dye
A  graph o f log bp versus R f  values was p lotted  using the standards 
from  the R N A  ladder. The size o f specific transcripts present on the 
b lo t were then calculated using the standard curve.
Sim ilarly, a  123 bp ladder w as used to determ ine the size o f D N A  
fragm ents on an agarose gel. The DNA bands were visualised by direct 
ethidium  brom ide staining o f the agarose gels (as described in  Section 
2 .9 .7 )
2.17.3 Staining o f R N A  m arkers
R N A  m arkers were visualised following their transfer onto H ybond 
N  as recom mended by Am ersham . The m em brane containing the 
m arkers was incubated at room  tem perature in 5%  (v/v) acetic acid for 
15 m inutes and then stained in  a solution containing 0 .5M  sodium  
acetate, pH 5.5, 0 04%  (w/v) M ethylene Blue (Sigm a) fo r 5 m inutes. 
The stain w as rem oved by  w ashing in  distilled w ater. T he filter was 
then dried and stored in  the dark.
2.17.4 Southern blotting
The principle o f Southern blotting is very sim ilar to that o f northern  
blotting except that D N A  is separated by electrophoresis under non 
denaturing conditions (Southern, 1975)
The DN A  was subjected to  electrophoresis on a 1% (w/v) agarose gel 
a t 50V  for approxim ately 3 hours using IX  TB E (Table 2.3) as the
buffering system . The DN A  was denatured by  incubating w ith 0.5M  
N aO H , 1.5M N aC l for 30 minutes at room  tem perature and then 
neutralised by  soaking in  0.1M  Tris.H Cl, pH 7.5, 1.5M N aC l fo r a 
further 30 m inutes. The D N A  was transferred onto H ybond N  
essentially as described for the transfer o f R N A  in  the previous section 
(Section 2.17.1), w ith the exception that the transfer took  place 
overnight. The filter was rem oved after this tim e and soaked in 2X  SSC 
(Table 2.3) fo r 10 m inutes, dried betw een tw o pieces o f 3M M  paper, 
then baked for 2 hours at 80°C in a vacuum  oven.
The filter was incubated in  10ml prehybridisation buffer (5X 
D enhardt’s (Table 2.3), 6xSSC (Table 2.3), 0.1%  (w/v) SDS,
100jig/m l salm on sperm DNA) for 4  hours at 65°C and then hybridised 
overnight at 65°C in fresh buffer containing 1x10^ cpm /m l of labelled 
probe (Section 2.16.2). The filter was w ashed at 65°C fo r 3x30 
m inutes in  2X  SSC, 0.1% (w/v) SDS and finally  in  0 .2X  SSC, 0.1%  
(w/v) SDS for 30 m inutes. The m em brane filter was then exposed to 
K odak X -O m at film  using an intensifier screen (Cronex lighting) and 
left for an appropriate tim e period at -70°C.
The control probe used in  both northern and Southern blotting was 
k indly donated by  D .P.Leader of this departm ent and w as a 700bp 
m ouse y  actin  cDNA in  the xba/pst 1 sites o f pU C  18.
CHAPTER THREE 
RESULTS
This chapter is divided into several sections: the first illustrates 
the preparation of the antibody probe w hich was used to screen the 
ra t liver Xgtl 1 expression library; the second section outlines the 
isolation o f the cD N A  clones from  this library and the final sections 
describe the characterisation o f these clones by im m unological 
m ethods and by direct com parison o f amino acid and nucleotide 
sequences with those o f ribonuclease inhibitor purified from  hum an 
placenta (Lee et al., 1988) and porcine liver (Hofsteenge et 
aL, 1988).
3.1 P R E P A R A T IO N  O F  T H E  A N T IB O D Y  P R O ttF ,
3.1.1 Purification o f ribonuclease inhibitor from  rat liver
Ribonuclease inhibitor w as routinely prepared by the m ethod o f 
B urton (1980) using rat liver as the source o f protein. D etails o f 
the purification procedure are outlined in  Sections 2.5.1 and 2.5.2. 
Initially, ribonuclease inhibitor was purified to be used as an 
antigen in  the production o f antiserum  (see Sections 2.7.1 and
3.1 .2  fo r details). In  the later stages o f the project, the pro tein  w as 
purified  for use in am ino acid sequence analysis (outlined in 
Section  3.4).
A  purification table for a typical preparation is show n (Table 
3.1) and is com prised o f the data obtained from  a preparation 
u tilising 20 rat livers and a 1ml sepharose affinity colum n. The 
first step, the preparation of a 35-60%  (w/v) am m onium  sulphate
TABLE 3.1 PURIFICATION OF RAT LIVER RIBONUCLEASE
INHIBITOR
The data w as derived from  a typical purification using the livers of 
20 W istar rats and a  1ml RNase A-Sepharose affinity colum n 
(described in  Section 2.5). Inhibitor activity was assayed as described 
in Section 2.5.4. Protein concentration was determ ined by the m ethod 
of B radford  (Section 2.4.1).
1 unit o f inhib itor activity was defined as the quantity required to 
inhibit by  50% the digestion of 5ng of RNase A.
R at liver cytoplasm
35-36% ammonium 
sulphate precipitate 
(after dialysis)
T otal Total Specific Purification 
protein activity activity factor
(mg) (units) (units/m g)
14,000 186,000 13.3 0
3,200 160,000 50 3.75
%
Yield
100
86
A ffinity chrom atography
eluate 0.72 80,000 111,100 8,400 43
FIG U RE 3.1 RNASE A-SEPHAROSE AFFINITY 
CHROMATOGRAPHY OF RAT LIVER RIBONUCLEASE INHIBITOR
The purification o f ribonuclease inhibitor from  rat liver was 
perform ed as described in Section 2.5.2. The activity o f the inhibitor 
was determ ined as described in Section 2.5.4 and protein 
concentration was determined by absorbance at 280nm.
The starting buffer at A was 45m M  potassium  phosphate, pH 6.4 and 
at B w as changed to starting buffer m ade 0.5M  w ith respect to NaCl. 
The elu tion  buffer at C was 0.05M  borate pH 6 ; 4M  NaCl; 15% (v/v) 
glycerol. A ll buffers also contained lm M  ED TA  and lOmM B- 
m ercaptoethanol.
The am ount o f protein in the fractions com ing through the colum n 
prior to  the addition of buffer B had  an absorbance at 280nm  greater 
than 1.0. A fter changing to buffer B, the absorbance at 280nm  
decreased until a value of 0.05 at 280nm  was obtained (this data is not 
show n on this figure). The protein eluted from  the affinity colum n 
after addition  of buffer C is shown.
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FIGURE 3.2 SDS PAGE ANALYSIS OF FRACTIONS ELUTED
FROM  THE RNASE A-SEPHAROSE AFFINITY COLUM N
A fter changing to elution buffer (0.05M  borate pH6; 4M  NaCl; 15% 
(v/v) glycerol; lOmM B-mercaptoethanol; Im M  EDTA), lOOpl o f each 
fraction eluted from  the colum n was acetone precipitated (Section 
2.4.2), the precipitate resuspended in  laem m li sample buffer and 
subjected to electrophoresis on a 10% SDS polyacrylam ide gel 
(Section 2.4.3). The gel was stained w ith Coom assie B lue and 
destained as described in Section 2.4.5.A.
Lanes 1 and 18 contained m olecular weight m arkers (Sigm a) as 
follow s: m yosin  (200 KDa); phosphorylase b (97 KD a); bovine serum  
album in (68 KDa); ovalbum in (45 KDa); carbonic anhydrase (30 KDa).
The arrow  show s the position o f the inhibitor.
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precipitate from  rat liver cytoplasm , resulted in a purification factor 
o f approxim ately 4. The second step, affinity chrom atography 
using the RNase A -Sepharose colum n, resulted in an overall 
purification of approxim ately 8,500 fold. The overall y ield  o f a 
typical purification was approxim ately 40% . The run-through 
fraction from  this stage o f the purification i.e. the proteins w hich 
did no t bind to the affinity colum n, was retained and used  to 
rem ove contaminating antibodies from  the im m une serum  (Section 
2.7.6 and Section 3.2).
The profile o f a typical affinity chrom atography fractionation is 
show n in  Figure 3.1. O ne tenth o f each fraction eluted from  the 
colum n after addition o f the borate buffer was subjected to SDS 
polyacrylam ide gel electrophoresis. This revealed that a m ajor band 
corresponding to a protein o f relative m olecular m ass (M r) o f 
46,700 Daltons was eluted. Several contam inating proteins w ere 
also observed (Figure 3.2).
3.1 .2  Preparation and characterisation o f im m une serum raised
against rat liver ribonuclease inhibitor.
A ntiserum  was required as a probe to  screen the rat liver cD N A  
library  in  the expression vector ^ g tl  1. A s m entioned in Section 
2.8.1, the library was constructed by insertion o f foreign cD N A  
into  the lac Z  gene of A,gtl 1. I f  the cD N A  o f in terest is in the 
correct fram e and orientation, it m ay be expressed as a fusion 
pro tein  w ith S-galactosidase and, therefore, an antibody can be 
used  to screen the library by detecting the protein  encoded by  the 
cD N A  of interest.
R ibonuclease inhibitor purified as described in  the previous 
section (3.1.1), was used to produce antiserum  as described in 
Section 2.7.1. The ribonuclease inhibitor purified  by  affinity 
chrom atography contained m inor amounts o f contam inating proteins 
(Figure 3.2.) and to prevent raising antibodies against these 
contam inants, the preparation was further purified  by  preparative 
SDS PA GE. Figure 3.3.A  shows 250jLig o f inhib itor preparation 
after preparative electrophoresis. The band corresponding to 
ribonuclease inhibitor (shown by arrow) was excised and again 
subjected to preparative SDS PAGE to ensure that the contam inants 
had  been  rem oved (Figure 3.3.B). The pro tein  band  corresponding 
to the inhibitor after two rounds of electrophoresis was excised and 
used  for imm unisation.
The titre of the immune serum was determ ined by ELISA 
(Section 2.7.4) and was defined as the dilution required for 
im m une serum  to give the same reading at 492nm  as did pre-
FIGURE 3.3 PREPARATIVE SDS-PAGE OF RIBONUCLEASE
IN H IB ITO R.
250 |ig  ribonuclease inhibitor, purified  by  affinity chrom atography as 
described  in  Section 2.5.2., was subjected to SDS PA G E on a 
preparative 10% (w/v) polyacrylam ide gel (Section 2.4.6), then  
stained w ith  Coom assie Blue and destained as described in  Section
2.5.4.A . T he band corresponding to  ribonuclease inhibitor w as 
excised  (show n by arrow in Figure A) and re-electrophoresed (Figure 
B).
T he m olecular w eight m arkers are described in Section 2.4.8.
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im m une serum. Two rabbits were im m unised, one o f w hich gave 
antiserum  with a w orkable titre (1/100,000). This titre was 
obtained after 5 booster injections follow ing the in itial injection. 
This rabbit provided antiserum  for the duration o f the project.
One m ethod of ascertaining w hether the im m une serum  has been  
raised against the protein o f interest is to determ ine if  the activity 
o f that protein is decreased in  the presence o f the antibody. 
Increasing amounts o f im m une serum  were added to a ribonuclease 
inhib itor assay. The assay contained a fixed am ount o f inhibitor 
w hich reduced the activity o f 0.25ng R N ase A  by 100%. The fixed 
am ount o f inhibitor was determ ined by  titrating 0.25ng o f R N ase A  
w ith increasing amounts o f ribonuclease inhibitor (Figure 3.4). 
Extrapolation of the curve revealed that 27ng o f inhibitor totally 
inactivated 0.25ng of RN ase A.
Thus, increasing amounts of im m une serum  w ere added to an 
inhibitor assay containing 27ng of inhibitor and 0.25ng of R N ase 
A. The activity o f the inhibitor was observed to decrease as 
increasing amounts o f im m une serum  were added. A fter the 
addition o f 8jil immune serum, the inhibitor was fully inactivated 
(Figure 3.5). As a control, increasing amounts o f pre-im m une 
serum  i.e. serum taken from  the rabbit prior to im m unisation, w ere 
added to the inhibitor assay. This revealed that the addition o f 16]il 
o f pre-im m une serum also decreased the activity o f the inhibitor. 
How ever, less imm une serum  was required to fully inactivate 
ribonuclease inhibitor, presum ably due to the presence of 
antibodies raised against the inhibitor.
The specificity of the antiserum  was tested by w estern blotting
FIGURE 3.4 TITRATION OF RNASE A  WITH RIBONUCLEASE
INHIBITOR
D ifferent am ounts o f affinity purified ribonuclease inhibitor (Section
2.5) w ere added to a ribonuclease inhibitor assay containing 0.25ng 
R N ase A  (Section 2.5.4).
RN ase A  was assum ed to be 100% active in  the absence o f inhibitor.
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FIGURE 3.5 TITRATION OF RIBONUCLEASE INHIBITOR WITH
PRE-IMMUNE AND IMMUNE SERUM
V arying am ounts o f pre-im mune and im m une serum  were added to a 
ribonuclease inhib itor assay containing 27ng o f inhib itor and 0.25ng 
R N ase A . T he inhibitor was assum ed to be 100% active in the absence 
o f serum .
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as outlined in  Section 2.7.3 and the result is show n in  Figure 
3.6.A. The im m une serum  detected purified ribonuclease inhibitor 
(lane 3). Analysis o f lane 1 shows that the im m une serum  detected 
ribonuclease inhibitor from  a preparation o f rat liver cytoplasm . 
A lso present in lane 1 w ere several other bands o f pro tein  w hich 
did not correspond to the inhibitor. This indicated that the im m une 
serum  also contained several contam inating antibodies. It should be 
noted that w hen a sim ilar w estern blot w as challenged w ith pre- 
im m une serum  , a band corresponding to the ribonuclease inhibitor 
was no t obtained but the additional bands were detected (data no t 
show n). Thus, the presence of the contam inating antibodies was 
not a consequence o f im m unisation.
As the im m une serum  was required to probe an expression 
library fo r the isolation o f ribonuclease inhibitor clones, it was 
necessary to remove the contam inating antibodies otherw ise false 
positives m ight be obtained. This was achieved by  
im m unoadsorption (Section 2.7.5). The run-through fraction from  
the RN ase A-Sepharose 4B colum n was retained (Section 3.1) and 
show n to be depleted o f all ribonuclease inhibitor activity by assay 
(Section 2.5.4) and by w estern blotting (Figure 3.6.A , lane 2). The 
w estern blot showed that the fraction contained little  o r no 
ribonuclease inhibitor but did contain the antigens that were 
recognised by the contam inating antibodies. Thus, it appeared that 
the run-through fraction m ight provide a m eans to rem ove 
contam inating antibodies from  the antisera.
Proteins from  the run-through fraction o f the RN ase A- 
Sepharose affinity colum n were conjugated to CN Br-Sepharose 4B 
and im m une serum  was passed through a bed o f this resin  (Section
FIGURE 3.6 ANALYSIS OF IMMUNE SERUM B Y  WESTERN
BLO TTIN G .
Sam ples w ere electrophoresed, transferred to nitrocellulose and 
challenged w ith  im m une serum as described in Sections 2.4.3 and 
2.7.3. T he blots w ere developed using horseradish peroxidase 
conjugated secondary antibody (SAPU).
FIG U R E  A : This filter was challenged w ith pre-adsorbed im m une 
serum .
lane 1: lOOjig rat liver cytoplasm ic proteins.
lane 2: 100jig run-through fraction from  RNase A-Sepharose affinity 
colum n.
lane 3: 500ng affinity purified ribonuclease inhibitor.
FIG U R E  B : This filter was challenged w ith adsorbed im m une serum. 
Lanes 1, 2 and 3 as above.
The position  o f ribonuclease inhibitor is shown by the arrows.
The m olecu lar w eight m arkers are as described in  Section 2.4.8
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FIG URE 3.7 ELISA OF FRACTIONS FROM  THE 
IMMUNOADSORBENT COLUMN
E L ISA  w as perform ed as described in  Section 2.7.4.
In  (A), the antigen w as lOOng o f affinity purified ribonuclease 
inhib itor.
In  (B), the antigen w as the run-through fraction from  the RN ase A- 
sepharose affinity colum n diluted 1/1000 with PBS.
The antisera were the fractions from  the im m unoadsorbent colum n 
diluted 1/1000 in  PBS.
The absorbance values were derived from  the average o f duplicate 
sam ples.
Im m unoadsorbance w as perform ed as described in  Section 2.7.5
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2.7.5). In  theory, the antibodies raised against ribonuclease 
inhib itor should pass directly through the colum n as there should 
be  little  or no inhibitor conjugated to the sepharose, w hereas the 
contam inating antibodies should bind to their respective antigens. 
The run-through from  the im m unoadsorption colum n was collected 
in  1ml fractions and tested for specificity by E LISA  (Section 
2.7.4). The results are show n in Figures 3.1.A  and  3.7.B. In  
F igure 3.7.A, the antigen was purified ribonuclease inhibitor and 
thus fractions containing antibodies raised against inhib itor w ere 
determ ined. In Figure 3.7.B , the antigen w as the run-through 
fraction from  the RNase A -Sepharose affinity colum n. These 
results show that fractions 5-12 contained antibodies w hich 
recognised the ribonuclease inhibitor bu t did not contain  
appreciable amounts o f antibodies w hich recognised other liver 
proteins (pre-adsorbed im m une serum  gave a reading o f 0.5 at 
495nm  w hen tested by ELISA  against the run-through fraction).
The specificity of the adsorbed im m une serum  w as confirm ed 
by  w estern blotting (Figure 3.6.B). The adsorbed im m une serum  
detected a single protein from  a preparation o f rat liver cytoplasm  
(lane 3) and this protein appeared to correspond to  the inhibitor 
protein (lane 1). Thus, the contam inating antibodies w ere rem oved 
and the imm une serum was now  functionally m onospecific i.e. it 
recognised only one protein.
3.1.3 Rem oval o f E.coli antibodies from  immune serum
A ntibodies are present in  polyclonal antiserum  w hich bind to 
antigens produced by E.coli. This binding activity m ay result in a 
h igh  background when screening a recom binant bacterial library 
and this m ay m ake the identification o f positive clones difficult. 
H ow ever, these contaminating antibodies can be rem oved from  
serum  b y  the m ethod outlined in Section 2.7.6. W estern  blot 
analysis was utilised to show that the contam inating antibodies had  
been  rem oved from  the serum  (Figure 3.8). Several preparations o f 
cell lysates of the bacterium  E.coli Y1089 (Section 2.8.3) w ere 
subjected to electrophoresis on a 7.5%  SDS polyacrylam ide gel and 
the proteins blotted onto nitrocellulose as described in  Sections
2.4.3 and 2.7.3. The m em brane in  Figure 3.8.A  w as challenged 
w ith pre-im m une serum  and several bands were observed on the 
blot. Thus, pre-im m une serum  contains antibodies w hich recognise 
and b ind  to several proteins w hich are present in  a bacterial cell 
lysate. The contaminating antibodies w ere rem oved from  the serum  
and an identical western blot was challenged w ith the antiserum  
(Figure 3.8.B). This w estern b lot shows that m ost o f the 
contam inating antibodies have been rem oved from  the serum. Pre- 
im m une serum  was used to show that the presence o f the bands on 
the w estern  blot was not due to antibodies raised  against 
ribonuclease inhibitor cross-reacting non  specifically w ith bacterial 
proteins. W hen immune serum was used to challenge the same 
w estern b lo t as shown in  Figure 3.8, the sam e bands were p resent 
and w ere thus not a consequence o f im m unisation. The E.coli
FIGURE 3.8 REMOVAL OF E.CO U  ANTIBODIES FROM IMMUNE
SERUM
FIG U R E A: W estern blot challenged w ith pre-im m une serum  before 
rem oval o f E.coli antibodies.
Lane 1: lOOjrg proteins from  a crude cell lysate o f IPTG -induced non­
recom binant A ,gtll/Y 1089 lysogen (prepared as in  Section 2.11.2). 
Lane 2: lOOjrg o f non-induced crude cell lysate of non-recom binant 
X g tll/Y 1089  lysogen.
FIG U R E B : W estern blot challenged w ith pre-im m une serum  from  
w hich the contam inating E.coli antibodies have been rem oved. Lanes 
1 and 2 as F igure A.
The w estern b lo t was perform ed as described in  Section 2.7.3 and 
developed using the biotin-streptavidin second antibody system .
The E .coli antibodies w ere rem oved from  the serum  as described in  
Section  2.7.6.
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antibodies w ere rem oved from  the imm une serum  before the library 
w as screened.
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3.1.4 Purification of IgG  from  im m une serum
To further reduce the background when screening the library, 
IgG  was used  as antibody probe in  preference to  to tal im m une 
serum. IgG  was prepared from  im m une serum  using the m ethod of 
Johnstone and Thorpe (1982) as described in Section 2.7.2
20m l im m une serum was precipitated w ith sodium  sulphate and 
the resultant 14% precipitate was resuspended, dialysed and applied 
to a 10ml D E 52 column. IgG  does not bind to this anion exchange 
colum n and hence runs directly through the colum n. The effluent 
was collected in  1ml fractions and the absorbance at 280nm  
m easured (Figure 3.9). The earliest fractions are reported to 
contain the purest IgG  (Johnstone and Thorpe, 1982) and thus 
fractions 2, 3 and 4 were pooled used  to screen the library.
FIGURE 3.9 PURIFICATION OF IgG FROM IMMUNE SERUM.
The protein concentration o f 1ml fractions o f the effluent from  the 
D E.52 anion-exchange colum n was determined by absorbance at 
280nm .
The m ethod for purifying IgG  from  im m une serum  is described in 
Section  2.7.2.
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3.1.5 D ot blot analysis o f ribonuclease inhibitor w ith IgG
D ot blot analysis was used to determine the m ost sensitive 
m ethod o f detecting the com plex form ed betw een ribonuclease 
inhibitor and its antibody and also to determine the concentration of 
IgG  w ith w hich to screen the library.
Various am ounts o f inhibitor (lOng, l.Ong and O .lng) w ere 
dotted onto strips o f nitrocellulose paper and then  challenged w ith 
IgG  (at a concentration o f lOOpg/ml). The bound antibody w as 
detected using one of the follow ing m ethods (as described in  
Section 2.7.3): ^ ^ I- la b e lle d  protein  A; horseradish peroxidase 
(HRP) conjugated to anti-rabbit IgG  or biotinylated anti-rabbit IgG  
follow ed by streptavidin conjugated HRP. The results are show n in 
Figure 3.10. D etection by ^ ^ I - l a b e l l e d  appeared to be
the least sensitive m ethod as it only detected lOng o f inh ib ito r after 
an exposure tim e o f 48 hours (Figure 3.8.A). The sensitivity  o f 
both  the H R P conjugated second antibody (Figure 3.10.B) and the 
biotin/streptavidin system  (Figure 3.10.C) appeared sim ilar as they 
detected 1 .Ong o f ribonuclease inhibitor. H ow ever, the signal fo r 
the H RP anti rabbit IgG  second antibody appeared to be slightly  
stronger than that fo r the biotin/streptavidin system . Thus it w as 
decided to use the H RP conjugated second antibody system  to 
detect the bound antibody in  the screening of the library.
D ot blot analysis also revealed that the low est concentration of 
IgG  to detect l.Ong o f ribonuclease inhibitor w as 50pg/m l. Thus, 
this concentration was used to screen the library.
FIGURE 3.10 DOT BLOT ANALYSIS.
lOng, ln g  and o .ln g  o f purified rat liver ribonuclease inhib itor was 
spotted  onto strips o f nitrocellulose. The control was the buffer in  
w hich  the inhibitor was diluted (50mM  Tris.H Cl pH7.5 containing 
lOOpg/ml BSA). The filters were challenged w ith IgG  and bound IgG  
detected  by  one o f the following m ethods:
FIG U R E A : l^ I - la b e l le d  protein A;
FIG U R E  B : horseradish peroxidase secondary antibody (S A PU ) 
FIG U R E C : biotinylated secondary antibody (Amersham).
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3.2 IS O L A T IO N  O F  C L O N E S  F R O M  A R A T  LTVKR cDNA 
L IB R A R Y  IN  XGT11
The preparation of the rat liver cD N A  library used in  this 
project is described by Schw arzbauer et al.,(1983) and w as kindly 
donated by Dr. R.O. Hynes.
3.2.1 D eterm ination o f the titre and num ber o f recom binants w ithin 
the library
Before the libary was screened, the titre o f the library  i.e. the 
num ber of p laque form ing units (p.f.u.) /p i was determ ined. 
V arious dilutions o f phage from  the library w ere adsorbed to  
bacteria (E.coli strain Y1088), p lated out and incubated overnight 
as described in  Section 2.10.4. The num ber of plaque form ing units 
was counted and the titre was determ ined to be 9.7x10^ p .f.u ./p l 
(Table 3.2).
The num ber o f recom binant phage within the library w as 
determ ined also. Phage from  the library were adsorbed to  E.coli 
strain Y1090, top agar containing isopropyl-B-D 
thiogalactopyranoside (IPTG) and 5-brom o-4-chloro-3-indolyl-B-D- 
galactopyranoside (X Gal) w as added and the infected bacteria  
p lated  out and incubated as described in Section 2.10.4. 56%  o f  the 
plaques were clear and therefore contained cD N A  inserts (Table 
3 .3 )
TABLE 3.2 DETERM INATION OF THE TITRE OF THE cDNA 
LIBRARY IN XGT11
Phage were taken from  the library, diluted in SM  buffer, adsorbed to 
E.coli strain Y 1088, plated out and incubated as described in  Section
2.10.4. The num ber o f plaque form ing units (pfju) was then counted 
and the titre (pJ&Vpl) determ ined
D ilutions p.f.u./plate p .f .u .x K p /p l A verage
p .f .u .x l0 “3 /p l
10-4 130 13
109 11
9.7
10-5 7 7
8 8
TABLE 3.3 DETERMINATION OF % RECOMBINANT PHAGE IN
THE RAT LIVER LIBRARY
Phage were taken from  the library, diluted in  SM  buffer and 
adsorbed to E.coli Y1090. Top agar, containing 2% (w/v) IPT G  and 
2%  (w/v) X -gal was added, the infected bacteria p lated out and 
incubated as described in  Section 2.10.4. Blue plaques (non­
recom binants) and white plaques (recombinants) were counted and the 
% recom binants determined.
D ilution blue plaques white plaques to ta l % recom '
1 0 '3 84 120 204 59
102 162 264 61
lO"4 37 36 73 48
45 53 98 54
1o 4 5 9 55
6 10 16 62
3.2.2 Isolation o f cDNA clones from  the rat liver cD N A  expression 
library
A  detailed description o f the procedure for screening the rat 
liver X g tll  expression library w ith antibody probes is g iven  in  
Section 2.10.2.
Initially, a total o f 300,000 recom binants w as screened w ith  
ribonuclease inhibitor antibodies and eight positive signals w ere 
identified on the nitrocellulose filters. O f these eight putative 
positive signals, five clearly had  the characteristic "doughnut” 
shape i.e. the edges of the positive signal were darker than  the  area 
in  the m iddle and it was decided to isolate the plaques 
corresponding to these positive signals. It was im possible to 
directly identify the positive plaques on the agar plate due to  the 
density of the plaques, thus the general area corresponding to  the 
positive signal was picked using the broad end o f a pasteu r p ipette. 
The phages were then purified from  the plaques as described in  
Section 2.10.3. The phages w ere taken through a second round  o f 
screening at a density o f 10,000 pfu  per 90mm plate. O f the five 
putative positives isolated from  the in itial screen, only three 
produced positive signals in the second round. A gain, the p laques 
corresponding to these positive signals were isolated and screened 
for a third tim e at a density o f approxim ately 500 pfu p e r p late. It 
was now  possible to directly identify the plaques giving rise  to a 
positive signal on the nitrocellulose filter. Thus, a single p laque 
was picked and the phage rescreened at a density o f 100 p fu  per 
plate. Each plaque now  gave rise to a positive signal on the filter.
FIGURE 3.11 ISOLATION OF cDNA CLONE. ARLRI7 FROM THE
RA T FIV ER EXPRESSION LIBRARY.
T he clone was isolated as described in  Section 2.10.2.
F IG U R E  A : Second round of screening.
10.000 plaque form ing units (pfu) w ere plated out. A rrow s show the 
positions o f three distinctly positive signals.
FIG U R E  B : T hird  round o f screening.
500 pfu  w ere p lated  out. A pproxim ately 5% o f the plaques appear to 
produce a positive signal.
F IG U R E  C : F inal round o f screening.
lOOpfu p lated out. E ach plaque gave rise to a  positive signal. 
F IG U R E  D : Control.
1.000 pfu  o f non-recom binant^g tll. N o positive signals observed.
The circles in  Figures A  and D outline the positive control w here 5ng 
o f purified  ribonuclease inhibitor was spotted directly onto the filter to 
ensure that the detection system  was working.
A B
C D
Thus, three clones were isolated and nam ed XRLRI 3, AJRJLRI 7 and 
A.RLRI 8.
The isolation of XRLRI 7 through the second, th ird  and final 
rounds o f screening is show n in Figure 3.11. S im ilar results were 
obtained in the isolation o f A,RLRI 3 and A.RLRI 8.
Several controls were carried out while screening the library  to 
decrease the possibility o f obtaining false positives.
During each round o f screening, a duplicate nitrocellu lose filter 
was obtained as described in  Section 2.10.2. This duplicate filter 
was screened w ith  IgG  purified from  pre-im m une serum . This 
control ensured that the positive signals obtained on the filte r w ere 
produced by  the antibody recognising and binding to a specific 
antigen (i.e. ribonuclease inhibitor) and not m erely due to a  non­
specific association with any expressed proteins. A t no tim e did the 
pre-im m une IgG  produce a positive signal on the filters. A n 
exam ple o f a filter screened w ith pre-im m une and im m une IgG  is 
show n in Figure 3.12.
A  second control was the screening o f non recom binant Xgtl 1 
w ith  ribonuclease inhibitor antibodies (Figure 3.11 D) to ensure 
that the antibodies did not bind to antigens produced by A,gtl 1 
itself. Again, a positive signal was never observed w ith  this 
control.
In  the earlier rounds o f screening, a third control w as also 
carried out. ln g  o f purified inhib itor was spotted onto the edge o f 
the nitrocellulose filters. W hen the filter was developed, a  sm all 
dark spot was obtained show ing w here the antigen had  bound  to the 
purified  antigen (see Figures 3.11.A  and D). Thus, i f  no o ther
FIG U RE 3.12 SCREENING OF ISOLATED CLONE. X RLRI7 W ITH 
IM M UNE AND PRE-IMMUNE IgG
A pproxim ately 250 p.f.u. o f ARLRI 7 obtained after the th ird  round 
o f screening w ere p lated  out (Section 2.10.1) and the filters probed 
w ith either im m une serum  (Figure A) or pre-im m une serum  (Figure B). 
The filters w ere developed as detailed in  Section 2.10.2.

positive signals were observed on the filter, it w as concluded that 
these plaques did not express a protein w hich w as recognised by 
the antibody.
3.3 C H A R A C TER ISA TIO N  O F THE cDNA CLO NK S
IS O L A T E D  F R O M  T H E  E X P R E S S IO N  L IB R A R Y
3.3.1 Preparation of A,gtll recom binant lvsogens in Y 1089
A,gtl 1 recom binant lysogens were generated in  Y 1089 as 
described in  Section 2.11.1. It is considered to  be advantageous to 
produce recom binant lysogens as cloned DNA is m ore stable w hen 
integrated into the bacterial chrom osome. A lso, preparative 
amounts o f the polypeptide specified by the cloned D N A  can  be 
obtained w hich is o f use w hen characterising the recom binant 
clones.
Figure 3.13 shows an exam ple o f Y1089 lysogenised  w ith  one 
o f the putative ribonuclease inhibitor encoding clones, AJRLRI 8. A  
putative lysogenic colony w as streaked out onto an LB plate  and 
incubated at 30°C (a tem perature at which the tem perature-sensitive 
repressor is functional) and then replica plated (Section  2.11.1). 
One plate was incubated at 42°C (Figure 3.13.A ) w hile the o ther 
was incubated at 30°C (Figure 3.13.B). The colonies have  grow n at 
30°C bu t not at 42°C and are thus assumed to be lysogenic.
Y1089 was also lysogenised w ith ^RLRI 3, XRLRI 7 and  non 
recom binant A g tll. A ll w ere tested for lysogeny as described  for 
AJRLRI 8 w ith identical results.
FIGURE 3.13 GENERATION OF A XGT11 RECOMBINANT
LYSO GEN IN Y1089
Y 1089 was lysogenised w ith ARLRI 8 as described in Section 
2.11.1. The figure shows replica plates, one o f w hich has been  grow n 
at 30°C  (Figure A), and the other at 42°C  (Figure B). Colonies have 
grow n only on the plate incubated at 30°C.
AB
3.3.2 Characterisation o f fi-galactosidase fusion proteins bv  SDS 
PAGE
As the cD N A  of recom binant A,gtl 1 is inserted in to  the EcoR I 
site o f the B-galactosidase gene, a fusion protein is p roduced  in the 
presence o f IPTG . This fusion protein com prises a large segm ent o f 
B-galactosidase (114,000 D altons) fused to protein  sequences 
encoded by the cDNA insert. E ach of the recom binant Xgtl 1 
lysogens were treated w ith IPTG  to induce the synthesis o f  fi- 
galactosidase. Crude cell lysates were then prepared from  them  and 
also from  a non-recom binant X g tll  lysogen (Section 2.11.2 .). The 
lysates were analysed fo r the presence o f fusion pro teins b y  SDS 
PA G E  on a 7.5%  polyacrylam ide gel (Figure 3.14). F usion  proteins 
w ere detected in  each of the three selected recom binants and  those 
produced from  A,RLRI 3 and ^JRJLRI 8 were dependent on  the 
induction w ith IPTG. An anom alous result was obtained  fo r the 
lysogen A.RLRI 7 as fusion protein  was synthesised in  bo th  the 
absence and presence of IPTG . (It should be no ted  that this 
anom alous result was not reproducible). The M r o f the fusion  
proteins were determ ined as described in Section 2.4.8. T he M r of 
the fusion protein produced by  the lysogens o f A,RLRI 3 and ^R L R I 
8 w as approxim ately 127,000 Daltons whereas that from  the 
lysogen o f A,RLRI 7 was 130,000 Daltons.
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FIGURE 3.14 CHARACTERISATION OF B-GALACTOSIDASE 
FU SIO N  PROTEINS B Y  SDS PAGE.
IPT G -induced and non-induced crude cell lysates (prepared as 
described in Section 2.11.2) were resolved on a 7.5% SDS 
polyacrylam ide gel and stained with Coom assie Blue as outlined in 
Sections 2.4.3 and 2.4.5.A .
Lane 1: 200pg o f IPTG -induced cell lysate from  non-recom binant 
X g tll  lysogen.
Lane 2: 200jJ.g o f uninduced crude cell lysate from  the lysogen o f 
ARLRI3.
Lane 3: 200pg o f IPTG -induced crude cell lysate from  the lysogen of 
XKLR1 3.
Lane 4: 200pg o f uninduced crude cell lysate from  the lysogen o f 
ARLRI7.
Lane 5: 200pg o f IPTG -induced crude cell lysate from  the lysogen of 
XKLR1 7.
Lane 6: 200 |ig  uninduced crude cell lysate from  the lysogen o f 
XRLRI8.
Lane 7: 200pg o f IPTG -induced crude cell lysate from  the lysogen of 
XRLRI 8.
Lane 8: M olecular w eight m arkers as described in  Figure 3.2.
The arrow  at (a) shows the position o f the induced fusion proteins 
and at (b) indicates the position of non-recom binant B-galactosidase.
Mr
x10*3
2 0 0
97 
68
45
3 0
3.3.3 Characterisation o f B-galactosidase proteins bv  w estern 
blotting
The fusion proteins detected as described above w ere further 
analysed by w estern blotting. Crude cell lysates w ere subjected to 
electrophoresis on a 7.5% SDS polyacrylam ide gel, b lotted  onto 
nitrocellulose and challenged w ith ribonuclease inhibitor antiserum  
as described in  Section 2.7.3. W hen the blot w as developed w ith 
the horseradish peroxidase conjugated second antibody system , no 
im m une positive bands were observed. How ever, w hen developed 
w ith the biotin  streptavidin system  (Am ersham ), an im m une 
positive band was observed fo r ARLRI 7and XRJLRI 8 in  the IPTG - 
induced cell lysates. N o im m une positive band w as observed for
A,RLRI 3. It was thus decided to discontinue characterising ARLRI 
3. Figure 3.15.A  represents a w estern blot o f non-induced  and 
IPTG -induced crude cell lysates o f XRLRI 7 (lanes 1 and 2)and
XRLRI 8 (lanes 3 and 4) and induced crude cell lysate o f non ­
recom binant ^ -g tll (lane 5) w hen challenged w ith  im m une serum . 
Figure 3.15.B shows the sam e w estern blot w hen challenged w ith  
pre-im m une serum. These blots dem onstrate the presence o f 
ribonuclease inhibitor antigenic determ inants w ithin the fusion  
protein. The antibodies are not recognising B-galactosidase 
antigenic determ inants as an im m une band is no t observed in  the 
lane containing induced non-recom binant B-galactosidase (lane 5). 
The additional bands w hich are observed in  Figure 3.15.A  are no t 
the result o f  an imm une response as they are also present in  the 
w estern b lot challenged w ith pre-im m une serum  (Figure 3.15.B)
FIGURE 3.15 WESTERN BLOT ANALYSIS OF B-GALACTOSIDASE
FU SIO N PROTEINS
Crude cell lysates (prepared as described in Section 2.11.2) were 
electrophoresed on a 7.5 % polyacrylam ide gel, blotted onto 
nitrocellulose and challenged w ith either im m une serum (Figure A) or 
pre-im m une serum  (Figure B) as outlined in Sections 2.4.3 and 2.7.3. 
The w estern b lot was developed using the biotin-streptavidin detection 
system .
O n both  Figures A  and B , each lane contains 200pg o f pro tein  from  
the appropriate crude cell lysate as follows: 
lane 1: uninduced lysate from  the XRLRI7/Y1089 lysogen; 
lane 2: IPTG -induced lysate from  the A RLRI7/Y 1089 lysogen; 
lane 3: uninduced lysate from  the ARLRI 8/Y1089 lysogen; 
lane 4: IPTG -induced lysate from  the 7-RLRI 8/Y1089 lysogen; 
lane 5: IPTG -induced lysate from  the non-recom binant A g tll/Y 1089  
lysogen.
A B
1 2 3 4 5 1 2 3 4 5
3.3.4 D eterm ination of the % concentration o f fusion  protein  in  a 
crude cell lvsate.
To estim ate the am ount o f fusion protein p resent in  a crude cell 
lysate, sam ples o f IPTG -induced and non-induced crude cell lysate 
(prepared as described in Section 2.11.2) w ere subjected to  SDS 
polyacrylam ide gel electrophoresis (Section 2.4.3) on a 7.5%  (w/v) 
polyacrylam ide gel, then stained w ith Coom assie B lue (Section 
2.4.5.A ). A fter destaining, both  tracks were scanned on a  LKB 
'm ultiscan' and a characteristic trace obtained. E ach  peak  on the 
trace correponds to a band o f protein on the gel. A  diagram atic 
representation o f the absorbance trace for the crude cell lysate 
containing the fusion protein from  ^R LR I 8 is show n in Figure 
3.15. The additional peak in trace B corresponds to the fusion  
protein. The area under each peak (curve) was calculated by  
com puter and expressed as a percentage o f the to ta l area (Table 
3.4). This analysis revealed that the area under the curve 
representing the fusion protein w as approxim ately 16% o f  the total 
area. H ence the fusion protein represents approxim ately 16% o f the 
Coom assie B lue stained protein present in the crude cell lysate.
FIGURE 3.16 SCAN OF UNINDUCED AND IPTG-INDUCED
CRUDE CEUL LYSATES ON SDS POLYACRYLAMIDE GELS
Crude cell lysates o f the lysogen ARJLRI 8/Y1089 (described in  Section 
2 .11.2) were subjected to electrophoresis on a  7.5% polyacrylam ide 
gel (Section 2.4.3), stained w ith  Coom assie B lue and destained as 
described in  Section 2.4.5.A . Individual tracks on the gel w ere 
analysed on an LKB 'm ultiscan' to determ ine the percentage o f fusion 
pro tein  in  the total protein preparation.
F igure A  is representative o f the trace obtained w hen the uninduced 
lysate was scanned.
F igure B is representative o f the trace obtained w hen the IPTG - 
induced cell lysate w as scanned.
The peak  corresponding to the fusion protein is shown by the arrow (l5) 
The percentage o f total protein represented by each peak is outlined in 
the follow ing table (Table 3 .if.)
J© Migration of proteins on SDS PAGE © 
<?--------------------------------------
_© Migration of proteins on SDS PAGE ©
TABLE 3.4 DETERMINATION OF THE AMOUNT OF FUSION
PROTEIN IN  AN  IPTG-INDUCED CRUDE CELL LYSATE
The peaks o f protein show n in  Figure 3.14.B are presented here ais a  
percentage of the total protein  in the crude cell lysate.
Peak 15 represents the fusion protein and is approxim ately 16% of 
the to tal protein.
Peak num ber 
1 
2
3
4
5
6
7
8
9
10 
11 
12
13
14
15
16
% A rea 
1.8
5.3 
0.7
6.3 
1.0
17.6
5.6
1.7
5.5
9.3
3.2
5.6
8.5
10.5
16.2 
1.2
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3.3.5 Com parison o f peptide m aps o f rat liver ribonuclease 
inhib itor and fusion protein
A fter isolation o f a cD N A  clone, the subsequent analysis m ust 
ensure that it encodes the protein  o f interest. In  general, the 
nucleotide sequence of the cD N A  is obtained and, from  this, the 
predicted amino acid sequence o f the protein encoded by  the clone 
is revealed. Then, if  the am ino acid sequence o f the pro tein  o f 
in terest is available, the predicted am ino acid sequence and the 
authentic sequence are com pared. How ever, at this stage in the 
pro ject i.e. after the clones w ere isolated from  the library, neither 
am ino acid sequence nor nucleotide sequence o f any ribonuclease 
inhibitor were available. A  com parison of the sequences w as thus 
im possible. Instead, a novel approach was used to determ ine if  the 
clones ARLRI 7 and ARLRI 8 encoded the ribonuclease inhibitor 
using a com bination of peptide m apping and w estern blotting.
W hen a protein is digested w ith a protease and the products 
separated on SDS PAGE, a characteristic pattern  o f bands is 
obtained. This banding pattern  is know n as a peptide m ap. I f  tw o 
proteins are sim ilar and both are digested w ith the sam e protease, - 
sim ilar peptide m aps are obtained. Thus, it was decided to com pare 
the peptide m aps obtained after digestion of purified  ribonuclease 
inhib itor and fusion protein. It was hoped that partia l iden tity  in  the 
peptide m aps w ould indicate that the cDNA encoded the inhibitor. 
H ow ever, digestion o f the B-galactosidase fusion pro tein  w ith  any 
protease leads to the generation o f m any peptides: som e derived 
from  the B-galactosidase portion o f the gene; others from  the
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FIGURE 3.17 IM M UNOBLOT ANALYSIS OF RIBONUCLEASE 
INHIBITOR DIGESTED W ITH CHYMOTRYPSIN
The protein w as digested w ith differing am ounts o f chym otrypsin at 
37°C  for two hours. The digested products were subjected to 
electrophoresis on  a 15% polyacrylam ide gel (Section 2.4.3), then 
transferred onto nitrocellulose and challenged w ith im m une serum  
(Section 2.7.3). The blot was developed w ith the H RP conjugated 
secondary antibody system  (SAPU) as described in  Section 2.7.3.
E ach lane contains inhibitor digested w ith chym otrypsin at a ratio o f 
proteim protease as outlined below: 
lane 1: 10:1; 
lane 2: 100:1; 
lane 3: 1000:1;
lane 4: undigested ribonuclease inhibitor.
T he arrow show s the position of undigested inhibitor.
1 2  3 4
protein encoded by the cDNA. Thus, to distinguish cD N A  encoded 
peptides from  B-galactosidase peptides, the digested products were 
blotted  onto nitrocellulose filters and challenged w ith ribonuclease 
inhib itor antiserum . Peptides obtained from  digestion o f purified  
inhibitor w ere sim ilarly analysed and com pared w ith antigenic 
fragm ents o f the fusion protein.
Initially a solution of purified  ribonuclease inhib itor w as 
digested w ith varying amounts o f chym otrypsin. The products o f 
digestion were subjected to electrophoresis on a 15% SDS 
polyacrylam ide gel (Section 2.4.3), transferred onto nitrocellu lose 
and challenged w ith imm une serum  (Section 2.7.3). The resu lt o f 
the im m unoblot after this procedure is shown in  Figure 3.17. The 
protein  has been digested w ith chym otrypsin and a clear, distinctive 
im m unogenic peptide map obtained (the additional bands seen in the 
lane containing undigested inhibitor m ay be due to either 
degradation o f the preparation during storage or contam ination w ith 
chym otrypsin while loading the gel).
V arious attem pts were m ade to isolate the fusion pro tein  from  a 
crude cell lysate so that protease digestion could be perform ed on 
purified protein. It has been reported that a large num ber o f genes 
expressed as fusion proteins in  the cytoplasm  o f E.coli are 
insoluble (Harris, 1983) and accum ulate in  a discrete form  know n 
as ’’inclusion bodies" (W illiams et al.,1982). Inclusion bodies are 
dense and sedim ent readily w ith  low  speed centrifugation e.g. 
5 ,000-12,OOOx gav Under these conditions, the inclusion bodies 
sedim ent m ore rapidly than the bulk  o f celi debris, thus allow ing 
the purification o f the fusion protein. Figure 3.18 show s that the 
fusion proteins from  the lysogens A7/Y1089 and X8/Y1089 w ere
FIGURE 3.18 SDS PAGE ANALYSTS OF THE SOLUBILITY OF
FUSION PROTEIN FROM THE LYSOGEN OF ?iRLRI 8/Y1089
H arvested IPTG -induced bacterial cells were resuspended in  50m M  
T ris.H C l pH7.5 containing different salt concentrations as follow s: 
0 .15M  N aCl (lanes 1 and 2); 0.5M  N aCl (lanes 3 and 4) o r 2M  N aC l 
(lanes 5 and 6). The cells w ere lysed by  repeated heating o f the 
sam ples to 37°C, then plunging them  into a dry ice/m ethanol bath. The 
lysates were subjected to low  speed centrifugation and the resultant 
pellets and supernatant fractions analysed by SDS PAGE (Section 
2.4.3), then stained w ith  Coom assie Blue and destained as described 
in  Section 2.4.5.A .
lane 1: lOOjig o f  supernatant fraction from  a non-induced lysate 
o f 2JRLRI 8/Y1089 lysogen.
lane 2 : lOOpg o f supernatant fraction from  IPTG -induced lysate 
o f ARLRI 8/Y1089 lysogen.
*lane 3: resuspended pellet from  a ARLRI 8/Y1089 IPTG -induced 
culture lysed in  the presence o f 0.5M  NaCl.
lane 4: lOOpg o f supernatant fraction from  a ARJLRI 8/Y1089 IPTG - 
induced  culture lysed  in  the presence o f 0.5M  NaCl.
*lane 5: resuspended pellet from  a ^R LR I 8/Y1089 IPTG -induced 
culture lysed in  the presence o f 2M  NaCl.
lane 6: lOOpg o f supernatant fraction from  a XRLRI 8/Y1089 IPTG - 
induced culture lysed  in  the presence o f 2M  NaCl.
* The pellets w ere resuspended in  500p i Laem m li sample buffer and 
5 0 p l loaded onto the gel.
Lanes 1 and 2 are controls w hich show the position o f the induced 
fusion protein (show n by arrow )
is  \ i
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soluble as they were present in the supernatant fraction o f the cell 
lysate after centrifugation at 10,000xgav. It w as thought that by 
altering either the ionic strength or the pH  o f the buffers in  w hich 
the cells w ere lysed m ight change the solubility o f  the fusion 
protein, thus allowing rapid purification. F igure 3.18 show s the 
result obtained w hen the cells were lysed in 50m M  T ris.H C l 
pH 7.5, 150m M  N aCl (lane 2), in  50m M  T ris.H C l pH 7.5 buffer 
containing 0.5M  N aC l (lanes 3 and 4) or 2M  N aC l (lanes 5 and 6). 
Lane 1 contained the supernatant fraction from  uninduced lysate to 
allow  identification of the position o f the fusion protein. A fter 
centrifugation o f the lysate, the fusion protein w as alw ays left in 
the supernatant fraction. S im ilar results were observed w hen lysis 
was perform ed in 50mM  sodium  acetate pH5 or 50m M  Tris.H C l 
pH 9 (data no t shown). Thus this potentially rapid  m ethod o f 
isolating the fusion proteins was unsuccessful. O ther m ethods 
w hich w ere attem pted centred on attem pting to recover the fusion 
protein  from  polyacrylam ide gels after their fractionation from  
other bacterial proteins. Num erous published m ethods o f d iffusion 
or electrophoretic recovery were attem pted. AH w ere unsuccessful, 
presum ably because of the very high relative m ass o f the protein .
A s it w as proving difficult to isolate the fusion  protein , it was 
decided to use the m ethod o f C leveland et al.,(1911) to d igest the 
protein  w ithin  polyacrylam ide and then to perform  a w estern  b lo t 
on the digested products as described above. C leveland m apping 
involves enzym atic digestion o f purified proteins in  an SDS 
polyacrylam ide gel. Again, the fusion protein w as fractionated  from  
the other proteins in a cm de cell lysate by electrophoresis and  the
FIGURE 3.19 IMMUNOBLOT ANALYSIS OF RIBONUCLEASE
INHIBITOR AND FUSION PROTEIN DIGESTED W ITH 
CHYMOTRYPSIN BY THE CLEVELAND METHOD.
G el slices of ribonuclease inhibitor, fusion protein and B- 
galactosidase were obtained and digested w ith chym otrypsin as 
described (Section 2.4.7). A fter electrophoresis, the digested products 
w ere analysed by w estern blotting (Section 2.7.3). The b lo t was 
developed using the H RP conjugated second antibody system  from  
SA PU .
lane 1: 10{xg inhibitor d igested w ith ljig  chymotrypsin. 
lane 2: 10p.g inhibitor digested  w ith 2pg  chymotrypsin. 
lane 3: lOOpg fusion pro tein  digested w ith 10 jig chym otrypsin. 
lane 4: lOOjig B-galactosidase digested w ith lOjig chym otrypsin.
T he arrows show possible sim ilar peptide bands occurring after 
digestion of inhibitor and fusion protein w ith chym otrypsin.
1 2  3 4
band  corresponding to the fusion protein was excised. T he gel band 
was then cut into sm all pieces and placed in the w ells o f  an SDS 
polyacrylam ide gel for digestion w ith chym otrypsin as described in 
Section 2.4.7. A  band o f ribonuclease inhibitor was excised from  a 
preparative gel and treated in  the same m anner. A fter variable 
periods o f digestion, the digested products w ere separated by 
electrophoresis on the polyacrylam ide gel, the products transferred 
to nitrocellulose and challenged w ith  ribonuclease inhib itor 
antiserum . A  typical result is show n in  Figure 3.19. This figure 
show s the results obtained w hen inhibitor and fusion pro tein  were 
digested w ith different am ounts o f chym otrypsin and it is evident 
that digestion o f both  proteins has occurred. H ow ever, this m ethod 
did no t produce as clear a peptide m ap as that obtained in  Figure 
3.17 and all the data obtained, both  w ith chym otrypsin and  w ith  V8 
protease, w as difficult to interpret. It is possible that the peptide 
bands m arked by arrows in Figure 3.19 correpond to sim ilar 
peptides but the evidence is no t clear cut.
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3.4 A M IN O  ACID SE Q U EN C E ANALYSTS O F R A T LIV ER  
RIBONIJCIJCASE IN H IB IT O R
As the com parison of im m unogenic peptide m aps o f fusion 
pro tein  and ribonuclease inhibitor (Section 3.3.5) had  failed  to 
confirm  the identity o f the clones isolated from  the library, it was 
decided to obtain as m uch am ino acid and nucleotide sequence data
r
as possible and then com pare the predicted am ino acid sequence 
obtained from  the nucleotide sequence with the am ino acid sequence 
o f the purified  protein.
The cD N A  used to construct this library w as prepared using 
oligo (dT) w hich creates a bias towards cloning the 3' end  o f  the 
m RN A . As the clones isolated from  the cDNA library w ere no t full 
length i.e. they were no t o f sufficient size to encode the entire 
protein, it was assum ed that they probably encoded the 3 ’ non  
coding region and the CO O H -term inal end of the protein. Thus, 
rather than attem pting to sequence the protein from  the N -term inus, 
it was decided to generate peptides by digestion o f the p ro te in  w ith 
various proteases and to obtain sequence data on the peptides. It 
was hoped that this strategy w ould generate sequence close to  the 
COOH-term inus and overlapping the amino acid sequence predicted 
from  the nucleotide sequence o f the cDNA.
3.4.1 Further purification o f ribonuclease inhibitor
As described in  Section 3.1.1, ribonuclease inh ib ito r w as 
purified from  rat liver by the m ethod o f Burton et al., (1980) (see
FIGURE 3.20 FPLC PURIFICATION OF AFFINITY PURIFIED
RIBONUCLEASE INHIBITOR
Ribonuclease inhibitor, obtained after affinity chrom atography on 
the RN ase A-Sepharose colum n, was subjected to ion-exchange 
chrom atography on the M ono Q colum n o f an FPLC (Pharm acia) as 
described in  Section 2.5.3. Bound protein was eluted w ith a N aC l 
gradient as shown. Inhibitor eluted at approxim ately 0.3M  N aCl. The 
elution of the protein was m easured by absorbance at 280nm  w ith  a 
fu ll-scale deflection from  0 to 2.0.
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FIGURE 3.21 ANALYSIS OF RIBONUCLEASE INHIBITOR BY
SDS PAGE AFTER PURIFICATION ON FPLC
A n aliquot (1/200) o f the fractions containing the peak o f protein  
eluted from  the M ono Q colum n (see Figure 3.20) were subjected to 
electrophoresis on a 10% (w/v) polyacrylam ide gel (Section 2.4.3) and 
protein  was visualised by  the silver staining m ethod described in 
Section  2.4.5.B .
Lanes 1 to 5 inclusive are the fractions w hich eluted from  the 
colum n with a  significant absorbance reading at 280nm. Lane 6 
contains m olecular w eight m arkers as described in  Figure 3.2.
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Section 2.5.2) W hen the purified protein was subjected to  SDS 
PA G E  and stained with Coom assie Blue (Figure 3.1), sm all 
am ounts o f contam inating proteins were observed. A s the protein 
was required to obtain amino acid sequence, it w as essential to 
rem ove these contaminants. The protein w hich eluted from  the 
R N ase A-Sepharose affinity colum n was subjected to ion-exchange 
chrom atography using the M ono-Q  colum n o f the Pharm acia FPLC 
system  as described in Section £.5.3. R ibonuclease inhib itor was 
eluted in  a sharp peak at approxim ately 30%  (0.3M ) N aC l (Figure 
3.20) and sm aller peaks o f protein were eluted at h igher salt 
concentrations. The purity o f the protein isolated  by  this procedure 
was determ ined by SDS PA G E and the gel stained w ith silver as 
described in  Section 2.4.5.A. Silver staining is a  m ore sensitive 
protein detection system than Coom assie Blue staining and trace 
am ounts o f proteins can be visualised. The result o f  the silver- 
stained gel is show n in  Figure 3.21. The pro tein  preparation 
appeared to be free from  all contam inating proteins and was, 
therefore, considered to be suitable for preparing peptides fo r 
am ino acid sequence analysis.
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3.4.2 Isolation o f trvptic and chvm otrvptic peptides o f ribonuclease 
inhibitor bv H PLC
The ribonuclease inhibitor isolated by FPLC as described in  the 
previous section (Section 3.4.2) was digested w ith  e ither trypsin or 
chym otrypsin as outlined in section 2.6.2. A n aliquot o f  the 
digested protein  was subjected to chrom atography using the reverse 
phase colum n ( C l8) of the HPLC system  (Beckm an) to separate the 
resultant peptides. In general, peptides o f a hydrophilic nature elute 
from  a reverse-phase colum n before the hydrophobic peptides. The 
elution profiles obtained for the protein digested w ith  trypsin  
(Figure 3.22) and w ith chym otrypsin (Figure 3.23) are show n. It 
was decided to collect the peaks (i.e. peptides) w hich  appeared to 
be w ell-separated and sharp. These are pointed out in  F igures 3.22 
and 23 by arrow s. The rem aining digested pro tein  w as applied to 
the C18 colum n and the peaks collected by hand using the original 
traces as a guide to their elution tim e. In  total, 13 peptides w ere 
collected.
The purity o f the peptides was determined by  applying an 
aliquot o f each peptide to the C l 8 colum n with a  buffering  system  
w ith a different pH  (Section 2.6.3). O f the 13 orig inal peptides, 
only five w ere represented by  a single peak on the second system . 
These were taken to A berdeen University to be sequenced on  the 
SERC gas phase sequencer m achine.
FIG U R E 3.22 PURIFICATION BY HPLC OF PEPTIDES 
PRODUCED BY DIGESTION OF RIBONUCLEASE INHIBITOR 
W IT H  TRYPSIN.
A n aliquot (1/10) of the digested protein (Section 2.6.2) was applied 
to the C l 8 colum n of a Beckm an HPLC. Peptides were eluted with a 
0-70%  gradient o f acetonitrile and were m onitored by absorption at 
220nm . The absorbance units fu ll scale (AUFS) were from  0 to 0.2. 
Peptides w hich were collected are indicated by  arrows and were 
denoted T1 to  T7.
The peak at A  was caused by  injection o f the sample into the colum n 
and the peak at B was assum ed to be protein  w hich did no t b ind to the 
colum n.
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FIGURE 23 PURIFICATION BY HPLC OF PEPTIDES PRODUCED
BY  DIGESTION OF RIBONUCLEASE INHIBITOR W ITH 
CHYMOTRYPSIN.
1/10 o f the protein  digested with chym otrypsin (Section 2.6.2) was 
subjected to chrom atography on a C18 reverse phase colum n o f a 
Beckm an H PLC. The peptides were eluted w ith a 0-70% acetonitrile 
gradient and w ere m onitored by absorption at 220nm  with AUFS from  
0 to 0.2. The arrow s show the peaks (peptides) w hich w ere collected. 
These peptides w ere denoted C l to C6 inclusive.
(A) represents the injection spike and (B) w as assum ed to be the 
protein  w hich did no t b ind  to the colum n.
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3.4.3 Gas phase sequencing o f the peptides
The five peptides isolated by HPLC purification w ere 
sequenced on an autom atic gas phase sequencer as described in 
Section 2.6.3. The first peptide to be sequenced (T6) provided a 
to tal o f 11 residues. The yields of residues recovered from  each 
cycle o f the sequence is show n in  Table 3.5. Sequencing was 
continued until no other PTH -am ino acid derivatives could be 
identified  above background level. As can be seen from  this table, 
the sequence o f the peptide included two successive glutam ine 
residues (residues 9 and 10). U nfortunately, this apparently  
quenched the sequencing reaction and hence no further sequence 
w as obtained from  this peptide (B. Dunbar, personal 
com m unication).
D isappointingly, the other peptides yielded no  sequence data at 
all. It was suggested that there were insufficient am ounts o f these 
peptides to allow sequencing, although H PLC data indicated that 
the recovery o f at least some o f them  should have been  m ore than 
adequate. The amino acid com positions o f the peptides w ere 
determ ined (show n in  Table 3.6) and this also revealed that there 
should have been sufficient amounts o f the peptides to  allow  them  
to be sequenced.
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TABLE 3.5 AM INO ACID SEQUENCE ANALYSIS OF PEPTIDE T6
Peptide T6, p repared  and isolated as described in Section 2.6.3, was 
applied to a Beckm an autom atic amino acid sequence analyser 
(operated by B .D unbar, D epartm ent o f B iochem istry, U niversity  o f 
Aberdeen).
SEQ U EN CE N U M B E R  RESIDU E pM O LES
RECO V ERED
1 LEU 107.5
2 TH R 27.0
3 GLU 22.5
4 LEU 32^0
5 G LY 9.0
6 PRO 20.0
7 LEU 17.5
8 ILE 22.5
9 GLN 20.3
10 GLN 24.0
11 TY R 6.3
TABLE 3.6 AMINO ACID COMPOSITION OF TRYPTIC AND
CHYM OTRPHC PEPTIDES
The peptides, C l ,  C2, T l ,  T5 and T6 w ere hydrolysed in  6M  HC1 
overnight, then applied to a Beckm an am ino acid analyser (operated by 
I.M cD onald, D epartm ent o f B iochem istry, University o f A berdeen). 
G lutam ine and glutam ate residues are both included in  GLU  and 
asparagine and aspartate are both  included in  ASP.
Cys AC, SCM  Cys and PE  Cys are derivatives of cysteine residues. 
T ryptophan was not detected.
AM INO ACID pMOLES RECOVERED FROM  PEPTIDE
C l C2 T l T5 T6
CYS A C 0 0 0 0 0
ASP 84 732 192 1236 816
GLU 180 588 576 1632 1692
SCM  CYS 0 0 0 0 0
SER 168 492 324 1536 1140
G LY 432 852 672 1248 1668
HIS 0 276 0 132 84
A RG 156 264 516 588 456
TH R 120 240 240 1020 1056
A LA 228 828 492 972 1056
PRO 48 72 132 516 780
TY R 48 48 36 228 288
VA L 156 480 240 816 744
M ET 0 0 0 60 60
PE  CYS 0 0 0 0 0
ILE 156 396 120 612 696
LEU 240 600 1572 1536 3264
PHE 96 336 72 276 192
LYS 120 228 132 480 288
Total pm oles 2232 6432 5316 12888 14280
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3.5 DN A S E Q U E N C E  A N A L Y SIS  O F  cD N A  C L O N E S
3.5.1 Subcloning of the rat liver cDNA clones
The cD N A  inserts from  the clones ARLRI 7 and A,RLRI 8 were 
subcloned into the m ultifunctional vector, pTZ  as described in 
Section 2.13. The lam bda D N A , purified as described in  Section 
2.12.1, was digested with E co R l and the digested products 
analysed by  agarose gel electrophoresis. This revealed that both  
clones contained an insert o f less than 500bp (data no t show n). The 
E coR l-d igested  lam bda D N A  was ligated to E co R l -digested vector 
w ith  a m olar ratio o f insertrvector o f 3:1 i.e. 2 .2jig  digested 1 D N A  
w as ligated w ith 300ng vector DN A. The ligated D N A  w as then 
transform ed into com petent DS941 bacteria (Section 2.13.5). 
Positive (white) colonies on LB agar plates containing am picillin, 
IPT G  and X gal were taken through two successive rounds o f 
purification to ensure that they w ere not false positives. P lasm id 
D N A  was purified from the positive colonies by  the m ini m ethod as 
described in  M aterials and M ethods (Section 2.12.3), d igested w ith 
E co R l and subjected to agarose gel electrophoresis to determ ine the 
size of the cDNA insert. The results o f the E co R l d igestion are 
show n in Figure 3.24 and the position  o f the cD N A  inserts are 
m arked by arrows. The size o f the inserts was determ ined using the 
123bp ladder as a standard (see Section 2.17.2) and found  to be 
approxim ately 371bp for the insert from  pR LR I 7 and 316bp for the 
insert from  pR LR I 8. The ribonuclease inhibitor protein  has a M r of 
circa 48,000 w hich would be encoded by a m R N A  species o f
FIGURE 3.24 DETERMINATION OF THE STZE OF INSERTS
SUBCLONED INTO p TZ
The cD N A  inserts subcloned into the E co R l site of pTZ were 
released by digestion w ith  E coR l (Section 2.13.1) and the digested 
products subjected to agarose gel electrophoresis (Section 2.9.7).
lane 2: 500ng uncut pTZ;
lane 3: lOOOng pR L R I 7;
lane 4: 500ng pR L R I 7;
lane 5: lOOOng pR L R I 8;
lane 6: 500ng pR LR I 8;
lanes 1 and 7: 123bp D N A  ladder.
RLRI7-
1 2 3 4 5 6 7
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approxim ately 1.5-2.0 Kbp. Thus, the clones isolated from  the rat 
liver library have the potential o f encoding circa 100 am ino acids 
w hich is approxim ately 20% of the total protein.
A fter ascertaining that the inserts had been successfully 
subcloned, recom binant plasm id D N A  was used  to transform  E.coli 
M V 1190. Transform ed colonies were used to prepare single 
stranded D N A  (Section 2.14.2) and T-tracking w as carried out to 
determ ine the orientation o f the subclones. The insert has the 
potential to be subcloned into the vector in  one o f tw o orientations 
and it is desirable to have the clones in  both  orientations so that 
sequencing o f both  strands can be carried out. A nalysis of 
approxim ately 50 subclones revealed that all w ere in the sam e 
orientation (data not shown). Thus, an alternative m ethod o f 
subcloning was utilised to obtain subclones in the opposite 
orientation. The inserts from  pR L R I 7 and pR L R I 8 w ere released 
from  the plasm ids by digestion w ith E coR l and purified  from  a low  
m elting poin t agarose gel as described in Section 2.16.1. A  know n 
am ount o f insert (50ng) was ligated to a 20ng o f vector D N A  
(w hich had also been digested w ith  E co R l) as described in  the 
A m ersham  Cloning M anual and Section 2.13.3 and transform ed into 
M V 1190. Positive colonies w ere again taken through tw o rounds o f 
purification, plasm id DNA isolated and digested w ith E co R l to 
ensure that inserts were present. A gain single stranded D N A  was 
prepared and the subclones analysed by T-tracking w hich revealed 
that tw o subclones of pRLRI 8 were in the opposite orientation 
com pared to the others. A  turn-around clone o f pR L R I 7 w as not 
obtained.
FIGURE 3.25 STRATEGY FOR SEQUENCING pRLRI 7 AND
pRLRI 8
Subclones o f pR L R I 7 and pR LR I 8 were obtained as described in  
the text (Section 3.5.), single stranded DN A  prepared and the D N A  
sequenced by the Sanger dideoxy chain term ination m ethod (Section 
2.14). The sam ples w ere electrophoresed for varying lengths o f tim e 
(betw een 1 to 3 hours) to allow  sequencing o f different regions o f the 
DNA.
--------------------► RLRI 7
---------------- ► RLRI 7
I------------------------► RLRI 8
I------------------------- ► RLRI 8
RLRI 8 << i . . . I .  ...
RLRI8 m . . .  —■■}
RLRI 8 . ... . - —    -h
3.5.2 Nucleotide sequence analysis o f rat liver cD N A  clones
Sequence analysis was carried out on the different subclones by 
the dideoxy chain term ination m ethod as described in  Section 2.14. 
As a control, non recom binant pTZ  DN A  was also sequenced to 
ensure that the sequence obtained from  the subclones was n o t 
derived from  the plasm id (data not shown). Figure 3.25 illustrates 
the strategy used  to determ ine the sequence of the subclones.
A  total o f 177 bases were sequenced using the single stranded 
tem plate from  pRLRI 8 in  one direction and 198 bases w ere 
sequenced from  pR LR I 8 in  the opposite direction. A n overlap o f 
92 bases was observed and the full length of the insert from  pR L R I 
8 was determ ined to be 283 bases. The size of the insert from  
pRLRI 8 had  previously been calculated to be 3 16bp (Section 
3 .5 .1 ) .
190 nucleotides were sequenced from  subclone pR L R I 7 on the 
one strand only (as a turn around clone was not obtained). T he first 
65 nucleotides were not present on the sequence o f pR L R I 8, but 
the rem aining 125 nucleotides w ere identical to that from  pR L R I 8. 
In  Section 3.5.1, the size o f the insert from  pR L R I 7 w as 
calculated from  the agarose gel and found to be 371bp and that 
from  pR LR I 8 was found to be 316bp i.e. a difference o f 55bp.
This com pares w ell w ith the result presented here w hich suggests 
that the insert from  pRLRI 7 is actually 65 nucleotides larger than  
that from  pR LR I 8.
A  com pilation of the DN A  sequence obtained from  the inserts o f 
pR LR I 7 and pR LR I 8 is show n in Figure 3.26. and the arrow
FIGURE 3.26 COMBINED DNA SEQUENCE OF nRLRT 7 AND
pR LR I 8
Sequencing was perform ed as described in  Section 2.14.
The DN A  sequence o f pRLRI 7 starts at nucleotide 1 and continues 
to nucleotide 190.
The DN A  sequence o f pRLRI 8 comm ences at position 65 (m arked 
by  the arrow) and continues to nucleotide 350.
B etw een nucleotide 65 and 190 inclusive, the sequence o f both 
pR L R I 7 and pR L R I 8 were identical.
10 20 30 40 50
GCGGCAGTAT GGAAGACATG GCTTTTGCAG AGCGATTTGT TGTTGAGGCA 
CXaCX^TGATACCnTCTGTAC03AAAACGnrCTCX^AAACAACAACrCCX3T
60 ^  70 80 90 100
GGAAAGCTCTTGGGTGGACT GGAC^TGCHG ATTCTCAATC ACATCAGAGA 
(XTTTCX3AGAA(XCACC7GACX^TGTACGAGTAAGAGTTAGTGTAGTGTGT
110 120 130 140 150
CGACCACTAT GTCTCTCTTC C^CGATGATATCXACTCTGT GCGAAGAAGC 
GCTGGTGATACAGAGAGAAGGTGCTACTATAGGTGAGACAOBGrnCTITCG
160 170 180 190 200
ATGGAGGTCA ACTTCCTCAG CTATGTGG7CCTGAGCACAG CAGOCTGCOC 
TACXJTTXAGTTGA^GGAGTGGATAGACX^AG GACrrGGTGTCGTTCGGAOGGG
210 220 230 240 250
ATGCTGAAAC AGAGGAATGG CAGCATGGCC ATGATCTCCT CCATGGCTGG 
TACGACTTTG TCTCGTTACCGTCGTACCGG TAGTAGAGGAGGTACCGACC
260 270 280 290 300
GAAAATGACCCAACXnCTXaATGCTCCTACT CTGCW\GGCAAGCTICTGGCT 
CTTTTAGTGG GTTGGAGACTACGAGGATGAGACGTTCGGTTCGAGACCGA
310 320 330 340 350
CnTBGATGGGTTCnTTTCCAC CATTAGAAAA GAACACTTGATGA(XAAGG 
GACCTACCCA AGAAAAGGTG GTAATCTTTT CTTGTGAACT ACTGGTTCC
lee
marks the beginning of the sequence o f pRLRI 8.
The open reading frames encoded by the nucleotide sequence 
were obtained using the M AP program m e of the U W G C G  package 
(U niversity o f W isconsin Genetics Com puter G roup) on a V A X  
com puter term inal in this department. As the cD N A  is read in  a 5' 
to  3 ’ direction and it is unknow n w hich is the coding strand, there 
are 6 possible reading fram es as show n in  F igure 3.27. N one o f 
these reading fram es appeared to be sim ilar to the am ino acid 
sequence obtained for porcine liver and hum an p lacenta RnaS6 inkibWor 
(H ofsteenge et al., 1988; Lee et al., 1988).
A t this tim e, the sequences o f the hum an ribonuclease inhibitor 
(Lee et al., 1988; Schneider et al., 1988) had no t been  entered into 
either the GENBANK or the DATABANK libraries. Thus a direct 
com parison o f the rat liver DN A  sequence and the hum an 
ribonuclease inhibitor sequence was m ade using the program m es 
BESTFTT and GAP. The form er program m e revealed that there was 
a 77%  hom ology over 52 bases as shown below :
1CGGCTGCGGGGTCCTGTCCAGCACACTACGCACCCTGCCCA 
2CA G CTA TG TG G TCCTG  A G CA CA  .G CA G CCTG CCCA
1 CCCTGCAGGAG
2 TGCTGAAACAG
Sequence 1 corresponds to nucleotides 421 to 472 o f the hum an 
p lacenta D N A  sequence whereas sequence 2 corresponds to 
nucleotides 168 to  212 o f the rat liver D N A  sequence.
The data from  GAP revealed that the two D N A  sequences were 
unrelated.
The rat liver DNA sequence was then used to search the
FIGURE 3.27 PREDICTED AMINO ACID SEQUENCES FROM THE
DN A  SEQUENCE OF pRLRI 7 AND pRLRI 8
The six amino acid sequences predicted from  the D N A  sequence o f 
pR L R I 7 and pR L R I 8 are shown. The amino acid sequences w ere 
determined using the M A P programme of the UW GCG package on a 
V A X  computer.
The sym bol * indicates a stop codon.
1 60 
GCGGCACTATGGAAGACATGGCTITTTGG^SASCGA'l"I IGIIGIIGAGQCAQGAAAGCTCT 
CGCXGTGATAJXrTTCTGTACCGAAA/^ CGTCTCGCTAAACAACAACTlCXXBTCCTTTCGAGA 
A A L W K T W L L Q S D L L L R Q E  S S  
R H Y G  R H G F C  R A  I C C * G R K A L  
G T  M E  D M A F A  E R F V V E A G  K L L
R C * P L C P  K Q L A I  Q Q Q P L F  A R  
P V I  S S M A K A S R  N T T S A P F S K  
A S H F V H S K C L S K N N L C S L E Q
61 120 
TGGGTGGACTGGACATGCTT^TTCTTCAATCACATCACACACGACXACTATGrCTCTCnTC 
A(XCACXJIGA0CTGTACGAGTAAGAGTTAGTGTAGrrGrGTGCTGGTTGATACAGAGA3AAG 
W V D W T C S F S I  T S  H T T T M S L F  
G W T G H A H S Q S H H T R P L C L S S  
G G L D M L I L N H  I T H D H Y V S L P
P H V P C A *  E * D C * V R G S H  R E E  
P P S S  M S  M R  L • * M V C S W  * T E R G  
T S Q V H E N E I V  D C V V V  I D R K W
121 180 
GAGGATGATATCCACTUrGTGCGA^GAAGCATGGAGGlGAAGnrTCCrcAGCTATGTGGrC
H D D H I S V R R S M E V N F L S Y V V  
T M  I S T L C  E E A W R  S T S  S A  M W  S 
R * Y P L C A K K H G G Q L P Q L C G P
V I  I D V  R H S S A H  L D V  E E A I  H D  
R H Y G S Q A F F C P P * S G * S H P G  
S S I W  E T R  L L  M S T L  K R L * T T R
181 240
CTGAGC^G4GG4GCXTGOCCy\TGCK3AAACAGA^
GACriO3rrGrr0GrTn3GA0GGGTA0G4CTTT GTCTCGTTACCGTGGTACOGGTAGTAGAC^
L S T A A C  P C *  N R A  M A  A W P S  S P  
* A  Q Q P  A H  A E  T E Q W Q H G H H L L  
E H S S L P M L K Q S N G S M A I I  S S
Q A C C  G A  W A S  V S C  H C  C P W * R R  
S C L L R G M S F C L L P L M A M M E E  
L V A A Q G  H Q F L A I  A A H G  D D G G
241 300
(XATQGCTGGGAAAATGAOOCAACXrTClGATQCTCCrACTCTGCAAGGCA/^ GCTCTGGCr 
GGTACOGACCCTTTTACriGGGTTGG^GAGTAOG/^ GGATGAGACXHnCOGnCGAGACCGA 
P W  L G  K * P  N L * C S Y  S A  R Q A  L A  
H G W E  N D P T  S D A P T L  Q G K L W L  
M A G  K M T Q P  L M L L L  C K A  S S G S
W P Q S  F S G V  E S A G V R C P L S Q S  
M A P F  I V W G R  I S R S Q L A L E P E  
H S P  F H G L R Q  H E * E  A L C A R A R
301 350
GACCTACCCAAGAAAAGGTGGTAATC11 I I C l IGTGAACTACTGGTTCC 
L D G F F S T I  R K E H L M T K  
W M G S F P P L E  K N T * * P
G W V L F H H * K R T L D D  Q
Q I P E K G G N  S F F V Q H G L  
P H T  R K  W W *  F L V S S S W  
S P N K E V M L F  S C K I V L
G EN BA N K  library to determine if  the rat liver clones w ere related 
to any other gene w hich has been sequenced. I t w as found  that the 
rat liver clones show ed no hom ology to any o ther gene.
3.6 FURTH ER C H A R A C TER ISA TIO N  O F TH E R A T
L IV E R  cPN A  C L O N E S
3.6.1 Com parison of the rat liver cD N A  clones w ith hum an 
placental ribonuclease inhibitor cD N A  bv Southern b lo t analysis
In  the latter stages o f this project, Lee et al., (1988) reported  
the isolation of a hum an ribonuclease inhibitor clone from  a  cD N A  
library in  Xgtl 1 using an antibody raised against p lacental 
ribonuclease inhibitor. The authors also reported the com plete 
nucleotide and am ino acid sequence o f the hum an placental 
ribonuclease inhibitor (abbreviated to HPI) and P rofessor 
B .L .V allee kindly gave som e o f this hum an clone to this 
laboratory. As it was still uncertain  that the clones pR L R I 7 and 
pR L R I 8 encoded the ribonuclease inhibitor, it w as decided to 
perform  a Southern b lo t (Section 2.17.4) to determ ine if  these 
clones cross-hybridised w ith the hum an clone.
It can be seen in  Figures 3.28.A, B and C that pR L R I 7 
hybridised to itse lf and to the other putative rat inh ib ito r clone, 
pR L R I 8, but it did not cross-hybridise to the hum an clone. 
Sim ilarly, the hum an clone, pH PI, hybridised to itse lf b u t did  no t 
cross-hybridise to either o f the rat clones. (A m ouse actin  cD N A , 
included as a control, hybridised to itself but to none o f the o ther 
clones).
A ll three probes have hybridised to the h igher m olecu lar w eight 
plasm id DNA. This was assum ed to be a non-specific in teraction  
due to the low stringency w ash o f the filters.
FIG URE 3.28 COM PARISON OF RAT LIVER CLONE. pRLRI 7 
W ITH HUM AN PLACENTAL INHIBITOR CLONE. pHPI BY  
SOUTHERN BLOTTING ANALYSIS.
The putative rat inhibitor clones, pR LR I 7 and pRLRI 8 and the 
hum an inhibitor clone, pH PI were digested w ith E coR l to cut out the 
inserts (Section 2.13.1) and subjected to electrophoresis on a 1%
(w/v) agarose gel (Section 2.9.7). M ouse actin cDNA w as included as 
a control (Section 2.17.3). The D N A  was transferred to H ybond N  
(Section 2.17.2) and the filter probed w ith ^ P - la b e lle d  inserts 
(Section 2.16.2) from  pR LR I 7 (Figure A), pH PI (Figure B) and 
m ouse actin (Figure C). The Southern blots were w ashed w ith  low 
stringency (2xSSc,0.1%  (w/v) SDS) at 60°C for 2x15 m inutes and 
exposed for one hour.
In  each o f the three figures, A, B and C, lanes 1 to 4  are as follows: 
lane 1: 400ng E co R l digested pRLRI 7 (w hich provides 40ng insert); 
lane 2: 400ng E co R l digested pRLRI 8 (40ng o f insert) 
lane 3: 160ng E co R l digested pH PI (40ng o f insert) 
lane 4: 40ng o f m ouse actin cDNA insert.
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3.6.2 Comparison of the rat liver cD N A  clones with the human
placental ribonuclease inhibitor cD N A  clone bv northern blot 
analysis
There w ere tw o possible explanations o f the data illustrated in  
the previous experim ent (Figure 3.28). E ither the rat and hum an 
ribonuclease inhibitors are so different that they do not cross- 
hybridise or the rat clones are no t o f the inhibitor. In an attem pt to 
resolve these possibilities, northern  blot analyses (described in  
Section 2.17.1) w ere perform ed to ascertain w hether rat liver 
contained any m RN A  species that w ould cross-react w ith the hum an 
probe. It can be seen in Figure 3.29 that while the rat and actin  
probes hybridised to the rat R N A  (lanes 1 and 3 respectively), no 
cross-hybridisation was detected betw een the hum an clone and the 
rat R N A  thus suggesting that the first o f the above alternatives is 
correct. The rat probe hybridised to R N A  of approxim ately 1.7 Kb 
w hich com pares w ell w ith a reported size for the hum an m R N A  o f 
1.9 K b (Lee et al., 1988; Schneider et al., 1988). The actin  probe 
hybridised to a m R N A  species o f 2.4 Kb.
Sim ilar northern blots were attem pted w ith R N A  purified  from  
hum an brain (data not shown) to determ ine if  the rat clone 
hybridised to a m R N A  species in  hum an. H ow ever, none o f the 
probes hybridised and it was assum ed that the R N A  had probably 
degraded.
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FIGURE 3.29 NORTHERN BLOTTING ANALYSIS OF RA T LIVER 
RN A  W ITH THE RAT AND HUMAN cDNA CLONES.
R at liver R N A  (prepared as described in  Section 2.15.1) was 
subjected to northern  b lo t analysis as described in  Section 2.17.1. As 
heterologous probing w as taking place, the filters were w ashed w ith 
low  stringency (2xSSC, 0.1%  (w/v) SDS) at 60°C for 2x15 m inutes.
lO pg o f total rat liver R N A  was present in  each o f the lanes and 
probed  w ith the follow ing: 
lane 1: ^ P - la b e lle d  insert from  pRLRI 7; 
lane 2: ^^P-labelled  insert from  pHPI;
A s no  hybridisation w as apparent on lane 2, this filter w as stripped 
and re-probed w ith  -^P -labelled  m ouse actin cD N A  (result show n in  
lane 3).
R N A  m arkers w ere run sim ultaneously and transferred to  H ybond N. 
This lane was rem oved and the RNA stained w ith m ethylene blue as 
described (Section 2.17.1). The stained m arkers w ere aligned to the 
autoradiogram s and m arked as shown. The size o f the transcripts 
recognised by  the probes was determ ined as described in  Section 
2 .1 7 .2

3.6.3 Expression o f the rat liver cD N A  clones in rat tissues
It was hoped during the course o f this project to  confirm  the 
identity  o f the isolated clones as rat ribonuclease inhib itor cD N A  
and to then use them  to study the expression o f the gene encoding 
the protein. It w as planned to com pare expression in  different rat 
tissues and to then concentrate on the liver and look at expression 
in  foetal versus adult tissue, after adrenalectom y and glucocorticoid 
treatm ent, after partial hepatectom y and in hepatom a. In  the event, 
difficulties in  confirm ing the identification o f the recom binants 
resulted  in  none of this w ork being carried out except an in itial 
analysis o f different rat tissues.
T otal R N A  was isolated from  the brain, heart, k idney  and liver 
o f ra t by the m ethod o f Chirgw in et al., (1979) as described in  
M aterials and M ethods (Section 2.15.1). 15p.g o f R N A  from  the 
different tissues was subjected to northern b lo t analysis as 
described in  Section 2.17.1. The filter was probed w ith  the insert 
from  pR L R I 7 labelled with ^  P  by the random  prim ing m ethod 
(Section  2.16.2).
Figure 3.30.A  shows that there appears to  be  a h igh  level o f 
expression o f sequences com plem entary to the ra t liver clone in rat 
k idney (lane 3) and liver (lane 4) and a low er level o f  expression in 
rat brain  (lane 1) and heart (lane 2). To determ ine if  this pattern  of 
expression is representative or is m erely due to incorrect loading of 
the RN A , the filter was stripped and re-probed w ith  an actin  cDNA. 
A pproxim ately equal levels o f actin m RN A  w ould be expected in  all 
fou r tissues. As seen in Figure 3.30.B , there w as an unequal
FIGURE 3.30 TISSUE EXPRESSION STUDIES USING THE RAT
LIV ER cDNA CLONE. pRLRI 7.
R N A  isolated from  rat brain, heart, kidney and liver (Section 
2.15.1) was probed w ith ^ P - l a b e l l e d  insert from  pR LR I 7 (Figure A) 
as described in Section 2.17.1. The filter was w ashed w ith h igh  
stringency (0.1XSSC, 0.1%  (w/v) SDS) at 60°C for 2x15 m inutes and 
exposed for 3 days. The filter was then stripped and reprobed w ith 
m ouse actin cD N A  (Figure B ) and processed as above.
In  both Figures A  and B , each lane contains 15 jig o f to tal R N A  from  
different tissues as follow s: 
lane 1: rat brain; 
lane 2: rat heart; 
lane 3: rat kidney; 
lane 4: rat liver.
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loading of R N A  i.e. the am ount o f heart (lane 2) and liver (lane 4) 
R N A  loaded onto the gel were comparable but w ere several orders 
o f m agnitude low er than that o f brain (lane 1) and kidney (lane 3). 
N otw ithstanding the inadequacies o f this experim ent, w hich  there 
was unfortunately no  tim e to repeat, some features are notew orthy. 
It is clear that the expression o f the cloned species in b rain  is less 
than that in  either liver o r kidney and there is a very  h igh  level of 
expression o f the clone in rat liver. Also, the clone appears to  
hybridise to tw o species o f R N A  in  the kidney.
CHAPTER FOUR 
DISCUSSION
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The aim of this project was to obtain a cDNA clone of the 
ribonuclease inhibitor to use as a probe in determ ining the extent to 
w hich inhibitor activities are controlled at the level o f gene 
expression. It was decided to w ork w ith the rat liver system  as it is 
an organ w ith a high level o f protein synthesis and a h igh  level of 
inhibitor activity and was therefore, an ideal source o f this protein  
(Shortm an, 1962; Roth, 1962). In  addition, several studies have 
been carried out on the rat liver and it has been show n that changes 
occur in the level of inhibitor activity depending upon the m etabolic 
state o f the liver e.g. in  the regenerating rat liver (M oriyam a et al., 
1969) and in the liver o f adrenalectom ised rat (Lui and M atiisian , 
1977).
The initial task in this project w as to purify ribonuclease 
inhibitor and use the purified protein  to obtain a h ighly specific 
polyclonal antibody w ith w hich to screen a rat liver A,gtl 1 
expression library. Thus, the ribonuclease inhibitor was routinely  
prepared from  rat liver by the m ethod of Burton (1980) w ith  the 
m odification that the protein was eluted at 4°C rather than  25°C . In 
general, the specific activity was approxim ately 1.1x10^ units/m g 
and a typical yield was 40% . These results are sim ilar to those 
obtained by N. Brockdorff, a  previous m em ber o f this laboratory  
w ho also routinely prepared inhibitor from  rat liver. In  th is study, 
the inhibitor was purified approxim ately 8,500-fold w hich  is in  
agreem ent with Yasuna and G oto (1986) who obtained a 
purification factor o f 10,000-fold. This is in  contrast to  that o f 
B rockdorff and K now ler (1986) w ho reported a purification  factor 
o f 26,000-fold. The reason fo r the discrepancy in  these results was
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unclear. The relative m olecular m ass (Mr) o f the rat liver inhibitor 
was calculated to be approxim ately 46,700 D altons by SDS PA G E 
w hich is in  agreem ent w ith that of Burton and Fucci (1982) w ho 
obtained a M r o f 48,600
Analysis o f the purified protein by  SD S-PAGE revealed that the 
preparation contained sm all amounts of contam inating proteins, a 
result sim ilar to that reported by  B urton and Fucci (1982)and 
B rockdorff (PhD thesis, 1985). They overcam e this problem  by 
subjecting the purified inhibitor to the affinity chrom atography step 
again w hich apparently yielded m ore hom ogenous preparations o f 
protein .
B rockdorff then utilised this hom ogenous preparation o f  
ribonuclease inhibitor to raise polyclonal antiserum  in  rabbits. 
Analysis o f this antiserum  by w estern blotting revealed  that it 
contained antibodies w hich recognised other proteins from  rat liver 
extracts in  addition to ribonuclease inhibitor. H ie  presence o f these 
contam inating antibodies was attributed to trace am ounts o f  protein  
thought to be present in the injected protein preparation, despite 
rechrom atography on the RN ase A-Sepharose affinity colum n. 
Therefore, in this study it was decided to apply the non  
hom ogenous protein preparation obtained after the affinity 
chrom atography stage to a preparative SDS polyacrylam ide gel to 
resolve the contam inating proteins from  the inhibitor. The band 
corresponding to the inhibitor was excised from  the gel and  used  in 
im m unisation. A  sim ilar m ethod fo r purifying antigen w as u tilised  
by A. H unter (PhD thesis, 1985) who isolated the indiv idual 
subunits o f m am m alian 2-oxo-glutarate dehydrogenase com plex and
used them  to raise polyclonal antiserum.
Despite these precautions, w hen the anti-ribonuclease inhib itor 
antiserum  was used to challenge a cytoplasm ic liver extract on  a 
w estern blot, a sim ilar result was obtained to that o f B rockdorff 
(PhD thesis, 1985) i.e. other im m une bands were apparent in  
addition to the band corresponding to the inhibitor, thus indicating 
the presence of additional antibodies in the im m une serum . In  this 
project, these additional antibodies were also present in  pre- 
im m une serum  (i.e. serum  obtained from  the rabbit p rio r to  the 
initial injection o f the antigen) w hich suggested that the p resence of 
these contam inating antibodies was no t due to im purities p resen t in 
the injected inhibitor preparation. The antibodies w hich w ere raised 
against ribonuclease inhibitor were separated from  the additional 
antibodies by ’negative’ affinity chrom atography. The im m une 
serum  was passed through a bed  of Sepharose 4B coupled to a rat 
liver protein preparation w hich was depleted in ribonuclease 
inhibitor. Thus, antibodies raised against the inhibitor d id  n o t bind 
to the colum n as no antigen was present. Antibodies recognising 
other liver proteins bound to their respective antigens on the 
colum n and were absorbed from  the im m une serum. The absorbed 
antiserum  was now  considered to be m onospecific as it now  
recognised only one protein (ribonuclease inhibitor) on  a w estern  
blo t o f a rat liver extract.
A n alternative m ethod fo r purifying specific antibodies is to  bind 
the antigen to a Sepharose colum n. The specific antibodies b ind  to 
the antigen and can be eluted using amm onium  hydroxide o r glycine 
pH 2 (Johnstoneand Thorps 1982). This was the preferred m ethod  o f
m any researchers who have screened Xgtl 1 expression libraries 
w ith polyclonal antibodies (Ny et al., 1986; Saris et al., 1986; 
Tam kun et al., 1986; Jahnsen et al., 1986; N agata et al., 1986 
and O gaw a et al., 1988).
It w as o f vital importance to obtain a high titre, m onospecific 
polyclonal antibody for screening the cD N A  expression library. I f  
the antiseram  recognised m ore than one protein from  a crude cell 
liver extract on a western blot, then there m ay be a chance that the 
serum  w ould recognise these additional proteins in a screen o f the 
library. Thus, there would be an uncertainty that the cD N A  of 
interest had  been cloned. M onoclonal antibodies have been  used  to 
isolate genes (Ishida et al., 1987) but they are no t as ideal fo r 
screening an expression library as polyclonal antibodies. In  
general, a m onoclonal antibody recognises a  single epitope o f  a 
protein. Thus, if  the cDNA was incom plete i.e. did not encode the 
entire protein and that part o f the protein w hich contained the 
epitope w as absent, the antibody w ould not recognise this clone. 
A lso, it is possible that an entirely different protein m ay contain  a 
sim ilar epitope and this m ay be recognised by the m onoclonal 
antibody. Thus, there is an increased chance that false positives 
m ay be obtained w hen using m onoclonal antibodies.
W hen screening an expression library, it is advantageous to 
obtain a high signal to noise ratio w hich facilitates in  the detection 
o f antigen producing plaques from  the background obtained from  
non-antigen expressing plaques. Several steps w ere taken to  reduce 
background levels; IgG was purified from  im m une serum  by  ion- 
exchange chrom atography and the IgG  preparation was adsorbed
w ith a bacterial lysate of the host strain o f bacteria to rem ove any 
antibodies w hich bound to E.coli antigens (H elfm an et al., 1985; 
H uynh et al., 1985).
Thus, a m onospecific, polyclonal antibody w as prepared  w hich 
produced a strong signal on a w estern  blot. H ow ever, before the 
library was screened, the best m ethod fo r detecting bound antibody 
was determ ined. Essentially, there were three options: l^^ I-labe lled  
pro tein  A  (prepared by J.A. H odgson,this departm ent); horseradish  
peroxidase (HRP) conjugated secondary antibody (SA PU ) and 
biotinylated secondary antibody (Am ersham ). D ot b lo t analysis of 
purified  ribonuclease inhibitor was carried out using each o f  the 
aforem entioned m ethods to detect bound antibody. It w as found 
that the two latter m ethods w ere com parable and at least ten  tim es 
m ore sensitive than the protein A  m ethod. These
results w ere different to those reported by Young and D avis (1985) 
w ho found that 125j protein A  was com parable to the b iotinylated 
secondary antibody and both w ere reported to be  5-10 tim es m ore 
sensitive than H R P conjugated secondary antibody. The result 
obtained using 125i_iabelled protein  A  in  this project can be 
explained as it had a specific activity 10 tim es less than  that used  
by  Young and Davis (J.A. H odgson, personal com m unication). As 
the other two m ethods provided sim ilar results and as H R P 
secondary antibody is provided gratis to  Scottish U niversity  
research groups, it was decided to  use this m ethod to detect bound 
antibody.
A  further point to arise from  the dot blot analysis w as that the 
antibody recognised native protein  despite being raised against 
denatured protein. This w as1 im portant as the fusion proteins w hich
are produced w hen screening the library are in the native state and 
the antibody m ust be able to recognise them  in  this form . It was 
also im portant that, when using the selected m ethod, it was 
possible to detect l.Ong of purified  ribonuclease inhibitor. The 
antigen-producing plaques m ay no t produce large quantities o f 
fusion protein and therefore the antibody m ust be able to detect 
sm all am ounts o f antigen.
The library w hich was used in  this study was donated by  R.O. 
H ynes in  1984 and its preparation is described by  Schw arzbauer et 
al., (1983). The authors o f this paper reported that the library  
contained 85-90%  recom binant phage whereas in  this study, the 
num ber o f recom binants from  the sam e library was found to be 
56% . As the library was stored fo r several years before use, it was 
possible that unstable recom binant phage had spontaneously ejected 
their inserts.
A fter three successive rounds o f screening, three recom binant 
clones were isolated from  the library and subsequently nam ed
A,RLRI 3, A.RLRI 7 and ARLRI 8. A t the onset o f  the project, it was 
hoped to screen the library w ith tw o separate antisera raised  against 
ribonuclease inhibitor i.e. to  take duplicate filters o f the p lated  
phage, screen w ith the two antibodies and choose the positives 
com m on to both antibody preparations. It was thought that 
screening the library with antiserum  from  two independent sources 
\yould decrease the probability o f isolating false positives.
H ow ever, the antiserum  produced by  the second rabbit did n o t have 
a w orkable titre, no r did it detect less than lOng o f purified 
ribonuclease inhibitor in dot b lo t analysis. It was therefore
considered to be unsuitable fo r screening the library.
Lysogens were prepared from  the three isolated recom binant 
phages fo r several reasons. Firstly, the phage D N A  was m ore 
stable w hen integrated into the bacterial chrom osom e and secondly, 
preparative amounts of fusion protein can be produced fo r further 
characterisation (Huynh et al., 1985)
A nalysis o f the fusion proteins produced by ARLRI 3 and ARLRI 
8 revealed that they were IPTG-inducible and had  an approxim ate 
relative m olecular mass (Mr) o f 127,000 Daltons. As the M r o f the 
B galactosidase portion o f the fusion protein was 114,000 D a 
(Young and Davis, 1985), the polypeptide encoded by the cD N A  
was approxim ately 13,000 Daltons. In  this particu lar experim ent, it 
w as noted  that the fusion protein produced by the XRJLRI 7 lysogen 
w as expressed constitutively i.e. it was no t IPTG -inducible. This 
m ay have been due to the lam bda repressor having been titrated  out 
o f this bacterial population. This result was no t reproducible as 
other preparations o f fusion protein from  this lysogen w ere 
inducible w ith IPTG. The fusion protein fo r this lysogen had  an 
approxim ate M r of 130,000 Daltons. As the M r o f rat liver 
ribonuclease inhibitor was approxim ately 48,000 D altons (Burton 
and Fucci, 1982), it was clear that none o f the three clones isolated  
from  the library encoded the entire inhibitor protein.
The isolated clones were further characterised by  w estern b lo t 
analysis o f the uninduced and IPTG -induced bacterial lysate o f  the 
three recom binant lysogens and the non recom binant lysogen,
A ,gtll/Y 1089. This revealed that the fusion proteins from  the 
lysogens of ARLRI 7 and AJRJLRI 8 produced an im m unopositive
fusion pro tein  whereas an im m une band was not observed for 
X.RJLRI 3 in  Y1089. The DPTG-induced bacterial lysate o f 
A,gtl 1/Y1089 contained non recom binant B-galactosidase and this 
was included in  the w estern b lot as a control to  ensure that the 
antibody w as recognising the protein encoded by  the cD N A  insert 
and n o t the B-galactosidase portion o f the fusion protein. Thus,
A-RLRI 7 and A.RLRI 8 appeared to contain ribonuclease inhibitor 
antigenic determ inants w ithin their respective fusion proteins. 
Interestingly, detection of the fusion proteins required  the 
biotinylated secondary antibody detection system  (w hich is a 
reputedly  10 times m ore sensitive than the H R P secondary antibody 
system ) before im m une positive bands w ere observed. This w as 
probably due to B-galactosidase antigenic determ inants m asking the 
antigenic sites o f the sm aller cDNA-encoded polypeptide. This 
hypothesis was corroborated by the results obtained from  the 
im m unogenic peptide m aps which were developed using the H R P 
secondary antibody system  i.e. digestion o f the fusion  proteins 
revealed the antigenic sites o f the cD N A -encoded polypeptide.
Phage D N A  was isolated from  the recom binant lysogens ARLRI 
7/Y 1089 and ARLRI 8/Y1089 and, after digestion w ith E co R l to 
release the insert, it was found that the insert from  ARLRI 7 w as 
371bp and that from  ARLRI 8 was 316bp. Thus insert 7 w as 55bp 
larger than that fo r insert 8. This was expected as the fusion 
protein  from  ARLRI 7 was larger than that o f ARLRI 8. A lso,
371bp is sufficient to encode a polypeptide of approxim ately 
15,000 D altons and 316bp has the potential o f encoding for a  
polypeptide o f 13,000 Daltons. These figures are very sim ilar to
the M r values obtained for the cD N A -encoded portion o f the fusion 
protein from  A.RLRI 7 (16,000 Daltons) and A.RLRI 8 (13,000 
Daltons)
The library used in  this project has also been used  to isolate 
fibronectin (Schw arzbauer et al.,1983) and U D P-glucuronyl 
transferases (B urchell et al.,1984) and a-inh ib ito r in  (A iello  et 
al., 1988). The in itial clone isolated by  Schw arzbauer and 
colleagues was 500bp and encoded a protein o f 14,000 D altons. 
The cD N A  insert was sequenced and the predicted am ino acid 
sequence com pared to that o f bovine plasm a fibronectin  w hich 
confirm ed that it was a fibronectin clone. The 500bp clone w as 
used to  re-screen the library by  plaque hybridisation and other 
clones w ere isolated  w hich ranged in  size from  500 to 3,000bp. 
Burchell et al. isolated 4 clones coding for U D PG T ranging in  size 
from  1500-2000bp w hich encoded proteins o f up to 32,000 
Daltons. The clone isolated by A iello et al.,was l,400bp  in  length. 
Thus, the clones isolated in  this project w ere sm aller than  those 
isolated by  o ther research groups using the sam e library.
Interestingly, the clones isolated by Schw arzbauer et al., (1983) 
did no t all encode the 3' term inal end of the protein  despite the 
cD N A  being prim ed by oligo(dT). O f the six clones isolated, only 
two encoded the 3 ’ end and 2 encoded the 5' end. Thus it  w as 
possible that the partial clones isolated in this study could  encode 
any part o f the inhibitor protein and not be confined to the 3' 
term inus. This can arise by incom plete synthesis o f the second 
cDNA strand.
The next stage o f this project was to determ ine if  the tw o clones,
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XJRLRI 7 and A,RLRI 8, encoded ribonuclease inhibitor. A s there 
was no published am ino acid or nucleotide sequence o f the inhibitor 
from  any source at this tim e, a novel m ethod w as attem pted to 
com pare peptide m aps of purified rat liver ribonuclease inhibitor 
and fusion protein. H ow ever, the task o f isolating the fusion 
protein  from  a cm de cell lysate proved to be som ew hat difficult. 
Initially, the m ethods o f isolating the fusion pro tein  w ere based 
upon attem pting to extract the fusion protein from  a polyacrylam ide 
preparative gel. The m ethod of Tolan et al., (1980) w hich involved 
extracting the protein by diffusion yielded little o r no protein. This 
m ethod has been used successfully in this laboratory by  Z. Seraj 
(PhD thesis, 1986) who eluted hnRN P core proteins from  SDS 
polyacrylam ide gels. Sim ilarly, electroelution o f  the pro tein  from  
the gel yielded only 1-2% o f the initial protein. It was unclear as to 
w hy the fusion protein proved difficult to isolate using these 
m ethods but it was possible that the size and conform ation o f the 
pro tein  was no t conducive to these types of elution.
As m entioned in  the Results chapter, (Section 3.3.5), there is 
evidence that in  a m ajority o f cases, genes expressed as fusion  
proteins in E.coli are present in  an insoluble form  know n as 
'inclusion bodies' e.g. insulin  A  and B chains (G oeddel et 
al.,1919), B-endorphin (Shine et al., 1980) and prochym osin  
(M arston et al., 1984). These inclusion bodies can  be iso lated  by a 
single centrifugation step. The fusion protein produced by  IPTG - 
induction o f A,RLRI7/Y1089 and A,RLRI 8/Y1089 w ere soluble as 
they were present in the supernatant fraction after centrifugation. 
A ttem pts w ere m ade to render the fusion protein insoluble by  
changing the pH  and ionic strength of the lysis bu ffer but, in  all
cases, the fusion protein rem ained soluble. It should be no ted  that 
exam ination of the literature concerning fusion proteins produced 
by Xgtl 1 recom binant lysogens show ed that, in  all cases exam ined, 
the fusion protein  was always present in  a soluble form  
(Schw arzbauer et al., 1983; B urchell et al., 1984; N y et al.,
1986; Evans et al., 1986; W eil et al., 1987).
In  retrospect, it m ay have been advantageous to attem pt to purify 
the fusion protein by  classical purification m ethods e.g. gel 
filtration or affinity chrom atography on p-am inophenyl b-D  
thiogalactoside-Sepharose (U llm ann, 1984).
W hen it becam e apparent that the fusion protein was not easily 
purified  from  a crude cell lysate by the aforem entioned m ethods, it 
was decided to isolate both the fusion protein and the purified  
inhibitor as a protein band from  a coom assie blue stained 
preparative gel and use the m ethod of C leveland et al., (1977) in 
conjunction w ith western blotting to produce an im m unopeptide 
m ap. U nfortunately, the resultant m aps were difficult to in terpret 
but there was som e evidence that there were peptides com m on to 
both  fusion protein and ribonuclease inhibitor after d igestion  w ith 
chym otrypsin.
W hen it becam e apparent that the combined m ethods o f  Cleveland 
m apping and w estern blotting w ere not aiding in  the identification 
o f the recom binant clones, it w as decided to obtain as m uch  am ino 
acid sequence of ribonuclease inhibitor as possible and then  to 
com pare this with the amino acid sequence predicted from  the D N A  
sequence of the clones.
O f the five peptides on w hich the sequencing reaction  w as
attem pted, only one provided som e sequence data. It w as unclear as 
to w hy the other peptides did no t yield data as it was show n that 
they were present in  sufficient quantities to be sequenced. It was 
possible that som e o f the peptides were derived from  the N -term inal 
end (which has since been show n to be blocked by Schneider et 
al., 1988) and this prevented them  from  undergoing the sequencing 
reaction. How ever, it seem ed unlikely that all four peptides w ere 
derived from  the N -tenninus. The procedure utilised in  this study 
to obtain peptides o f hum an ribonuclease inhibitor was very  sim ilar 
to that used by Hofsteenge et al., 1988. Both procedures involved 
reducing and alkylating the protein, follow ed by digestion w ith  
protease and isolation o f peptides using reverse phase 
chrom atography on HPLC. The m ain difference betw een the 
m ethods was in the choice o f proteases. In  this study, the inh ib ito r 
was digested w ith either trypsin or chym otrypsin w hereas 
H ofsteenge and colleagues used cyanogen brom ide, trypsin and 
S.aureus V8 protease. Sim ilar system s were also used  to sequence 
the peptides, how ever, H ofsteenge et al., obtained am ino acid  
sequence o f the entire protein w hereas only 11 am ino acids w ere 
obtained in  this project.
W hen the above data became available, the amino acid sequence 
for the rat liver obtained from  this project was com pared to tha t o f 
porcine liver (Hofsteenge et al., 1988) and hum an p lacenta (Lee et 
al., 1988). The short stretch o f am ino acid sequence from  the rat 
liver corresponded to residues 20-31 in the hum an placental 
sequence and to residues 15-26 in  the porcine sequence and are 
show n below:
rat liver: L T E L G P L I Q Q Y G
porcine liver: W  T E L  L P L L Q Q Y E
hum an placenta: W A E L L P L L Q Q C Q  
The hom ology between residues 20-31 o f hum an placenta and 15- 
26 o f porcine liver was calculated to be 75%. This com pared w ell 
w ith the hom ology o f the total protein from  pig and hum an w hich 
was found to be 77% (personal calculation) Thus, the ribonuclease 
inhibitor from  different species appears to be hom ologous as 
predicted by  the amino acid com positions (Burton, 1980; B urton 
and Fucci, 1982; B lackburn et al., 1977; Fom inaya et al., 1988a). 
Furtherm ore, if  the hom ology o f the above stretch o f am ino acids 
w as representative o f that betw een the whole protein  sequence, then 
it w ould be expected that ribonuclease inhibitor from  rat and pig  
w ould show 66% hom ology w hile that from  rat and hum an w ould 
be 50%  hom ologous.
B urton and Fucci (1982) raised antiserum  against hum an 
placental inhibitor which did no t cross-react to a  great extent w ith  
the ribonuclease inhibitors from  the livers o f five m am m alian 
species, including pig. They proposed that the secondary structure 
o f the hum an placental inhibitor m ay be different to that o f 
m am m alian liver, despite the sim ilarity in amino acid com positions. 
H ow ever, recently B loem endal and Jansen, (1988) used antibodies 
raised against hum an placental ribonuclease inhibitor to detect 
inhibitor from  a wide variety o f tissues and species using w estern  
blotting analysis w hich suggests that the secondary structures o f 
the inhibitors are conserved.
Six translational reading fram es were obtained from  the cD N A
sequence o f the clones, none o f which appeared to encode an amino 
acid sequence sim ilar to that o f ribonuclease inhib itor from  pig or 
hum an. H ow ever, it should be noted that it is difficult to be 
entirely sure o f predicted amino acid sequences w hen the D N A  has 
not been  sequenced totally on both  strands as insertion or deletion 
o f a  single nucleotide can alter the reading fram e. There were 
several reasons as to w hy the clones were no t sequenced fully  on 
both  strands: Firstly, as m entioned in  Section 3.5.1, there was 
great difficult in obtaining 'turn around1 clones and secondly, w hen 
a turn  around clone was obtained, the single-stranded D N A  
preparations were not of high quality w hich hindered the reading of 
the sequencing gels. Analysis o f the predicted am ino acid 
sequences obtained from  the region of D N A  w hich had  been read  on 
bo th  strands should, in  theory, provide the m ost accurate am ino 
acid sequence. However, no hom ology was discernible betw een 
this region and the hum an or porcine am ino acid sequences.
A n alternative strategy to obtaining D N A  sequence on both  
strands w ould have been to sequence as m uch as possible o f one 
strand, then determ ine possible restriction sites w ith in  this strand 
and, using these restriction sites, generate sm aller subclones w hich 
m ay have been easier to read. H ow ever, tim e did no t allow  fo r this 
to  be  carried out.
The lack o f hom ology betw een the hum an and porcine inhibitors 
and the predicted amino acid sequences o f the isolated clones 
extended to the DN A  sequences themselves. The com bined D N A  
sequence o f the clones pRLRI 7 and pR LR I 8 w as com pared by 
com puter to that o f hum an placental inhibitor and no hom ology was
evident (except fo r a stretch o f 52 nucleotides w hich show ed 77%  
hom ology). This was not entirely unexpected as the hum an cD N A  
clone did no t hybridise to the rat liver clones on a Southern blot.
N orthern  blotting analysis o f rat R N A  probed w ith  the isolated 
rat clones showed that the corresponding m RN A  was approxim ately 
1.7Kb. This is sim ilar in  size to the RN A  w hich encodes the hum an 
ribonuclease inhibitor (Schneider et al.,1988; L ee et al., 1988) 
w ho obtained a value o f 1.9Kb. Thus, the R N A  corresponding to 
the rat clones is o f a sufficient size to encode a pro tein  w ith  a  M r 
sim ilar to that o f the inhibitor.
W hen rat liver RN A  was probed w ith the hum an p lacental clone, 
no  hybridisation was evident. This was a  surprising resu lt as the 
proteins from  different species appear to exhibit a  h igh  degree o f 
hom ology, and it would be expected that the hom ology at the 
nucleotide level w ould also be relatively high. It is possib le  that the 
m R N A  encoding ribonuclease inhibitor is o f very low  abundance 
and if  m ore RN A  had been loaded, then a signal m ay have been  
detected.
The prelim inary results on the tissue specificity w ere interesting 
in  that the clones appeared to be expressed in  all four tissues 
studied i.e. brain, heart, kidney and liver. This w as the expected  
expression pattern for ribonuclease inhibitor as the pro tein  has been  
found in  alm ost all tissues (B lackburn and M oore ,1982). A lso, the 
gene was expressed to a h igher level in  the liver and k idney than  in  
the brain. Again, this was the pattern  expected for the ribonuclease 
inhibitor as it has been reported that the level o f inh ib ito r p ro tein  in  
the brain  was one fourteenth that o f placenta (Burton, 1980)
W ith the available evidence, it was difficult to decide i f  an
authentic rat liver ribonuclease inhibitor clone had  been isolated. 
The clones reacted very strongly w ith the m onospecific anti- 
ribonuclease inhibitor antibodies and produced an im m unopositive 
fusion protein. Also, the m RN A  w hich hybridised to the clones was 
o f a size w hich was large enough to encode a protein  the size o f 
ribonuclease inhibitor. Furtherm ore, the gene appeared to be 
expressed in  the expected m anner o f ribonuclease inhibitor. 
H ow ever, the clones did no t hybridise to the hum an p lacental clone 
in Southern analysis, nor did the D N A  sequences com pare (except 
fo r one sm all stretch of nucleotides). In  addition, the predicted  
am ino acid sequence of the rat liver clones did no t appear to be 
sim ilar to those from  human! o r porcine inhibitor (and it w ould be 
expected that at least 50% hom ology w ith hum an and 67% w ith  pig 
w ould be apparent).
As the clones isolated from  the rat liver library did no t show  any 
hom ology to the hum an inhibitor, the D N A  sequence w as used  to 
search the GENB ANK to ascertain if  another ra t liver pro tein  had 
been cloned instead. Interestingly, this sequence o f D N A  did no t 
appear to be hom ologous to any other rat liver gene w hich has been 
sequenced and entered into the GENB AN K  files. A lso, the cD N A  
did not appear to be sim ilar to any gene from  other sources. Thus, 
the identity  o f the clones isolated from  the rat liver library  rem ains 
unknow n.
W hat w ent wrong?
This is an extrem ely difficult question to answer. W hen an
expression library is screened, the quality o f the antibody probe is 
o f vital im portance and it w as thought that reasonable care was 
taken to  ensure that the antibody was optimal. The antibody 
appeared to be m onospecific as it reacted with a single protein  from  
a cytoplasm ic fraction o f ra t liver proteins. How ever, the antibody 
w as not tested against a fraction containing m em branes and it is 
possible that the antibody cross-reacted with a m em brane-bound 
protein  w ith a  sim ilar M r to that o f ribonuclease inhibitor.
One m ethod for determ ining the identity o f isolated clones using 
the antibody is to affinity purify the antibodies w hich bind  to the 
fusion protein and then, using these antibodies, to perform  w estern 
b lo t analysis on the protein o f interest. I f  the affinity purified  
antibodies also recognise this protein, then it can be assum ed that 
they share antigenic determ inants. This procedure has been  used  
successfully by  several groups (N y et al.,1986 and W eil et 
al., 1987).
. A n  alternative approach to proving the identity o f an iso lated  
clone is to perform  hybrid-release translation as suggested by  
Y oung and Davis, (1985), B randis et al., (1986) and W eiss et al.,
(1986). Briefly, this involves binding the isolated clone to a 
m em brane filter and incubating w ith poly(A)+ R N A  prepared from  
the tissue of interest. U nbound R N A  is washed away, the bound 
poly(A )+ eluted and translated in  an in vitro system. The translated 
products are subjected to SDS page, blotted onto nitrocellulose and 
challenged w ith the antibody that was originally used to isolate the 
clone. In  this p ro je c t , this approach was not taken as, firstly  it 
was know n from  northern blotting analysis that the m RN A
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corresponding to the cDNA clone encoded a protein of 
approxim ately the correct m olecular weight and secondly, i f  a 
positive result was obtained, this w ould only show  that a gene 
w hich encoded a protein recognised by the antibody had been 
cloned. It w ould still be uncertain if  that protein was ribonuclease 
inhibitor.
W ith the advantage of hindsight it is worth analysing w hether the 
correct approach to this project was to attem pt to  clone the inhibitor 
protein from  an expression library. The literature includes m any 
testam ents to the fact that this approach can be successful. Indeed, 
this is how  the hum an placental inhibitor was recently cloned (Lee 
et al., 1988). N evertheless, discussion w ith colleagues and other 
scientists in a num ber of institutions reveal that the experience o f 
this project, in  cloning w hat are probably false positives from  a
A-gtl 1 library, is far from  unique. A  specific exam ple is that 
reported by  B outin et al., (1988) w ho attem pted to isolate the 
prolactin  receptor from  a Xgtl 1 expression library using bo th  
polyclonal and m onoclonal antibodies. They repeatedly isolated 
false positives as determ ined by northern  blotting analysis. 
Eventually, these authors constructed oligonucleotides from  the 
am ino acid sequence and used these to isolate the required clones 
from  the sam e library.
W hen trying to clone a protein for which no sequence is know n, 
p roo f o f the identity o f isolated clones is likely to rest on 
sequencing both the cloned D N A  and at least som e o f the protein . If  
then, som e protein sequencing m ust be done, it can be argued that 
it is better done sooner than later so that the sequence generated can
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be used  to synthesise corresponding oligonucleotides. O ne could 
then screen a non-expressing cD N A  library, such as XgtlO, and 
save the labour o f raising and purifying antisera. H ow ever, m any 
w orkers also record false positives after screening w ith 
oligonucleotides. This is especially true w hen only short stretches 
o f protein  sequence are know n as there is then little  flexibility  in 
the nature o f the oligonucleotides that can be m ade. U nder these 
circum stances, it is unlikely that it w ill be possible to choose an 
oligo encoding a high percentage o f amino acids w ith a low  level o f 
redundancy in their genetic code and oligos w ith a  h igh  level of 
redundancy are very likely to select false positives.
Perhaps, in  the present case, m ore effort should have been  pu t 
into sequencing earlier in the project so that oligonucleotides could 
be m ade. Recom binants selected by  antibody screening o f the Xgtl 1 
library could then have been rapidly checked fo r cross­
hybridisation to the oligonucleotides.
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